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Stellingen 
De structurele overeenkomst van hydroxy-metabolieten van PCBs, PCDDs en 
PCDFs met het schildklierhormoon verklaart de selectieve retentie in het plasma 
via binding aan TTR (Dit proefschrift). 
De aanwezigheid van een meta- of /?ara-hydroxy-groep met aangrenzende 
chlooratomen vormt een voorwaarde voor binding van hydroxy-metabolieten van 
PCBs, PCDDs en PCDFs aan TTR (Dit proefschrift). 
De waterstofbrug-vorming tussen de hydroxygroep van een PCB metaboliet en 
het aminozuur-residu Serine 117 in de bindingsplaats van het TTR, verklaart de 
sterkere binding van deze hydroxy-PCB metaboliet dan thyroxine aan TTR (Dit 
proefschrift). 
Tot dusver zijn de in vivo effecten van hydroxy-PCB metabolieten, waarvan is 
aangetoond dat zij selectief in het bloed van verschillende diersoorten en de mens 
aanwezig blijven, onderbelicht. 
Voor de gangbare hypothese dat de toxische werking van dioxines en verwante 
stoffen in hoofdzaak tot stand komt via Ah receptor-gemedieerde processen, is de 
mechanistische onderbouwing mager. 
Het toeschrijven van de afname van de gemiddelde spermaproductie van de man 
aan de blootstelling aan oestrogene stoffen in het milieu is voorbarig. 
(Skakkebaek en Sharpe (1993), Lancet 341, 1392-1395). 
Bij het leggen van claims voor de gezondheidsbeschermende werking van 
individuele voedingscomponenten wordt te vaak voorbijgegaan aan de 
mitigerende invloed van de voedselmatrix. 
Het gebruik van niet gevalideerde modellen in toxicologisch onderzoek draagt bij 
aan onjuiste beeldvorming omtrent de gevaren van chemische stoffen in de 
samenleving. 
Het ongegrond in stand houden van een "milieuprobleem" teneinde 
onderzoeksgelden te vergaren, mag als onethisch worden beschouwd. 
10 De betekenis van het woord mens als "redelijk aards wezen" (Prisma 
Woordenboek Nederlands) gaat in deze samenleving niet op. 
11 Zingeving is vaak uit de lucht gegrepen. 
12 Ook aan het gedrag van mannen tijdens wetenschappelijke congressen waaraan 
ook vrouwen deelnemen (waaronder het jaarlijkse Dioxine congres), is niet te 
merken dat de milieuverontreiniging met oestrogene stoffen van invloed is op de 
mens. 
13 There are two kinds of silence. One in which no word is spoken. The other 
where perhaps a torrent of words is employed. 
(H. Pinter) 
Stellingen behorende bij het proefschrift "Thyroid hormone binding proteins as novel targets for 
hydroxylated polyhalogenated aromatic hydrocarbons (PHAHs): possible implications for 
toxicity", doorMartine C. Lans, te verdedigen op dinsdag 17 Oktober, 1995 te Wageningen. 
Creatie 
Uit 'n overrompelende slaap ontwaakt 
in de holen van de nacht. 
De muren suizen. Spiegel die blaakt 
van een geheimzinnig vuren op haar ziel. 
Uit welk heelal? En met welk licht? 
Wat wordt hier al uren verricht? 
Er viel 
iets uit de hoeken naar omlaag. 
De kamer snikt, omdat er traag 
en genadeloos iets uit haar glijdt, 
dat zich genadeloos bevrijdt, 
waarna de lege morgen daagt. 
Gerrit Achterberg (1905-1986) 
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CHAPTER 1 
General introduction 
General introduction 
Over the past decades extensive research was performed to elucidate the toxic 
mechanism of polychlorinated dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs) and 
biphenyls (PCBs). These compounds belong to the class of polyhalogenated aromatic 
hydrocarbons (PHAHs) and cause a broad range of toxic effects in different species, eg. 
dermal, immuno- and hepato-toxicity, carcinogenic, teratogenic, neurobehavioural and 
endocrine effects as well as diverse biochemical responses, like the induction of several 
drug metabolizing enzymes (for reviews see: Ahlborg et al., 1992, Safe, 1994, 1992, 
1990, Van den Berg et al, 1994, Peterson et al, 1993, McConnell, 1980, Brouwer et 
al, 1995). 
A common mechanism of action, the Ah-receptor pathway, has already been 
described in detail (Poland and Knutson, 1982). The interaction of PHAHs with this Ah-
receptor can result in induced expression of numerous Ah-receptor responsive genes, 
which may result in the observed toxic effects. In addition, effects of PHAHs have 
recently been described that may not be directly mediated through the Ah-receptor 
pathway (Ahlborg et al., 1992; Brouwer, 1991). Among the observed effects of PHAHs 
were changes in endocrine systems, essential for many physiological functions. In this 
thesis particular emphasis will be put on the interference of PHAHs and especially their 
hydroxylated metabolites with the thyroid hormone endocrine system. 
Polyhalogenated aromatic hydrocarbons: 
PCDDs, PCDFs and PCBs 
Sources and structures 
As early as in the 1960s PCBs were discovered in environmental samples (Jensen et al, 
1966) and diverse wildlife species like cormorants (Koeman et al., 1969). Since then 
numerous studies reported the occurrence of PCDDs, PCDFs and PCBs in the global 
environment including air, water, sediments, fish, wildlife and human tissues (McFarland 
and Clarke, 1989, Rappe and Buser, 1989, Duinker et al., 1989, Kannan et al, 1989). 
Long range atmospheric and oceanic transport are important pathways of global 
(re)distribution of PHAHs (Tanabe and Tatsukawa, 1986), leading to the ubiquitous 
presence throughout the world, including Arctic and Antarctic ecosystems (Norstrom et 
al., 1990). 
PCDDs and PCDFs are entering the environment mainly as unwanted persistent 
byproducts in industrial chemicals like chlorophenols, chlorophenoxy-herbicides and 
PCBs that are still in use (Rappe et al., 1991) and by combustion processes of 
chlorinated organic- or inorganic compounds in municipal or hospital waste incinerators 
and car engines (Hutzinger and Fiedler, 1989). The wide spread presence of PCDDs and 
PCDFs in environment and foodstuffs for human consumption, like cow's milk, led to 
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strict regulations on the emission of PCDDs and PCDFs from municipal and chemical 
waste incinerators in the Netherlands. Unlike PCDDs and PCDFs, PCBs mixtures have 
been commercially produced and used for industrial purposes from the early 1930s. The 
intrinsic properties that made PCBs suitable for the use in transformers and capacitors, 
eg. inflammability, chemical stability and dielectric properties, simultaneously led to the 
bioaccumulation through the foodchain of these persistent lipophilic compounds to high 
and sustained levels in top-predators like humans, sea-mammals, fish eating birds 
(McFarland and Clarke, 1989). The bioaccumulation and long half life of certain PCBs 
and simultaneously growing knowledge on their potential toxicity, resulted in the ban of 
production of PCBs in the early eighties. 
However, it is estimated that two-thirds of PCBs produced worldwide are still in 
use or entering the environment through leakage from closed systems and disposal of 
PCB-contaminated materials so their environmental levels are unlikely to decline fast in 
the near future (Loganathan and Kannan, 1994). In addition to the industrialized 
countries in Europe, North America and Japan, PCBs are also detected in food for 
human consumption in developing countries. Nevertheless, declines in PCB levels were 
documented in environmental compartments, like some foods for human consumption, 
human adipose tissue, shellfish and various fish species especially between the late 
1970s and the mid-1980s. These declines are expected to continue but at much slower 
rates (Fensterheim, 1993). Still, the main source of human exposure to PHAHs is via the 
diet. 
All PCDD, PCDF and PCB structures consist of two halogenated phenylrings, 
with resp. 75, 135 and 209 possible congeners dependent on the degree and place of 
chlorine substituents (Fig. 1). PCDDs and PCDFs are rigid planar structures, while the 
two phenyl rings of the PCBs can rotate along the central C-C bond. 
5 6 6' 5' 
PCDD 
3 2 2' 3' 
PCB 
PCDF 
Figure 1 Structure and ring positions of PCDD (polychlorodibenzo-pa/-a-dioxin), PCDF 
(polychlorodibenzofuran) and PCB (polychlorobiphenyl). o = ortho, m=meta, p=para. 
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Non-o/t/io-substituted PCBs can adapt a planar conformation and have a 3-methyl-
cholantrene (3-MC) type of induction of biotransformation enzymes, like cytochrome 
P450 1A1 and 1A2 isoenzymes. Orf/jo-substituted PCB congeners with chlorine 
substituents on two or more orffto-positions may preferably adapt a non-planar confor-
mation and consequently are phenobarbital (PB) type of inducers of biotransformation 
enzymes, like cytochrome P450 2B isoenzymes. Mono-ortho substituted PCBs can adapt 
both co-planar and non-planar conformations (mixed-type inducer). The non-planarity of 
PCBs is dependent on the degree of chlorine substituents on the orrto-positions of the 
phenylrings; the more ortfto-chlorine substituents the lower the possibility to adopt a 
planar conformation. 
Metabolism of PCBs, PCDFs and PCDDs takes place mainly by cytochrome 
P450 mediated oxidation, preferentially on the lateral positions. This oxidation is 
mediated through an arene-oxide intermediate which can spontaneously rearrange to a 
phenolic metabolite or readily react with glutathione to form a sulfur-containing 
metabolite. In addition a concommitant shift (NIH-shift) is possible of chlorine 
substituents from the site of hydroxylation to the next neighbour carbon atom in the 
aromatic ring. The presence of 2 vicinal unsubstituted carbon atoms greatly facilitates 
metabolic hydroxylation (Safe, 1989). The hydroxylated metabolites can further be con-
jugated to glucuronic acid or sulfate, facilitating excretion in urine, bile and faeces. 
Subsequently the sulfur-containing metabolites can be further metabolised to methyl-
sulphone-metabolites via the mercapturic acid pathway (Safe, 1989, Bakke et al., 1982). 
In the environment, PCDDs and PCDFs that are at least 2,3,7,8-substituted are 
the most persistent and slowest metabolisable PCDD/F congeners due to the lateral 
chlorine substitutions and consequently are selectively retained and bioaccumulated in 
the foodchain (Van den Berg et al., 1994, Tulp and Hutzinger, 1978). The relative con-
centrations of the 2,3,7,8-substituted PCDD or PCDF congeners in biota increase with 
increasing chlorination. 
Metabolism of PCB congeners is slow when they have no adjacent unsubstituted 
carbon atoms on at least one of the rings, chloro-substituents on the lateral positions and 
increasing number of chloro-substituents (Safe, 1989). This results in the presence of 
non-planar, di-ortho substituted 2,2',4,4',5,5'-hexaCB, 2,2',3,4,4',5'-hexaCB and 
2,2',3,4,4',5,5'-heptaCB in most species in the ecosystem. The bioaccumulation through 
the foodchain of individual PCB isomers may depend on the species, their exposure 
situation or dietary intake and the ability of PCB metabolism (Sipes and Schnellman, 
1987, Murk et al, 1994). This results in specific PHAH congener patterns in the species 
of various trophic levels that are different from PCB congener patterns present in 
commercial PCB mixtures. The ease of metabolism of PCBs seems to decrease in the 
order terrestrial mammals > marine mammals > birds > fish (Safe, 1989, Tanabe et al;., 
1987, 1988). Coplanar non- and mono-ortho PCB congeners were detected in relatively 
high levels in shell-fish, fish and marine mammals (McFarland and Clarke, 1989; 
Kannan et al., 1989). In terrestrial mammals, including humans, di-ortho PCB congeners 
concentrations were relatively high compared to non-and mono-ortho PCB congeners. In 
both marine and terrestrial mammals, nearly equal PCDD and PCDF concentrations 
were detected (Kannan et al., 1989). 
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Toxicity and mechanisms of action. 
In animal species PHAHs can cause thymic atrophy, immunotoxicity , hepatotoxicity 
and porphyria, reproductive and developmental toxicity, endocrine responses, tissue 
specific hypo- and hyper-plastic responses and carcinogenesis. In humans and primates 
PHAH exposure can also cause chloracne and related dermal lesions (McConnell et al., 
1989). Risk assessment of PHAH exposure for humans has been focused on the 
potential carcinogenity of these compounds, since carcinogenic effects of TCDD were 
observed in experimental studies (Kociba et al, 1978). In addition PHAHs were 
suggested to act as human carcinogens after occupational exposure or in the Yu-cheng 
incident in Taiwan, the Yusho incident in Japan or the Seveso incident in Italy although 
no conclusive evidence has been obtained (Safe, 1994). 
However, recently observed effects of low levels of PHAHs on immune system 
function (Neubert et al., 1992) and behavioural and reproductive development of 
perinatally exposed animals and human infants (Brouwer et al, 1995, Peterson, 1993) 
has led to the re-evaluation of the risk assesment of TCDD and related compounds in 
the US (EPA report) and the Netherlands. Two Dutch human studies revealed decreased 
birth weights, changes in the thyroid hormone endocrine system and effects on 
neurological development in perinatally exposed children from mothers with background 
body burdens of PCDDs, PCDFs and PCBs (Koopman-Esseboom et al, 1994, Pluim et 
al., 1993). In addition, in children from mothers exposed to relatively high dietary levels 
of PCBs, PCDDs or PCDFs, defects in cognitive and neuromotor functions were found 
(Jacobson et al, 1985, 1990, Rogan et al, 1988). 
Developmental toxicity and changes in neurochemistry and endocrine systems, 
like thyroid hormones, have also been found in experimental animals (Peterson, 1993, 
Tilson et al, 1990, Morse, 1995). Recently disturbances in thyroid hormones after 
exposure to PCBs, led to increased sperm production and testes size in rats (Stone, 
1995). In wildlife species exposed to PHAHs, like seals and cormorants, effects on 
plasma thyroid hormone levels were found (Brouwer, 1991), while seals also showed 
impaired reproduction and immune system functions possibly related to PHAH exposure 
(Reynders, 1986, De Swart, 1995). 
Ah-receptor pathway and Ah-receptor mediated toxicity 
A majority of the toxic and biochemical effects of PHAHs are explained by a single 
mechanism of action, the arylhydrocarbon (Ah) receptor pathway (Poland and Knutson, 
1982). The compounds acting through this Ah-receptor mediated pathway are the planar 
laterally substituted 2,3,7,8-PCDDs and PCDFs, with 2,3,7,8-TCDD as the most potent 
congener, and related coplanar and mono-ortho substituted PCB isomers. The Ah-
receptor (AhR) is present in cytosol as a complex with the chaperone protein hsp90, 
which dissociates when a ligand binds to the Ah-receptor. Subsequently the ligand-Ah-
receptor complex is translocated to the nucleus by the Ah-receptor nuclear translocator 
(Arnt) protein. In the nucleus the ligand-AhR-Arnt complex binds selectively to dioxin-
responsive elements (DRE) on the DNA. This interaction induces expression of DRE-
regulated genes, like the marker gene CYP1A1, which causes an increased expression of 
cytochrome P450 1A1 mRNA and protein, a phase 1 biotransformation enzyme. 
Likewise expression of other genes under control of the Ah-receptor pathway can be 
induced after activation by TCDD, such as CYP1A2 and phase 2 biotransformation 
enzymes like UDP-glucuronyltransferase I and glutathion-S-transferase n (Sutter and 
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Greenlee, 1992). Recently, mice lacking the Ah-receptor by knocking out the gene 
encoding the receptor protein were found to suffer severe liver damage and decreased 
immune function, suggesting that the Ah-receptor may play a physiological role in the 
development of the liver and immune system (Fernandez et al., 1995). 
The induction of the cytochrome P450 1A1 isoenzyme, which can be measured 
by deethylation of the model substrate ethoxyresorufin (EROD-activity), and the Ah-
receptor binding affinity show a good correlation with certain toxic effects, like thymic 
atrophy, hepatotoxicity and body weight reduction, for a broad range of PCDD, PCDF 
and PCB congeners. Therefore a toxic equivalency factor (TEF) concept for Ah-
receptor-mediated effects based on additivity could be developed, which allows the 
expression of the toxic potency of a complex mixture into one toxic equivalency (TEQ) 
value, relative to the potency of TCDD, the most toxic congener (Safe, 1990). TEF 
values of individual toxic PCDD, PCDF and PCB congeners were set internationally 
(Ahlborg et al., 1994, Nato/CCMS, 1988). 
However, antagonistic or synergistic effects of combined exposures of specific 
PCB congeners and TCDD indicated that the additivity of the TEF concept may under-
or overestimate toxic effects of complex PHAH mixtures (Van Birgelen et al. 1994a,b, 
Bannister et al., 1987, Leece et al., 1987). Neurobehavioural, neurochemical and 
carcinogenic effects and endocrinological changes were found in experimental animals 
after exposure to planar PHAHs, suggesting these may be Ah-receptor mediated effects. 
Yet exposure to non-planar mono-ortho and di-ortho PCB congeners, PCB metabolites 
and PCB mixtures can also result in comparable classes of effects (for review see: 
Ahlborg et al., 1994, Brouwer et al., 1995). These findings make the use of the TEF 
concept for risk assesment of PHAHs for specific endpoints like reproductive and 
developmental toxicity and endocrine disturbances difficult. 
Effects of PHAHs that may not be Ah-receptor mediated 
Recently more attention is paid to effects of PHAHs that may not directly be mediated 
by the Ah-receptor pathway. Non-planar PCBs can cause various toxic effects. For 
instance, neurological disturbances are found in non-human primates after exposure to 
Aroclor 1016, a PCB mixture that contains low-chlorinated di-ortho substituted PCB 
isomers (Schantz and Bowman, 1989) while mainly changes in dopamine concentrations 
were found in rats and primates exposed to Aroclor 1016 (Seegal, 1992). In experimen-
tal animals both coplanar and nonplanar PCB isomers can be tumour promotors 
(Silberhorn et al., 1990, Sargent et al., 1992). Especially 2,2',4,4',5,5'-hexaCB, a PB 
type PCB, has been described as a potent tumour promoting agent by Buchmann et al. 
(1986, 1991). So carcinogenic effects of PCBs cannot be solely explained by Ah-
receptor mechanisms of action. Changes in vitamin K dependent blood coagulation are 
described in rats exposed to either 2,2',4,4',5,5-hexaCB or TCDD, again suggesting a 
not strictly Ah-receptor mediated pathway (Bouwman et al., 1990). 
In general biotransformation of xenobiotics lead to detoxification and enhanced 
excretion, PHAH metabolites, however, are described to own specific biological 
activities. Although the Ah-receptor mediated induction of CYPlal/2 can be necessary 
for the formation of hydroxylated and methylsulphone metabolites, these metabolites 
may cause non-Ah-receptor mediated responses. Methylsulphone PCB metabolites can 
accumulate in adrenals and lungs and binds to specific endogenous proteins, eg. renal 
and urinary alpha2u-globulin and intestinal fatty acid binding protein (Larsen et al., 
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1992, 1994). Furthermore these metabolites can also alter AHH activity in vitro and in 
vivo and strongly induce PB-type biotransformation enzymes in rats (Kato et al., 1995). 
A hydroxylated 3,3',4,4'-tetraCB metabolite, 4-OH-3,3',4',5-tetraCB, was 
described to interact with transthyretin (TTR), the major plasma thyroid hormone 
transport protein, in rats. This led to decreased plasma thyroid hormone, retinol and 
retinol-binding protein (RBP) levels (Brouwer and van den Berg, 1986) through 
displacement of T4 from TTR and disruption of the TTR-RBP complex by the binding 
of 4-OH-3,3',4',5-tetraCB metabolite to TTR (Brouwer, 1987). 
Thyroid hormone endocrine system and effects of PHAHs. 
Disruption of the thyroid endocrine system after exposure to PHAHs has been found in 
several species, including experimental animals, wildlife species, like seal (Brouwer et 
al.,1989, Brouwer 1991), and man (Koopman-Esseboom et al., 1994, Pluim et al., 
1993). Changes in thyroid hormone homeostasis can also be caused by Ah-receptor 
mediated changes in thyroid hormone excretion after exposure to PCBs, PCDFs and 
PCDDs. However, hydroxylated PCB metabolites may also have an effect on thyroid 
hormone transport, thereby decreasing plasma thyroid hormone levels.In the following 
paragraphs thyroid hormone synthesis and function, metabolism and plasma transport 
and the effects of PHAHs on the thyroid hormone system are described in more detail. 
Synthesis and function of thyroid hormones 
Thyroid hormones, also known as iodothyronines, play an important role in cellular 
metabolic processes and growth, differentiation and development processes of ver-
tebrates like the development of the brain and central nervous system (for review see: 
Legrand, 1986). Thyroid hormones are synthesized in the follicular cells of the thyroid 
gland. In mammals the thyroid mainly secretes 3,3',5,5'-tetraiodo-L-thyronine 
(thyroxine, T4, fig. 2), which is regarded as a prohormone since it has relatively low 
bioactivity (Chopra, 1991). Less than 20 % of the circulating 3,3',5-triiodo-L-thyronine 
(T3, fig. 2), e.g. the bioactive hormone, is produced by the thyroid. The majority of T3 
present in the blood is mainly generated by mono-deiodination of T4 in liver and kidney. 
Local conversion of T4 to T3 is also found in other extrathyroidal tissues like brain, 
pituitary and brown adipose tissue. 
Genomic mechanisms of thyroid hormone action resemble steroid hormone 
action. The free T3 hormone is the physiologically active thyroid hormone and is 
transported to the nucleus where it acts at the transcriptional level through binding to 
nuclear T3 receptor (TR) (Oppenheimer and Schwartz, 1986, Oppenheimer, 1991). The 
binding affinity of T4 for TR is 10 times lower than the binding affity of T3 for TR. 
There are several different TRs which are products of C-erbA proto oncogenes (Wei-
nberger et al., 1986, Sap et al, 1986). The T3-TR complex binds to specific genetic 
sequences on the DNA, the thyroid hormone responsive elements (TRE), resulting in 
expression of thyroid hormone responsive genes. 
Non-genomic mechanisms of action of thyroid hormones, like the interaction with 
plasma membranes, mitochondrial membranes and cytoplasmatic proteins are described 
by Davis (1991) and Segal and Ingbar (1986). 
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Figure 2 Structures of 3,3',5,5'-tetraiodo-L-thyronine (thyroxine, T4) and 3,3',5-triiodo-L-
thyronine (T3) 
The thyroid hormone levels in blood are not only dependent on the rate of 
synthesis but also on the rate of excretion from the circulation. Reduced levels of 
circulating thyroid hormones or the release of thyrotropin releasing hormone (TRH) by 
the hypothalamus can induce the release of thyroid stimulating hormone (TSH) into the 
blood by the pituitary gland, successively leading to increased thyroid hormone synthesis 
and secretion in blood by the thyroid gland (Taurog, 1991). 
Metabolism of thyroid hormones 
Thyroid hormones can be metabolized through various pathways in several organs and 
tissues (for review see: Kohrle et al., 1991). These metabolic processes have a role in 
control of hormonal activity by regulating the amount and form of thyroid hormone 
present in the cell. The mechanisms of deiodination and conjugation of thyroid hor-
mones wil be described in more detail. 
Thyroid hormone deiodination 
As stated before, mono-deiodination of the phenolic ring (outer ring deiodination 
(ORD)) of T4 is necessary for production of the majority of bioactive T3 present in the 
body (Leonard and Visser, 1986). However, deiodination of the tyrosyl ring of T4 (inner 
ring deiodination (IRD)) results in the inactive reverse T3 (3,3',5'-triiodothyronine, rT3). 
All other forms of thyroid hormone metabolism, like further deiodination of T3 to T2, 
lead to inactivation of the thyroid hormones. 
At least three iodothyronine deiodinases are present in mammals, mainly as 
membrane associated proteins, located in the tissue micosomal fraction. They require 
sulfhydryl cofactors, like dithiotreitol for their catalytic activity in vitro. However, these 
enzymes show clear differences in iodothyronine substrate specificity, tissue distribution 
and amount of cofactor required. Furthermore they are dissimilar in susceptibility to 
inhibitors and regulation by thyroid hormone status. Type 1 iodothyronine deiodinase 
(ID-I) is abundantly present in liver, kidney and thyroid, and capable of both ORD and 
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IRD. This enzyme is important for both production of plasma T3 and clearance of 
plasma rT3. Type 2 deiodinase (ID-II), mainly present in pituitary, brown adipose tissue 
and the central nervous system (neurons of cerebral cortex and cerebellum), only 
deiodinates the outer ring (ORD) of T4, and therefore plays a role in the local production 
of T3. Type 3 deiodinase (ID-HI) can only deiodinate the inner ring, and thus inactivates 
T4 by rT3 production in the central nervous system (glial cells of cerebral cortex, 
placenta, skin, fetal rat intestine and chick embryo liver). Rat and human hepatic ID-I 
deiodination and rat and human placental ID-II and ID-III deiodination seem to be 
strikingly similar. During a hypothyroid status, ID-I activity is decreased while ID-II 
activity is increased, suggesting a regulation to maintain constant T3 levels in tissues 
(Kaplan, 1986). 
Thyroid hormone conjugation 
Another important pathway in the metabolism of thyroid hormones is conjugation of the 
phenolic hydroxyl group with glucuronic acid (UDPGA) or sulfate, both so-called phase-
II biotransformation reactions (Burger, 1986, Kohrle et al., 1991). Glucuronidation of 
thyroid hormones by UDP-glucuronyltransferases (UGTs) is mainly found in the 
microsomal fractions of liver, but also of kidney, intestines and other tissues. 
UGTs can be induced by a broad range of xenobiotics or endogenous com-
pounds, in order to increase elimination of these compounds in bile, faeces and urine. T4 
and rT3 appear to be glucuronidated by the 3-methylcholantrene inducible p-nitrophenol-
UGT and the clofibrate inducible bilirubin-UGT isoenzymes, while T3 is glucuronidated 
by the androsterone-UGT isoenzyme in rat liver (Beetstra et al., 1991, Visser et al., 
1993). The produced inactive glucuronides (T4G and T3G) are better water soluble and 
subsequently excreted in bile. 
Plasma thyroid hormone transport 
The majority of thyroid hormones present in blood of mammals are non-covalently 
bound to specific transport proteins (for reviews see Robbins, 1991, Robbins and 
Bartalena, 1986). These proteins function as a circulating reservoir of thyroid hormones 
to buffer sudden changes in thyroid hormone levels and to avoid high levels of free 
thyroid hormones in circulation, which are considered to be directly available to tissues 
and organs. The main thyroid hormone carrier proteins in man are thyroxine-binding 
globulin (TBG), transthyretin (TTR) and albumin, while in rat mainly TTR and albumin 
are present. 
TTR was formerly known as prealbumin due to its ability to migrate faster than 
serum albumin on gel-electrophoresis of whole plasma. TTR has a molecular weight of 
55000 D, and is composed of four identical polypeptide chains, each of 127 amino acid 
residues. Not only the complete amino acid sequence of TTR is known (Kanda et al., 
1974), but also its full three-dimensional structure has been resolved by X-ray crystal-
lography (Blake et al., 1978). Only one molecule of T4 binds to TTR with high affinity 
(107-108 M"1), while the second binding site has a ten to hundred fold lower affinity for 
T4 (106 M"1) due to negative cooperativity (De la Paz et al., 1992). TTR is important not 
only for the TRANSport of THYroxine, but also of RETINol through the co-transpor-
tation of retinol binding protein (RBP). The interaction of TTR with T4 appears not to 
be affected by binding of the retinol-RBP complex (Robbins et al., 1978, Raz and 
Goodman, 1969). The precise binding site of RBP on TTR is not known yet, although 
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recent studies suggest the interference of the He 84 amino acid residue located on the 
outside of the TTR molecule in RBP binding (Berni et al, 1994). 
TTR is a highly conservative plasma protein and present in plasma of most 
mammalian species and birds, and in reptiles at very low concentrations but is absent in 
bloodplasma of fish and amphibians (Larsson et al., 1985, Schreiber et al., 1993). TTR 
is synthesized mainly in liver (Dickson et al., 1985). Secretion of TTR from liver to 
blood is not dependent on thyroid hormone binding (Robbins and Bartalena, 1986). 
Degradation of TTR takes place in the liver, muscle and skin (Makover et al., 1988). 
TTR has a higher production and disappearance rate that TBG, resulting in a half-live in 
plasma of 1-2 days. 
In addition TTR is synthesized in the visceral yolk sac (Soprano et al., 1985) and 
choroid plexus of the brain (Kato et al, 1986, Harms et al., 1991), even at a very early 
stage in development of rats (Thomas et al., 1988). High levels of mRNA coding for 
TTR were found in the choroid plexus of rats and humans (Schreiber et al., 1990). TTR 
gene expression was alo detected in choroid plexus of reptiles, but not in liver, in-
dicating that the expression of TTR in choroid plexus appeared earlier in evolution than 
TTR expression in liver (Richardson et al, 1994, Harms et al., 1991). 
Most T4 in CSF is bound to this locally synthesized TTR which does not appear 
to reach circulation (Schreiber, 1987). It was suggested that TTR played a role in the 
transport of T4 from blood to the brain through the blood-CSF barrier. However, recent 
studies suggest that T4 is transported to the brain primarily through the blood brain 
barrier and not via the choroid plexus (Blay et al., 1993). Moreover, the T4 transport to 
CSF takes place not through TTR binding, but depends on free T4 levels (Van Raay, 
1994; Chanoine et al, 1992). 
TBG is a high affinity, low-capacity T4 transport protein, synthesized in the liver 
of some higher mammals, inculding man. It has a molecular weight of 54000 D 
(Robbins and Bartalena, 1986) and is an acidic glycoprotein consisting of a single 
polypeptide chain with one thyroid hormone binding site per molecule (Korcek and 
Tabachnik 1976). TTR and TBG have different T4 binding properties; in human plasma 
TBG transports a higher percentage of T4 (50-80 %) than TTR (10-40 %) (Petterson, 
1989, Larsson et al., 1985). Despite the low serum concentration TBG (15 mg/1) carries 
the bulk of the thyroid hormones in humans because of its high affinity for these com-
pounds. TTR, with a 20 fold higher concentration than TBG in human plasma (300 
mg/1), has a 100 fold lower thyroid hormone binding affinity and acts as a secondary 
carrier protein in man, but as the primary carrier protein in rodents. Not only humans 
but also rats and mice possess TBG, which is very similar to their human counterpart. 
The rodent TBG was recognized only recently because it is a dramatically development-
regulated protein, highly expressed during post-natal growth but virtually undetectable in 
adults except in hypothyroidal state (Rouaze-Romet et al., 1992, Savu et al., 1989, 
Vranckx et al., 1990). The total absence of TBG in some individuals due to genetic 
polymorphism, constitutes evidence that TBG does not play an essential role in thyroid 
hormone action. No genetic polymorphism resulting in the absence of TTR is described 
in mammalian species, suggesting that TTR may be important during development 
(Robbins and Bartalena, 1986). However, recently produced transgenic mice lacking the 
TTR gene, showed normal development and reproduction, although the levels of thyroid 
hormones, retinol and RBP were low (Episkopou et al., 1993). 
Albumin carries a relatively small portion of thyroid hormones (10-20 %) due to 
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the low binding affinity, despite high serum concentrations. Other T4 binding plasma 
proteins, apo-lipoprotein apoA-1, apoB and apoE, were recently described by Benvenga 
et al. (1989, 1993). 
Effects of PHAHs on thyroid hormone homeostasis in man and 
experimental animals 
Changes in plasma thyroid hormone levels 
The thyroid hormone endocrine system can be disrupted by exposure to PHAHs in 
diverse species, including experimental animals and man. In pregnant women exposed to 
background PHAH levels a negative correlation between the levels of PCDD/F and PCB 
congeners in human milk and plasma thyroid hormone levels was found. In the newborn 
infants higher plasma TSH levels were detected when they were exposed to relatively 
high PCDD/F and PCB concentrations through maternal body burden (Sauer et al., 
1994, Koopman-Esseboom et al., 1994). In addition, increases in plasma TSH and T4 
levels in newborn babies exposed to increasing levels of PCDD/Fs were reported by 
Pluim et al. (1992). Changes in human serum T4 levels following occupational or 
accidental exposure to high levels of PCBs or polybrominated biphenyls (PBBs) were 
found by Emmett et al. (1988), Murai et al. (1987), Bahn et al. (1980) and Kreiss et al. 
(1982). 
In experimental animals, like rats or mice, disruption of the thyroid hormone 
endocrine system was found after exposure to different PHAHs. Exposure to TCDD 
resulted in reduced plasma T4 levels while plasma T3 levels were reported to be 
increased, unchanged or decreased after TCDD exposure (Bastomsky, 1977, Potter et al., 
1983, Lans et al, 1990, Potter et al, 1986, Roth et al, 1988, Jones et al, 1987, Henry 
and Gasiewicz, 1986, 1987, Pohjanvirta et al, 1989, Pazdernik and Rozman, 1985). 
These contradicting effects on plasma thyroid hormones after TCDD exposure, did not 
give clear evidence on the thyroid status of the exposed animals. In turn thyroid 
hormone status may modulate TCDD toxicity in rodents as was described by Rozman et 
al. (1984, 1985, 1987), Pazdernik and Rozman (1985) and Lamb IV et al. (1986). 
Thyroidectomized rats exposed to TCDD seemed to be partly protected for loss of body 
weight when compared to TCDD exposed non-thyroidectomized rats. 
Analogous to TCDD, several individual PCB congeners can decrease plasma T4 
levels in rodents, like 3,3',4,4'-tetraCB (TCB) (Brouwer, 1989; Murk et al, 1991), 
3,3',4,4',5,5'-hexaCB (Morse et al, 1993a), 2,3,3',4,4',5-hexaCB (Van Birgelen et al, 
1994a) 3,3',4,4',5-pentaCB (Van Birgelen et al, 1994b) and 3,3',4,4',5,5'-
hexabromobiphenyl (Spear et al, 1994). In primates, eg. marmoset monkeys, exposure 
to TCB caused hypothyroidism (Van den Berg et al, 1988). Commercial PCB mixtures 
like Aroclor 1254 also strongly decreased plasma T4 levels in rodents (Gray et al, 1993; 
Byrne et al, 1987, Murk et al, 1991) while plasma T3 levels were not decreased 
(Brouwer, 1989; Bastomsky, 1974; Beetstra et al, 1991). Commercial PBB mixtures 
decreased serum T3 and T4 levels and the rate of T4 production in rats leading to 
hypothyroidism (Byrne et al, 1987) that was also observed in mice after exposure to a 
PBB mixture (Gupta et al, 1983). 
The observed changes in plasma thyroid hormone levels after exposure to 
PHAHs have been explained by different mechanisms, eg. impaired thyroid gland 
function, changes in thyroid hormone metabolism and possible disturbed plasma 
transport of thyroid hormones. 
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Changes in thyroid gland function and morphology 
Direct effects of PHAHs on thyroid gland function may result in disturbed plasma 
thyroid hormone levels. On the contrary, disturbed thyroid gland structure and function 
by PHAH exposure may be caused by changes in plasma thyroid hormone levels, 
leading to a feedback stimulation of the thyroid gland. A possible increase in incidence 
of thyroid cancer in women exposed to high levels of TCDD during the Seveso accident 
(Bertazzi et al., 1989, Pesatori et al., 1993) and histological changes in the thyroid of 
TCDD treated rats could be interpreted as sustained thyroid activation, probably due to 
lowered plasma T4 levels (Gupta et al. 1973; Rozman et al, 1986). Pups from pregnant 
rats exposed to the PCB congener 2,3',4,4',5-pentaCB showed histological changes in 
the thyroid suggestive of sustained TSH elevation (Ness et al., 1993) while another 
individual PCB congener, 3,3',4,4',5-pentaCB, caused mild thyroid alterations in rats 
(Chu et al, 1994). Likewise, effects on thyroid function and morphology in adult, 
perinatal and Gunn rats and adult cynomolgus monkeys by Aroclor 1254 exposure are 
described by Collins and Capen (1980a,b,c), Collins et al. (1977), Sepkovic and Byrne 
(1984), Capen and Martin (1989) and Tryphonas et al. (1984). Aroclor 1254 and a PBB 
mixture caused ultrastructural lesions in thyroid follicular cells which appeared to 
interfere with synthesis and secretion of T4 (Kasza et al., 1978). The ultrastructural and 
functional alterations of rat thyroid glands after Aroclor 1254 exposure were dissimilar 
to thyroid gland alterations found after iodide excess and deficiency and thyrotropin or 
thyroxine administration (Collins and Capen, 1980c), suggesting an additional or specific 
effect of Aroclor 1254 exposure. 
Changes in thyroid hormone metabolism 
Changes in thyroid hormone metabolism are also suggested to lead to the observed 
decreased plasma T4 levels after PHAH exposure. Increase in T„ excretion by TCDD 
was caused by the induction of T4-UGT activity, an Ah-receptor mediated pathway 
(Beetstra et al., 1991; Lucier et al, 1975, Sutter and Greenlee, 1992, Van den heuvel 
and Lucier, 1994). TCDD can induce phenol-UGT activities in the rat towards p-
nitrophenol (Rozman et al., 1985b, 1987), 1-naphtol (Eltom et al, 1992) and T4 (Henry 
and Gasiewicz, 1987) and highly induce phenol-UGT mRNA levels in rat liver (Munzel 
et al., 1994). However, TCDD did not or weakly induce the UGT activity towards 
bilirubin, testosterone or estrone as substrates (Visser et al., 1993; Umbreit et al, 1989, 
Lucier et al, 1975), resulting in increased T4 glucuronidation, but no change in T3-
glucuronidation. These findings agree with the early observations of Bastomsky (1977), 
who found an increase in biliary excretion of T4 (mostly T4-glucuronide) but not T3. 
T4 glucuronidation is also induced after exposure to other individual halogenated 
biphenyl congeners, like hexachlorobenzene (HCB) (Van Raay et al, 1993), TCB 
(Visser et al, 1993), 3,3',4,4',5,5'-hexabromobiphenyl (Spear et al, 1990) and 
3,3',4,4',5,5'-hexaCB (Morse et al, 1993), compounds which simultaneously decrease 
plasma T4 levels. In addition exposure to commercial PCB mixtures like Aroclor 1254 
and Kanechlor 400 increased T4 glucuronidation and bile flow in rats (Bastomsky, 1974; 
Beetstra et al, 1991; Saito et al, 1991; Bastomsky and Murthy, 1976; Barter and 
Klaassen, 1992, 1994). 
Another enzyme involved in thyroid hormone metabolism, hepatic ID-1, was 
inhibited in rats in vivo following treatment of rats with several Ah-receptor agonists, 
such as 3-methylcholantrene, TCB and TCDD (Visser et al, 1993; Eltom et al, 1992; 
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Rickenbacher et al., 1986, Adams et al., 1990). Hydroxylated TCB metabolites could 
also inhibit ID-1 activity in vitro using rat hepatic microsomes (Adams et al., 1990, 
Rickenbacher et al., 1989). Furthermore brain ID-II activity was increased in fetal and 
neonatal rats exposed to 3,3',4,4',5,5'-hexaCB, which had severely reduced plasma T4 
levels, probably to compensate and maintain T3 levels in brain (Morse et al., 1993a). 
Changes in thyroid hormone transport 
Effects of PHAH exposure on plasma transport of thyroid hormones leading to altered 
plasma thyroid hormone levels, were already described by Bastomsky (1974). He 
proposed a possible reduction of thyroid hormone binding to plasma proteins in Aroclor 
1254 exposed rats. Kanechlor 400, another commercial PCB mixture, increased T4 
glucuronidation in rats but still the authors suggested an additional role of disturbed 
plasma T4 transport in the plasma T4 decreases (Saito et al., 1991). Moreover in Gunn 
rats, deficient in UGT activity towards bilirubin, phenolic compounds and T4 (Visser et 
al., 1993), the T4-UGT activity could be induced by Aroclor 1254 to some extent in the 
heterozygous rats but not in the homozygous rats. However, the decreases in plasma T4 
levels were similar in both strains, suggesting an additional interference with plasma 
transport proteins (Collins and Capen, 1980a). Rickenbacher et al. (1986) and McKinney 
et al. (1985) described interactions of PHAHs, like TCDD and 3,3',4,4',5,5'-hexaCB, 
and some hydroxylated metabolites, with thyroxine binding prealbumin (TBPA, 
synonymus to TTR) using in vitro binding studies and graphics modelling studies. 
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Figure 3 Model for interference of thyroxine (T4) and retinol transport in serum after binding of a 
PCB metabolite to transthyretin (TTR), and its effect on T4, retinol and retinol binding protein 
(RBP) levels (Brouwer, 1987). The thin lines represent the normal situation with TTR transpor-
ting T4 and retinol (bound to RBP), the solid and interrupted bold lines represent the interaction 
of the 4-OH-3,3',4',5-tetraCB (4-OH-TCB) metabolite with TTR after exposure of rats to 
3,3',4,4'-tetraCB (TCB) and subsequent predicted effects. MFO: mixed function oxidases, b: 
blockage. 
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Brouwer and Van den Berg (1986), suggested a mechanism based on disturbed plasma 
transport for the decrease in plasma T4 levels in rats exposed to TCB, a coplanar PCB-
congener. A hydroxylated TCB metabolite (4-OH-3,3',4',5-tetraCB) present in plasma 
interacted with TTR in vivo, resulting in the competitive displacement of T4 from TTR. 
In addition the interaction of 4-OH-3,3',4',5-tetraCB with TTR, diminished RBP-TTR 
binding (Brouwer, 1987) which successively led to decreases in plasma RBP and retinol 
(Brouwer and Van den Berg, 1986, Brouwer et ah, 1988). This proposed mechanism 
(Fig. 3) was the basis for the work on the interactions of hydroxylated PHAH 
metabolites with thyroid hormone binding proteins described in this thesis. 
Objectives and approaches 
Objectives 
Based on the interaction of the 4-OH-3,3',4',5-tetraCB metabolite with TTR in serum of 
rats exposed to 3,3',4,4'-tetraCB (Brouwer and van den Berg, 1986, Fig. 3) and the 
structural resemblance of this metabolite with thyroxine (T4), we hypothesized that 
hydroxylated metabolites of related PHAHs could also interact with TTR. Moreover, 
hydroxylated PHAH metabolites may interact with thyroid hormone binding proteins 
other than TTR. Consequently hydroxylated PHAH metabolites may possibly attribute to 
the observed plasma T4 decreases and changes in thyroid hormone metabolism observed 
in experimental animals after PHAH exposure in vivo. 
Approaches 
Structural requirements for binding to TTR by hydroxylated metabolites of PCBs, 
PCDDs and PCDFs and parent compounds were determined using in vitro T4-TTR 
binding competition studies (Chapter 2). Analogous to TTR, binding of hydroxylated 
metabolites of PCBs, PCDDs and PCDFs and parent compounds to other thyroxine 
binding proteins eg. thyroxine-binding globulin (Chapter 3) and type-1-deiodinase 
(Chapter 4) were investigated in vitro and structural requirements for interactions were 
determined. In addition, in vivo animal experiments were carried out to differentiate the 
effects on thyroid hormone metabolism and plasma transport by possible hydroxylated 
metabolites of a complex PCB mixture (Aroclor 1254) (Chapter 5) and the persistent 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Chapter 6). Finally, the exact structural re-
quirements of hydroxylated PCB metabolites for binding to TTR were determined using 
computer assisted graphics modelling and structure analysis of a protein-complex of 
TTR with a hydroxylated PCB metabolite, using X-ray crystallography (Chapter 7). 
CHAPTER 2 
Structure dependent, competitive interaction of hydroxy-
polychlorobiphenyls, -dibenzo-p-dioxins and dibenzofurans 
with human transthyretin 
Abstract 
Previous results from our laboratory indicated specific and competitive interactions of 
hydroxylated metabolites of 3,3',4,4'-tetrachlorobiphenyl with the plasma thyroid 
hormone transport protein, transthyretin (TTR), in rats in vivo and with human TTR in 
vitro. In the present study the structural requirements for competition with thyroxine (T4) 
for TTR-binding were investigated in more detail. Several hydroxylated poly chlorinated 
biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) were tested 
in an in vitro competitive binding assay, using purified human TTR and 125I-T4 as a 
displaceable radioligand. All hydroxylated PCBs, but not the single PCB tested, 
competitively displaced 125I-T4 from TTR with differential potency. The highest 
competitive binding potency was observed for hydroxylated PCB congeners with the 
hydroxygroup substituted on meta or para positions and one or more chlorine atoms 
substituted adjacent to the hydroxy-group on either or both aromatic rings (IC50 range 
6.5 - 25 nM; Ka range: 0.78 - 3.95 * 108 M"1). The relative potency of all meta or para 
hydroxylated PCBs was higher than that of the physiological ligand, T4 (relative potency 
range: 3.5 - 13.6 compared to T4). There were no marked distinctions in TTR-T4 
competitive binding potencies between the ortho- and non-orrto-chlorine substituted 
hydroxy-PCB congeners tested. Marked differences in TTR-T4 binding competition 
potency were observed between the limited number of hydroxylated PCDDs and PCDFs 
tested. The hydroxy-PCDD/Fs, with chlorine substitution adjacent to the hydroxy-group 
i.e., 7-OH-2,3,8-trichlorodibenzo-/?-dioxin, 2-OH-l,3,7,8-tetrachlorodibenzo-p-dioxin and 
3-OH-2,6,7,8-tetrachlorodibenzofuran, all showed a similar or higher relative binding 
potency, i.e. 1, 4.4 and 4.5 times higher respectively, than T4. No detectable 125I-T4 
displacement was observed with 2-OH-7,8-dichlorodibenzofuran, 8-OH-2,3,4-trichlorodi-
benzofuran and 8-OH-2,3-dichlorodibenzo-p-dioxin, which did not contain chlorine 
substitution adjacent to the OH-group. These results indicate a profound similarity in 
structural requirements for TTR binding between hydroxy-PCB, -PCDD and -PCDF 
metabolites and the physiological ligand, T4, e.g., halogen substitution adjacent to the 
para or meta hydroxy-group, while planarity does not seem to influence the ligand 
binding potency. 
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Introduction 
Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofiirans 
(PCDFs) are ubiquitous environmental pollutants that induce a broad spectrum of toxic 
signs and lesions in animals and man (McConnell, 1980). One aspect of the toxicity of 
these chemicals is their profound effect on thyroid hormone metabolism, which may 
play a role in the onset of certain toxic endpoints, such as the wasting syndrome, 
neurotoxicity and carcinogenicity. 
There are several reports on the interaction of halogenated biphenyls with thyroid 
hormone metabolism. Administration of, for instance, 3,3',4,4'-tetrachlorobiphenyl 
(TCB) (Brouwer and Van den Berg, 1986) and 3,3',4,4',5,5'-hexabromobiphenyl (Spear 
et al., 1990) to rats caused changes in thyroid hormone metabolism and decreased 
plasma thyroxine (T4) levels. In addition, exposure to TCB is known to induce T4, but 
not triiodothyronine (T3) glucuronidation in rats (Beetstra et al., 1991). Exposure of 
marmoset monkeys to TCB caused hypothyroidism in these animals (Van den Berg et 
al, 1988). Rats treated with Aroclor 1254, a commercial PCB mixture, exhibited 
decreased T4 but no changes in T3 levels in serum and increased biliary T4 excretion was 
observed (Bastomsky, 1974). Saito et al. (1991) found that Kanechlor 400 also increased 
T4 glucuronidation in rats. Chronic exposure of rats to commercial PCB and polybromi-
nated biphenyls (PBB) mixtures led to decreases in serum T3 and T4 levels and a 
decrease in the rate of T4 production which led to hypothyroidism (Byrne et al., 1987). 
Commercial PBB mixtures have also been reported to cause hypothyroidism in the 
mouse (Gupta et al, 1983). Moreover, changes in human serum T4 levels following 
exposure to PCBs or PBBs are described in several studies (Emmett et al., 1988; Murai 
et al, 1987; Bahn et al, 1980, Kreiss et al, 1982). 
Other related compounds, such as PCDDs and PCDFs are known to affect 
thyroid hormone metabolism in a similar way. For example, 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) markedly increased the biliary excretion of T4 (Bastomsky, 1977). The 
increase in T4 excretion was most likely due to induction of T4 glucuronyltransferase 
activity by TCDD (Beetsta et al, 1991, Lucier et al., 1975). Administration of TCDD to 
rats resulted in reduced serum T4 levels but unchanged serum T3 levels (Potter et al., 
1983). The induction of T4 glucuronidation by certain PCBs, PCDDs and PCDFs may 
explain, in part, the hypothyroidism induced by these chemicals. 
However, Brouwer and Van den Berg (1986) have reported another possible 
pathway for the interaction of PCBs and related compounds with thyroid hormone 
metabolism. Hydroxylated metabolites of TCB have a marked structural resemblance to 
T4, the natural ligand for transthyretin (TTR), the major thyroid hormone transport 
protein in rat plasma. Due to this resemblance T4 could be specifically displaced from 
TTR by the hydroxylated metabolites, causing a decrease in plasma T4 levels. In the 
blood of rats administered TCB the TCB metabolite 4-OH-3,3',4',5-tetrachlorobiphenyl 
(4-OH-TCB) was identified (Brouwer, 1989). The metabolite exhibited strong binding 
affinity with TTR, thus decreasing in plasma T4 levels. 
Furthermore Rickenbacher et al. (1986) found that both PCBs and hydroxylated 
derivatives of PCBs competitively interacted with TTR, using computer modelling and 
in vitro binding studies. However, in other in vitro TTR-T4 competition studies it was 
shown that only hydroxylated metabolites of TCB, but not the parent compound were 
able to compete with T4 for binding to TTR (Brouwer et al., 1990). Similar results were 
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obtained for halogenated benzenes and their phenolic metabolites (Van den Berg, 1990, 
Den Besten et al., 1991) where it was shown that the presence of a hydroxy-group on 
the parent compound was essential for TTR binding. In contrast, McKinney et al. (1985) 
showed that an adipamide-derivative of TCDD competed with T4 for binding to TTR 
using computer modelling. 
The major objective of the present study was to further investigate the structural 
requirements of hydroxylated PCB, PCDD and PCDF metabolites and a parent com-
pound for interaction with TTR. Various synthetic hydroxylated PCB, PCDD and PCDF 
congeners were used for in vitro competitive binding studies, using purified human 
TTR. Similar biochemical properties of TTR were found in human, rat and other species 
(Larsson et al., 1985; Herbert et al., 1986). In another study rat TTR was compared with 
human TTR and was found to be highly conserved at the binding sites for T4 (Dickson 
et al., 1985). Therefore and for practical reasons we used human TTR as a model 
protein for rats. 
Two different classes of compounds were chosen for this study (Fig. 1), namely 
(i) PCB and PCDD metabolites which have been identified from in vivo studies 
(Klasson-Wehler et al, 1990; Koga et al, 1990, Mason and Safe, 1986) (compounds B, 
C, D, E, I, J, K, P, Q) and (ii) congeners which vary both in their chlorine and hydroxyl 
group substitution patterns (compounds F, G, H, L, M, N, O). The first group of 
compounds (i) contains 2,3,3',4,4'-pentachlorobiphenyl (PeCB 105, A in Fig. 1) and its 
hydroxylated metabolites (B, C and D). This PeCB 105 is a major mono-ortho PCB with 
a relatively high toxicological impact, in addition a hydroxylated metabolite (C) 
appeared to have a selective retention in rat-, polar bear- and seal-blood and is also 
found in human serum samples (Klasson-Wehler et al., 1992). The binding affinities of 
the latter group of compounds (ii) can more accurately define the structural basis for the 
interaction of hydroxylated PCBs, PCDDs and PCDFs with TTR. 
Materials and methods 
Materials 
Radiolabeled L-3',5'-['25I] thyroxine (46 uCi/|ag thyroxine) was purchased from 
Amersham, Buckinghamshire, England and contained 5-10% free iodide, determined by 
Sephadex LH-20 (Pharmacia LKB, Woerden, the Netherlands) gel filtration. TTR 
(human prealbumin, 98% pure) and 3,3',5,5'-L-thyroxine (T4) were obtained from Sigma 
Chemical Company (St. Louis, MO, USA). 
The tested hydroxylated chlorodibenzo-p-dioxins and chlorodibenzofurans (2-OH-7.8-
diCDF (L), 8-OH-2,3,4-triCDF (M), 3-OH-2,6,7,8-tetraCDF (N), 8-OH-2,3-diCDD (O), 
7-OH-2,3,8-triCDD (P) and 2-OH-l,3,7,8-tetraCDD (Q)), shown in Figure 1, were 
synthesized as previously described (Mason and Safe, 1986; Denomme et al., 1985; 
Denomme et al, 1986). 2,3,3',4,4'-Pentachlorobiphenyl (CB 105) (A, Fig. 1) was 
purchased from Promochem GmbH, Wesel, Germany. The hydroxylated PCBs (Fig. 1) 
used in the present study: 2-OH-2',3,3',4,4'-pentaCB (B), 4-OH-2',3,3',4',5-pentaCB 
(C), 5-OH-2',3,3',4,4'-pentaCB* (D), 4-OH-3,3',4'-triCB (E), 4-OH-2,3,3',4'-tetraCB 
(F), 4-OH-2,2',3,3',4'-pentaCB (G), 4,4'-(OH)2-2,3,3',5,5'-pentaCB (H), 4,4'-(OH)2-
3,3',5,5'-tetraCB (I), 4-OH-3,3',4',5,5'-pentaCB (J) and 5-OH-3,3',4,4'-tetraCB* (K) 
were obtained by demethylation of the corresponding methoxy-PCBs (Klasson-Wehler et 
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al., 1990). The methoxy-PCBs were prepared and structures verified as described 
elsewhere (Bergman et al, 1995; Safe and Safe, 1984). 
Methanol (HPLC grade) was obtained from Merck Chemical Company (Darmstadt, 
Germany). Biogel P-6DG desalting gel was obtained from Bio-Rad Laboratories 
(Richmond, CA, USA). 
The numbering of the hydroxy-substituents on the biphenyl does not follow IUPAC 
rules but has been chosen in order to facilitate comparison of the structures. 
••a ^Y^C I ^Y^a 
OH OH OH 
E F G 
OH OH CI a 
a^A^a a^Js^a ck^k^a CK 
:3W" "«:»: 
Ho'-k^o-'^^-a 
Figure 1 Structures of hydroxylated PCBs, PCDDs and PCDFs tested in the TTR-T4 competition 
binding assay and synthesized as described in Materials and Methods. CB 105: 2,3,3',4,4'-
pentaCB (A). Hydroxylated PCBs: 2-OH-2',3,3',4,4'-pentaCB (B), 4-OH-2',3,3',4',5-pentaCB 
(C), 5-OH-2',3,3',4,4'-pentaCB (D), 4-OH-3,3',4'-triCB (E), 4-OH-2,3,3',4'-tetraCB (F), 4-OH-
2,2',3,3',4'-pentaCB (G), 4,4'-(OH)2-2,3,3',5,5'-pentaCB (H), 4,4'-(OH)2-3,3',5,5'-tetraCB (I), 
4-OH-3,3',4',5,5'-pentaCB (J) and 5-OH-3,3',4,4'-tetraCB (K). Hydroxylated PCDDs and 
PCDFs: 2-OH-7,8-diCDF (L), 8-OH-2,3,4-triCDF (M), 3-OH-2,6,7,8-tetraCDF (N), 8-OH-2,3-
diCDD (0), 7-OH-2,3,8-triCDD (P) and 2-OH-1,3,7,8-tetraCDD (Q). 
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In vitro T4 competition-binding assays on TTR 
The gel-filtration procedure as decribed by Somack et al. (1982) with minor modifica-
tions was used for the T4 competition-binding assay. The assay, using human TTR, was 
performed as follows: TTR (30 nM, dissolved in 0.1 M Tris-HCl, 0.1 mM NaCl, 1 mM 
EDTA buffer, pH 8) was incubated with a mixture of 125I-T4 and unlabeled T4 (70.000 
cpm, 55 nM) in Tris-HCl buffer, and competitors (T4, parent or hydroxylated PCBs, 
PCDDs or PCDFs) were added in increasing concentrations (dissolved in methanol, 
volume added was 5 ui). Control incubations were made by adding 5 ul methanol 
instead of competitor. Total 125I-radioactivity added to each of the incubation mixtures 
(200 ul total volume) was checked by gamma-counting (Multi Prias, Packard Instrument 
co., USA). The incubations were allowed to reach binding equilibrium overnight at 4 °C. 
Protein-bound 125I-T4 and free l25I-T4 were separated on 1 ml Biogel P-6DG columns 
(prepared in a 1 ml disposable syringe, equilibrated in Tris-HCl buffer) that were 
equilibrated with 300 |al 10 % (W/V) saccharose-Tris-HCl buffer) and centrifuged for 1 
min at 1000 rpm (100 g) in a precooled centrifuge (Difuge, Hereaus). The columns were 
spin-forced eluted with an additional 200 ul Tris-HCl buffer. The first 2 eluate fractions, 
containing the protein bound ,25I-T4 fraction, were combined; radioactivity was counted 
and compared to the control incubations. Free T„ was bound to the Biogel matrix and 
therefore was not present as a contaminant in the fractions eluted. Competition binding 
curves were made by plotting relative 125I-T4-protein binding (% of control) against 
added log competitor concentration. Competition binding assays with unlabeled T4 were 
used as reference assays to make comparisons between different experiments. 
Analysis of binding data 
Binding characteristics are given as relative potency: the ratio of inhibitor concentration 
at 50 % inhibition (IC50) of OH compounds vs the IC50 of unlabeled T4 [IC50(competi-
tor)/IC50(T4)]. Affinity constant analysis was performed with the Ligand-program 
(obtained from Dr. K.J. van den Berg, MBL-TNO, Rijswijk, the Netherlands) (Munson 
and Rodbard, 1980). 
Statistics 
Data are given as means with standard deviations (S.D.). Significant differences were 
determined by statistical analysis using the Student's t-Test (with a probability value p < 
0.05). 
Results 
CB 105 and its hydroxy-metabolites 
The results in Figure 2 summarize the competitive binding of different hydroxylated 
metabolites of CB 105 (B,C,D) and the parent compound CB 105 (A) using 125I-T4 as 
the displaceable radioligand. The parent compound did not show any interaction with 
TTR, whereas the hydroxylated metabolites all competitively displaced ,25I-T4 from 
TTR. The 2-OH-2',3,3',4,4'-pentaCB metabolite (B) competed with ,25I-T4 for TTR 
binding, but with lower potency than unlabeled T4 (IC50 950 nM and 88.3 nM, respec-
tively). 
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Figure 2 Competitive binding of CB 105 (A) and its hydroxy metabolites (B,C and D), as 
measured by the TTR-T4 competition-binding assay (Materials and Methods). Datapoints are 
mean values of duplicate incubations. Relative 125I-T4-TTR binding (% of control value) is plotted 
against the log concentration (nM) of competitor or T4 added. 
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Figure 3 Competitive binding of non-ortho (E), mono-ortho (F) and di-ortho (G) chlorine 
substituted para-hydroxylated PCBs, as measured by the TTR-T4 competition-binding assay 
(Materials and Methods). Datapoints are mean values of duplicate incubations. Relative 125I-T4-
TTR binding (% of control value) is plotted against log concentration (nM) of competitor or T4 
added. 
Chapter 2 29 
Table 1 Competitive 125I-T„-TTR binding inhibition concentrations (IC60), relative potencies and 
TTR binding affinity constants (Ka) of parent and hydroxylated polychlorobiphenyls (PCBs). 
No 
A 
B 
C 
D 
E 
F 
G 
H 
1 
J 
K 
Structure 
Thyroxine 
2,3,3' ,4,4'-pentaCB 
2-OH-2',3,3',4,4'-pentaCB 
4-OH-2',3,3' ,4' ,5-pentaCB 
5-OH-2',3,3',4,4'-pentaCB 
4-OH-3,3',4'-tr iCB 
4-OH-2,3,3',4'-tetraCB 
4-OH-2,2'3,3' ,4'-pentaCB 
4,4'-(OH)2-2,3,3',5,5'-pentaCB 
4,4'-(OH)2-3,3',5,5'-tetraCB 
4-OH-3,3' ,4' ,5,5'-pentaCB 
5-OH-3,3',4,4'-tetraCB 
IC50 
(nM) 
88.3 
> 1 0 0 0 
950 
15.0 
19 
10.5 
8.8 
17.5 
6.5 
16.5 
10.3 
25 
Rel. 
Pot. 
1 
< < 1 
0.09 
5.9 
4.6 
8.4 
10.2 
5.0 
13.6 
5.4 
8.5 
3.5 
Ka (M1) 
(means ± s.d.) 
2.05 ± 0.57 * 107 
N.D. 
8.85 ± 3.98 * 104* 
3.41 ± 0.72 * 108" 
7.78 ± 2.02 * 107* 
8.28 ± 2.15 * 108* 
5.11 ± 1.38 * 10s" 
6.22 ± 1.18 * 10 7 ' 
3.95 ± 2.17 * 108* 
4.31 + 1.60 * 10s" 
4.65 + 1.86 * 108" 
6.80 + 2.0 * 107" 
Note: Compounds are numbered as in Figure 1. Relative potency is given as the ratio of 
IC50(T4)/IC50(competitor). Binding affinity constants (Ka) are determined by non-linear curve 
fitting of T4 displacement curves. Results shown are means ± S.D. of triplicate measurements. 
Values that differ significantly (Student's t-Test) from the natural ligand, T4 are indicated: 'p < 
0.05 
In contrast the 4-OH-2',3,3',4',5-pentaCB (C) and 5-OH-2,3,3',4,4'-pentaCB (D) 
were more potent than unlabeled T4 in this assay system (IC50 15.0 and 19 nM, respec-
tively, Table 1). The binding affinity constants (Ka's) deduced from the displacement 
curves by non-linear curve fitting showed that para- (C) and meta- (D) hydroxylated 
metabolites of CB 105 had higher binding affinities to TTR than the ort/zo-hydroxy-
metabolite (B) (Table l).The non-ort//o-chlorine substituted 4-OH-3,3',4',5,5'-pentaCB 
(J), a metabolite of 3,3',4,4',5,-pentaCB (CB 126) was also a potent inhibitor of TTR-T4 
binding (IC50: 10.3 nM, Ka: 4.65 * 108 M"1) 
Hydroxylated PCBs with different degree of coplanarity 
The ease with which the biphenylrings can adopt a co-planar configuration is dependent 
on the degree of orf/jo-chlorine substitution of PCBs. Therefore the influence of the 
degree of ortho-chlorine, substitutions of meta- or para-hydroxylated PCBs on the TTR-
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Figure 4 A) Competit ive binding of hydroxylated PCDFs (L,M,N) and B) hydroxylated PCDDs 
(0,P,Q) measured by the TTR-T4 competit ion-binding assay (Materials and Methods). Datapoints 
are mean values of duplicate incubations. Relative 125I-T4-TTR binding (% of control value) is 
plotted against the log concentrat ion (nM) of competitor or T4 added. 
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T4 displacement potency of the compounds was investigated. The TTR-T4 displacement 
potency and TTR affinity constants of all non- (E), mono- (C,D,F,H), and di-ortho (G) 
chlorine substituted hydroxy-PCBs were within the same order of magnitude i.e., IC50 
and Ka values ranging from 6.5 - 17.5 nM and 6.2 * 107 - 8.3 *108 M"1 (Table 1). Th: 
data indicate that these groups of hydroxy-PCBs were more potent than the natural 
ligand T4 (Fig. 3). The binding affinities of non- and mono-ortho chlorine substituted 
PCB-metabolites 4-OH-3,3',4'-triCB (E) and 4-OH-2,3,3',4'-tetraCB (F) were similar 
(IC50 resp. 8.8 and 10.5 nM), while the di-ortho chlorine substituted compound 4-OH-
2,2',3,3',4'-pentaCB (G) exhibited lower potency. 
The binding characteristics of 5 other hydroxylated PCB congeners with a 
different degree in ortho-chlorine substitution are summarized in Table 1. Both the two 
dihydroxylated PCBs, the 4,4'-(OH)2-3,3',5,5'-tetraCB (H) and the 4,4'-(OH)2- 2,3,3',5,-
5'-pentaCB (I) had a high affinity for TTR (IC50 16.5 and 6.5 nM) and again the degree 
of or/Ao-chlorine substitution did not seem to have much influence on binding to TTR. 
Hydroxylation on both para positions (H,I) did not result in significantly stronger TTR 
binding. The binding affinities and Ka values for the 2 meta hydroxy-PCBs, 5-OH-
3,3'4,4'-tetraCB (K) and 5-OH-2',3,3',4,4'-pentaCB (D) (Table 1) were also similar (6.8 
* 107 and 7.78 * 107 M"1, respectively). 
Table 2 Competitive 125I-T4-TTR binding inhibition concentrations (IC50), relative potencies and 
TTR binding affinity constants (Ka) of hydroxylated polychlorodibenzo-p-dioxins (PCDDs) and 
polychlorodibenzofurans (PCDFs). 
No 
L 
M 
N 
0 
P 
Q 
Structure 
Thyroxine 
2-OH-7,8-diCDF 
8-OH-2,3,4-triCDF 
3-OH-2,6,7,8-tetraCDF 
8-OH-2,3-diCDD 
7-OH-2,3,8-triCDD 
2-OH-1,3,7,8-tetraCDD 
IC50 (nM) 
138 
> 1 0 0 0 
> 1 0 0 0 
30.2 
> 1 0 0 0 
136 
31.6 
Rel. 
Pot. 
1 
< < 1 
< < 1 
4.5 
< < 1 
1.0 
4.37 
Ka (M1) 
(mean ± s.d.) 
2.27 ± 0.13 * 107 
N.D. 
N.D. 
5.35 ± 1.44 * 108* 
N.D. 
4.33 ± 1.17 * 107 
6.33 + 4.93 * 108" 
Note: Compounds are numbered as in Figure 1. Relative potency is given as the ratio of 
IC50(T4)/IC50(competitor). Binding affinity constants (Ka) are determined by non-linear curve 
fitting of T4 displacement curves. Results shown are means ± S.D. of triplicate measurements. 
Values that differ significantly (Student's t-Test) from the natural ligand, T4 are indicated: 'p < 
0.05 
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Hydroxylated PCDDs and PCDFs 
In addition to hydroxylated PCB compounds, a number of hydroxylated PCDDs and 
PCDFs were also tested in the TTR competitive binding assay. Large differences were 
observed in T4-TTR binding inhibition potencies and affinity constants between the 
various hydroxylated PCDDs and PCDFs (Fig. 4a,b; Table 2). 2-OH-l,3,7,8-tetraCDD 
(Q) and 3-OH-2,6,7,8-tetraCDF (N) exhibited the highest TTR-T4 binding inhibition 
potential with IC50 values of 31.6 and 30.2 nM, respectively. These 2 compounds were 
both substituted with one or two chlorine atoms adjacent to a OH-group. A significant 
difference in potency was noted between 7-OH-2,3,8-triCDD (P) and 3-OH-2,6,7,8-
tetraCDF (N), the latter more highly chlorinated compound was approximately 4 times 
more potent than the former (Table 2). 
The hydroxylated PCDFs, 2-OH-7,8-diCDF (L) and 8-OH-2,3,4-triCDF (M) did 
not possess chlorine atoms substituted adjacent to the OH-group and did not interact 
with TTR at the concentrations tested in this study (Fig 4a). The TTR binding affinities 
of the hydroxylated chloro-dibenzo-p-dioxins 7-OH-2,3,8-triCDD (P) and 2-OH-l,3,7,8-
tetraCDD (Q) were equal or higher than that observed for T4 whereas 8-OH-2,3-diCDD 
(O), lacking adjacent chlorine and hydroxy groups was inactive in this binding assay. In 
addition the parent compound 2,3,7,8-tetraCDD (TCDD) was unable to compete in the 
TTR-T4 binding assay. No inhibition of T4 binding to TTR was found, even at high 
concentrations (595 nM TCDD in incubation, data not shown). The potencies of the 
hydroxylated PCDDs and PCDFs (N,P,Q) in the TTR-T4 binding assay were similar to 
those observed for the hydroxylated PCBs (Table 1 and Table 2). 
Discussion 
The main objective of this study was to gain further insight in the structural require-
ments of hydroxy metabolites of PCBs and related compounds as competitors for T4 
binding to TTR. 
The in vitro TTR-T4 competitive binding data obtained in this study indicate an 
essential requirement of a hydroxy-group on the PCB molecule for displacement of 125I-
T4 from the TTR protein. The hydroxy-PCBs with the hydroxy-group substituted on 
either metct, or para positions (compounds C - K) showed a much higher competitive 
binding potency (35 - 136 fold) than the corresponding ortho hydroxy substituted 
compound, 2-OH-2',3,3',4,4'-pentaCB (B). In addition, there is an essential requirement 
of at least one, but preferably more chlorine substitutions adjacent to the meta, or para 
hydroxy-group on the PCB molecule. However, coplanarity of the hydroxy-PCB 
molecule does not appear to be a requirement for competitive binding to TTR, since 
there is little or no difference in 125I-T4 displacement potency between the non-, mono-
and di-ortho hydroxy-PCB congeners tested (E, F, G). This result is not surprising in 
view of the non-planar structure of the natural ligand (T4) for TTR. 
Some hydroxylated derivatives of PCDD and PCDF also showed a potent 
competitive 125I-T4 displacement capacity on TTR. Similar to the hydroxy-PCBs; 
chlorine substitution adjacent to the hydroxy-group on the PCDD and PCDF molecule 
(compounds N,P,Q) appeared to be an essential requirement for competitive binding to 
TTR. Again, the most toxic PCDD isomer, TCDD, did not show any competition for T4 
due to the absence of a hydroxy-group. The relative binding potencies of the hydroxy-
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PCDD/F compounds N,P,and Q were in the same range as the /weta//?ara-hydroxylated 
PCBs (compounds C - K) and one to four fold higher than the TTR binding potency of 
the natural ligand, T4. Apparently, the rigid, planar structure of the hydroxylated PCDDs 
and PCDFs (N,P,Q) did not negatively influence the TTR-T4 competitive binding 
capacity, compared to the more flexible structures of the weta/^ara-hydroxylated PCBs. 
The structure-activity data on competitive binding to TTR of hydroxy-PCBs, 
PCDDs and PCDFs obtained in this study are in good agreement with previous studies 
on hydroxylated metabolites of 3,3',4,4'-tetrachlorobiphenyl (CB 77) (Brouwer and Van 
den Berg, 1986,; Brouwer et al., 1990), of several other PCB congeners (Rickenbacher 
et al., 1986; Brouwer et al., 1990) and of chlorinated benzenes and their phenolic 
metabolites (Van den Berg, 1990; Den Besten et al., 1991). Favourable structural 
features for ,25I-T4 displacement on TTR of CB 77 metabolites involved metalpara 
hydroxylation with one or more chlorine substitutions adjacent to the hydroxy-group. 
Similarly, competitive binding studies with chlorinated benzenes and -phenols indicated 
an essential requirement for adjacent chlorine and hydroxy substitution (Van den Berg , 
1990). Rickenbacher et al. (1986) also observed that substitution of PCBs with a 
hydroxy-group, in particularly on the meta, or para positions with adjacent chlorine 
substitution greatly facilitated competitive binding to TTR. 
However, there are several differences between the results of our studies 
(Brouwer and Van den Berg, 1986, Brouwer et al., 1990) and the reports of Rickenba-
cher et al. (1986) and McKinney and coworkers (1985). For example, they reported that 
laterally substituted PCBs showed the highest affinity for TTR and further ortho-
chlorine substitution lowered the binding affinity of these compounds to a great extent. 
This was not observed in this study, where non-ortho, mono-ortho and di-ortho chlorine 
substituted hydroxy-PCBs showed similar competitive binding to TTR. Furthermore, 
using computer modelling the potentially high competitive binding of TCDD and its 
adipamide-derivative to TTR was also reported (McKinney et al., 1985), but we were 
unable to find any competitive binding potency of TCDD in our in vitro TTR-T4 
competitive binding assay. In fact, no 125I-T4 displacement on TTR has been observed 
using either parent PCB congeners (CB 77, CB 105), a commercial PCB mixture 
Aroclor 1254, TCDD or several different chlorobenzenes. This indicates an essential 
requirement of a, preferably lateral substituted hydroxy-group for competitive binding. 
In contrast, Rickenbacher et al. (1986) reported high competitive binding of the parent 
PCBs, 3,3',5,5'-tetraCB and 3,3',4,4',5,5'-hexaCB to thyroxine binding prealbumin 
(TBPA, synonymus to TTR), which suggests that there may be no strict requirement for 
a laterally substituted hydroxy-group. The reason for this discrepancy is unknown, and 
will be further investigated in our laboratory. 
The structural requirements of hydroxylated PCBs, PCDDs and PCDFs for 
competitive binding to TTR observed in this study resemble those for T4 binding to TTR 
(Blake and Oatley, 1977). Halogen-substitution on the phenolic ring adjacent to the para 
hydroxy-group enhance the binding of T4 to TTR (Andrea et al., 1980), similar to the 
effects of chlorine substitution adjacent to the metalpara hydroxy-group observed for the 
hydroxylated PCBs, PCDDs and PCDFs investigated in this study. Also the diphenyl 
ether structure of T4 is not necessary for strong TTR binding (Pages et al., 1973), which 
suggests that there is flexibility in the T4-binding pocket on the TTR molecule thus 
facilitating the binding of compounds with markedly different three-dimensional 
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conformation. 
T4 can bind to TTR in probably 2 different modes; the "forward" and "reverse" 
mode (De la Paz et oil., 1992). In the "forward" mode the phenolic ring is buried deep in 
the TTR binding site while the phenyl-ring with amino-side chain is close to the binding 
site entrance. In this way the phenolic ring can form hydrogen-bonds with watermolecu-
les inside the protein. In the "reverse" binding mode the amino-side chain is closest to 
the centre of the binding site, while the phenolic ring hydrogen-binds with the charged 
residues at the entrance. Hydrogen-bonds seem to be important for T4 binding. This may 
explain the hydroxy-group requirement for TTR binding of PCBs and related com-
pounds, as shown in this study. The actual entrance and docking of hydroxy-PCBs in the 
T4-binding pocket of TTR will be further investigated. 
The close structural resemblance between T4 and the hydroxy-PCBs, PCDDs and 
PCDFs, and the high in vitro competitive 125I-T4 displacement potency of all metalpara 
hydroxylated PCBs and the hydroxy-PCDD/F compounds (N,P,Q), suggests that 
hydroxy-metabolites of these compounds may also play a role in the in vivo observed 
marked alterations in thyroid hormone metabolism, following exposure of rodents and 
other species to these compounds. In fact, high affinity, competitive binding of 4-OH-
3,3',4',5-tetraCB to TTR, accompanied by marked plasma total T4 reductions was 
observed in rats, mice (Brouwer and Van den Berg, 1986, Brouwer, 1989) and marmo-
set monkeys (Beetstra et al., 1991, Brouwer, 1987), following exposure to CB-77. 
For other PCB congeners and commercial PCB mixtures, such as Aroclor 1254, 
it is still unknown whether hydroxy-metabolites also occupy T4-binding sites on plasma 
TTR to such an extent that they may play a role in plasma thyroid hormone reductions 
observed, following exposure to these chemicals. However, several of the tested hydroxy 
PCBs and related compounds have been identified in vivo, such as the hydroxy metab-
olites of CB 105 (compounds B,C and D) which have been identified in mice following 
exposure to this compound (Klasson-Wehler et al., 1990). Recent results on exposure of 
rats to Aroclor 1254, indicate the presence of considerable amounts of several hydroxy-
PCB metabolites in the blood, including the 4-OH-2',3,3',4',5-pentaCB (Klasson-Wehler 
et al., 1992). The latter hydroxylated PCB compound was tested in our study and found 
to possess a potent competitive binding affinity to TTR (IC50: 15.0 nM). Furthermore, 4-
OH-3,3',4',5,5'-pentaCB (J), a metabolite of 3,3',4,4',5-pentachlorobiphenyl (CB 126), 
which is shown to have a high competitive TTR-binding affinity, has been detected after 
in vivo exposure of rats to CB 126 (Koga et al., 1990). The 2 major hydroxy-metaboli-
tes of 2,3,7,8-tetraCDD (compounds P and Q) identified in mammalian species (Mason 
and Safe, 1986; Ramsey et al., 1982) were found to be potent TTR-T4 binding competi-
tors. 
Due to the important function of TTR in rodent T4 plasma transport, T4 decreases 
found in rodents after PCB exposure in vivo can be caused by TTR blockage by 
hydroxylated metabolites. Still, one cannot exclude the role of induced T4 glucuroni-
dation by PCBs in plasma T4 decrease. The extent of involvement of hydroxy-metaboli-
tes of PCBs and related compounds in the observed reduction in plasma T4 levels will 
be investigated further in several laboratory and wildlife species, including man. Other 
studies in our laboratory, showed marked decreases in plasma T4 levels, and alterations 
in thyroid hormone metabolism in TCB exposed pregnant rats, their fetuses and their 
offspring (Morse et al., 1993a). The possible neurotoxic consequences of PCB exposure 
in fetal and neonatal rats may be caused by interference of PCBs in thyroid hormone 
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metabolism. Although TTR is not the major human T4 transport protein (10-40 % T4 
binding in plasma) when compared to thyroxin binding globulin (TBG, 50-80 % T4 
binding in plasma) (Larsson et al., 1985), TTR is essential for T4 transport over the 
blood-brain barrier in mammals (Herbert et al., 1986). The role of T„-TTR displacement 
in T4 levels in man may be marginal, but the suggested role of TTR in the brain may 
selectively put the brain at risk for toxic consequences. 
In conclusion, highly potent, competitive interactions of hydroxylated PCBs, 
PCDDs and PCDFs with the thyroid hormone transport protein TTR, were found in vitro 
using human TTR. The structural requirements for this competitive binding resembled 
those observed for the natural TTR ligand, T4. The possible role of hydroxylated 
metabolites in the toxicity of PCBs, PCDDS and PCDFs is unknown. However based on 
the data presented herein it is possible that hydroxylated PCBs, PCDDs, PCDFs and 
related compounds may contribute to some of the toxic responses of these chemicals, 
especially those that may relate to reduced thyroid hormone levels, such as wasting 
syndrome, developmental neurotoxicity and carcinogenicity. 
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CHAPTER 3 
Different competition of thyroxine binding to transthyretin 
and thyroxine binding globulin by hydroxy-polychloro-
biphenyls, -dibenzo-p-dioxins and -dibenzofurans 
Abstract 
In a previous study several hydroxylated polychlorinated biphenyls (PCBs), dibenzo-p-
dioxins (PCDDs) and dibenzofurans (PCDFs) competitively displaced 125I-thyroxine (T4) 
from transthyretin with different potencies. Transthyretin is the major T4 transport 
protein in plasma of rodents. In man, however, fhyroxine-binding globulin transports 
most T4 in blood. In this study, hydroxylated PCBs, PCDDs and PCDFs were tested in 
an in vitro competitive binding assay, using purified human fhyroxine-binding globulin 
and l25I-T4 as the displaceable radioligand. None of the tested hydroxylated PCBs, 
PCDDs and PCDFs inhibited 125I-T4 binding to thyroxine-binding globulin. In addition, 
some T4 derived compounds; e.g. tyrosine, mono-iodotyrosine, di-iodotyrosine and tri-
iodophenol were tested on both transthyretin and thyroxine-binding globulin to investi-
gate possible differences in structural characteristics determining T4 binding to thyro-
xine-binding globulin and transthyretin. The T4 derived compounds also did not inhibit 
125I-T4 binding to thyroxine-binding globulin as tested in the in vitro assay. However, tri-
iodophenol and to a lesser extent di-iodotyrosine inhibited 125I-T4-transfhyretin binding. 
These results indicate a marked difference in T4 binding to thyroxine-binding globulin or 
transthyretin. The hydroxylated PCBs, PCDDs and PCDFs can inhibit T4 binding to 
transthyretin, but not to thyroxine-binding globulin, and thus may cause different effects 
in rodents and man. 
Martine C. Lans, Cecile Spiertz, Abraham Brouwer and Jan H. Koeman 
European Journal of Pharmacology [Environmental Toxicology and Pharmacology 
Section] 270 , 129-136 (1994) 
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Introduction 
Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans 
(PCDFs) are widespread, persistent environmental contaminants (Ballschmitter et al., 
1989; Rappe and Buser, 1989). These compounds are present in higher levels in top 
predators like fish-eating birds, marine mammals and man due to the biomagnification 
through the foodchain. Background levels found in human breastmilk range from 0.3 to 
2.8 ppm total PCBs in milk fat whereas in human blood (lipid) levels of 650-7700 ppt 
PCBs, 150-1000 ppt PCDDs and 25-190 ppt PCDFs are found (Ahlborg et al, 1992). 
PCBs, PCDFs and PCDDs cause a range of common toxic effects in laboratory 
animals such as hepatotoxicity, thymic atrophy (McConnell, 1980), chloracne and related 
dermal lesions, immunotoxicity, reproductive and developmental toxicity and different 
endocrine responses including disturbances in thyroid hormone homeostasis (Ahlborg et 
al., 1992, McConnell, 1989). Exposure to mixtures of PCBs (Bastomsky, 1974, Saito et 
al, 1991) and polybrominated biphenyls (PBBs) (Byrne et al, 1987, Gupta et al, 1983, 
Spear et al, 1990) changed thyroid hormone metabolism in rats and mice and especially 
induced thyroxine (T4) glucuronidation. Certain PCBs and PCDDs like 3,3',4,4'-
tetrachlorobiphenyl (TCB) (Brouwer and Van den Berg, 1986, Brouwer, 1989, Beetstra 
et al, 1991) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Bastomsky, 1977, Lucier 
et al, 1975, Potter et al, 1983, Lans et al, 1990) reduced plasma total (TT4) and free T4 
levels and simultaneously induced T4-glucuronidation and inhibited thyroxine-5'-
deiodinase type 1 activity in rats (Adams et al, 1990). Exposure of marmoset monkeys 
to TCB caused hypothyroidism in these animals (Van den Berg et al, 1988). In man, 
several studies indicate changes in human serum T4 levels after exposure to PCBs or 
PBBs (Emmett et al, 1988, Murai et al, 1987, Bahn et al, 1980, Kreiss et al, 1982). 
The decreases in plasma T4 levels after exposure of rats and mice to PCBs, 
PCDDs and PCDFs are caused in part by increased hepatic T4 glucuronidation. In 
addition, a disturbance of plasma T4 transport may be involved in the reduction of 
plasma T4 concentrations by PCBs. Exposure of rats (Brouwer, 1989) and mice 
(Brouwer and Van den Berg, 1986) to TCB in vivo severely reduced plasma T4 levels. 
Hydroxylated metabolites of TCB specifically interacted with the T4 binding site of 
transthyretin, the major plasma thyroid hormone transport protein in rodents, and 
inhibited T4-transthyretin binding causing T4 levels to drop (Brouwer, 1989). Different 
hydroxylated PCBs, PCDDs, PCDFs (Lans et al, 1993, Brouwer et al, 1990) and rela-
ted chlorophenols (Van Den Berg, 1990, Den Besten et al, 1991) specifically inhibited 
T4-transthyretin binding in vitro. 
Transthyretin is a highly conserved plasma T4 transport protein present in most 
mammalian species (Larsson et al, 1985). Another important plasma T4 binding protein, 
thyroxine binding globulin, is present in higher mammals, including man. Thyroxine-
binding globulin, however, is not present in rats and mice, except during the first 3 
weeks after birth or in hypothyroidal state (Savu et al, 1989). 
Thyroxine-binding globulin is a high affinity, low capacity T4 transport protein 
and levels in human blood circulation (15 mg/1) are lower than transthyretin levels (300 
mg/1, De la Paz et al, 1992). Transthyretin and thyroxine-binding globulin have 
different T4 binding properties; in human plasma thyroxine-binding globulin transports a 
higher percentage of T4 (50-80 %) than transthyretin (10-40 %) (Larsson et al, 1985). 
The T4 binding affinity for thyroxine-binding globulin is higher than for transthyretin 
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(Ka's: 10'° M"1 and 107-108 M"1 respectively). In addition thyroxine-binding globulin has 
only one T4 binding site while transthyretin has two T4 binding sites with different 
binding affinities. 
Different structural characteristics of the T4 molecule seem to be important for 
binding to thyroxine-binding globulin as compared to transthyretin. The phenolic 
hydroxyl group and iodine substituents on the phenolic ring of T4 are clearly important 
for binding to transthyretin (Andrea et al., 1980). The necessary structural characteristics 
of T4 for binding to thyroxine-binding globulin are the iodine-substituents on the inner 
amino-phenyl ring and the outer phenolic ring, the L-configuration of the alanyl side 
chain and the presence of a 4'-hydroxyl-group (Snyder et al., 1976, Terry and Blake, 
1992). 
In vitro competitive interactions of hydroxylated PCBs, PCDDs and PCDFs with 
purified human transthyretin have already been observed in an earlier study (Lans et al., 
1993). However, thyroxine-binding globulin appears to be quantitatively more important 
than transthyretin for T4 transport in man. It was considered important to investigate the 
potential competitive binding affinity of the hydroxylated metabolites of these com-
pounds to thyroxine-binding globulin to be able to predict possible reductions in plasma 
T4 levels in man, following exposure to PCBs, PCDDs and PCDFs. 
Several hydroxylated PCB, PCDD and PCDF metabolites and parent compounds 
(Fig. 1,3 and 4) were tested in this study for T4 displacement potential on thyroxine-
binding globulin in vitro using competitive binding assays. Additionally, T4-derived 
compounds were tested in vitro to investigate possible differences in structural charac-
teristics determining T4 binding to thyroxine-binding globulin and transthyretin. Tyrosine 
(Tyr), mono-iodotyrosine (MIT) and di-iodotyrosine (DIT) are structurally related to the 
amino-phenylring of T4, with a phenolic hydroxyl-group present. 2,4,6-Triiodophenol 
(TIP) is structurally related to the iodophenolic ring of T4. 
Materials and methods 
Materials 
Radiolabeled L-[3',5'-l2SI] thyroxine (spec. act. 46 uCi/|ig) was purchased from 
Amersham, Buckinghamshire, England and contained 5-10% free iodide, as determined 
with Sephadex LH-20 (Pharmacia LKB, Woerden, the Netherlands) gel filtration. 
Transthyretin (human prealbumin, 98% pure), thyroxine-binding globulin (human, 100% 
pure) and 3,3',5,5'-L-thyroxine (T4) were obtained from Sigma Chemical Company (St. 
Louis, MO, USA). Methanol (Lichrosolv) was obtained from Merck Chemical Company 
(Darmstadt, Germany). Biogel P-6DG desalting gel was obtained from Bio-Rad 
Laboratories (Richmond, CA, USA). 
Tyrosine (Tyr), mono-iodotyrosine (MIT) and di-iodotyrosine (DIT) were kindly 
provided by Dr. T.J. Visser, Erasmus University Rotterdam, the Netherlands. 2,4,6-
triiodophenol (TIP) was purchased from Aldrich Chemical Co. Ltd., Brussels, Belgium. 
2,3,3',4,4'-Pentachlorobiphenyl (CB 105) (A, Fig. 3) and 3,3',4,4'-tetrachlorobi-
phenyl (TCB or CB 77) (a, Fig. 1) were purchased from Promochem GmbH, Wesel, 
Germany. The hydroxylated metabolites of TCB (fig.l) eg. 2-OH-3,3',4,4'-tetraCB (b), 
4-OH-3,3',4',5-tetraCB (c), 5-OH-3,3',4,4'-tetraCB (d) and 6-OH-3,3',4,4'"tetraCB (e) 
were synthesized as previously described (Lans et al., 1993, Klasson-Wehler et al., 
1990). The other hydroxylated PCBs (fig. 3) used in the present study: 2-OH-2',3,3',4,-
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4'-pentaCB (B), 4-OH-2',3,3',4',5-pentaCB (C), 5-OH-2',3,3',4,4'-pentaCB (D), 4-OH-
3,3',4'-triCB (E), 4-OH-2,3,3',4'-tetraCB (F), 4-OH-2,2',3,3',4'-pentaCB (G), 4,4'-
(OH)2-2,3,3',5,5'-pentaCB (H), 4,4'-(OH)2-3,3',5,5'-tetraCB (I), 4-OH-3,3',4',5,5'-
pentaCB (J) and 5-OH-3,3',4,4'-tetraCB (K)* were obtained as a gift from Dr. E. 
Klasson-Wehler, Environmental Chemistry, Wallenberg Laboratory, Stockholm Univer-
sity, S-10691 Stockholm, Sweden. "The numbering of the hydroxy-substituents on the 
biphenyl does not follow IUPAC rules but has been chosen in order to facilitate 
comparison of the structures. 
The tested hydroxylated polychloro-dibenzo-p-dioxins and polychloro-dibenzo-
furans (2-OH-7,8-diCDF (L), 8-OH-2,3,4-triCDF (M), 3-OH-2,6,7,8-tetraCDF (N), 8-
OH-2,3-diCDD (O), 7-OH-2,3,8-triCDD (P) and 2-OH-l,3,7,8-tetraCDD (Q)), shown in 
figure 3, were synthesized as previously described (Denomme et al., 1985, 1986, Mason 
and Safe, 1986) and kindly donated by prof. dr. S. Safe, Department of Veterinary 
Physiology and Pharmacology, A & M University, College Station, Texas, U.S.A. 
In vitro T4 competition-binding assays for TBG and TTR 
The gel-filtration procedure as decribed by Somack et al. (1982) with minor modifica-
tions was used for the T4 competition-binding assay. The assay, using human 
transthyretin or thyroxine-binding globulin, was performed as described by Lans et al, 
1993. Transthyretin or thyroxine-binding globulin (30 nM, dissolved in 0.1 M Tris-HCl, 
0.1 mM NaCl, 1 mM EDTA buffer, pH 8) was incubated with a mixture of ,25I-T4 and 
unlabeled T4 (70.000 cpm, 55 nM) in Tris-HCl buffer, and competitors (T4, mono-
iodotyrosine, di-iodotyrosine, tyrosine, tri-iodophenol and parent or hydroxylated PCBs, 
PCDDs or PCDFs) in increasing concentrations or methanol (control) were added. Total 
125I-radioactivity added to each of the incubation mixtures (200 ul total volume) was 
checked by gamma-counting (Cobra Auto-gamma, Packard Instrument co., USA). The 
incubations were allowed to reach binding equilibrium overnight at 4 °C. Protein-bound 
l25I-T4 and free l25I-T4 were separated on 1 ml Biogel P-6DG columns and were spin-
forced eluted with Tris-HCl buffer. The first 2 eluate fractions, containing the protein 
bound 125I-T4 fraction, were combined; radioactivity was counted and compared to the 
control incubations. Non-protein bound T4 was retained on the Biogel matrix. Competi-
tion binding curves were made by plotting relative l25I-T4-protein binding (% of control) 
against added log competitor concentration. 
Analysis of binding data 
Binding characteristics are given for transthyretin as relative potencies: the ratio of 
inhibitor concentration at 50 % inhibition (IC50) of unlabeled T4 vs the IC50 of hydroxy-
lated metabolites of PCBs, PCDDs and PCDFs. 
Statistics 
Data are given as means with standard deviations (S.D.). Significant differences were 
determined by statistical analysis using the Student's t-test (with a probability value p < 
0.05). 
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Results 
Effects of different PCB metabolites on T4 binding to TTR and TBG 
The competitive binding potency of unlabeled T4 expressed as IC50 was 52.2 - 85 nM 
for thyroxine-binding globulin (data not shown) and 88.3 - 138 nM for transthyretin 
(Table 1 and 2) in the in vitro T4 binding competition assays, in accordance with the 
higher T4 binding affinity of thyroxine-binding globulin. TCB and its OH metabolites 
(Fig. 1) did not compete with T4 for binding to thyroxine-binding globulin (Fig. 2a) in 
the in vitro binding studies; only very high concentrations of 6-OH-3,3',4,4'-tetraCB (e) 
and 5-OH-3,3\4,4'-tetraCB (d) inhibited T4 binding to thyroxine-binding globulin (IC50: 
1380 and 8000 nM respectively). On the contrary, all OH-metabolites of TCB inhibited 
T4-transthyretin binding, but with different inhibition potencies of : 5-OH-3,3',4,4'-
tetraCB = 4-OH-3,3',4',5-tetraCB > T4 > 2-OH-3,3',4,4'-tetraCB > 6-OH-3,3',4,4'-
tetraCB > TCB (with relative potencies : 2.7, 2.6, 1, 0.5, 0.05 and « 1 , respectively) 
(Fig. 2b). TCB apparently did not inhibit T4-transthyretin binding. 
Several other hydroxylated PCB metabolites (Fig. 3) tested on thyroxine-binding 
globulin did not inhibit T4 binding to thyroxine-binding globulin ( » 90% binding at 
250 nM competitor added) (Table 1). All hydroxylated metabolites of 2,3,3',4,4'-PeCB 
(Fig. 3, B,C,D) showed T4-transthyretin binding competition in contrast to the parent 
compound 2,3,3',4,4'-PeCB (Table 1). The 2-OH-2',3,3',4,4'-pentaCB metabolite (B) 
had a higher IC50 than T4 (950 and 88.3 nM respectively), while the other metabolites 4-
OH-2,3,3',4',5-pentaCB (C) and 5-OH-2,3,3',4,4'-PeCB (D) had IC50's lower than T4 
(15 and 19 nM). 
OH X A OH ^ 
DI JUL JUL O 
Cl CI T Cl OH T CI 
CI OH Cl 
Q 
Figure 1 3,3',4,4'-Tetrachlorobiphenyl (TCB, a) and its hydroxymetabolites, 2-OH-3,3',4,4'-
tetraCB (b), 4-OH-3,3',4',5-tetraCB (c), 5-OH-3,3',4,4'-tetraCB (d) and 6-OH-3,3',4,4'-tetraCB 
(e) as tested in the ^-transthyretin or T4-thyroxine-binding globulin competition binding assays 
and synthesized as described in Materials and Methods. 
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Figure 2 A) Competitive binding to thyroxine-binding globulin or B) competitive binding to 
transthyretin of T4( + ), TCB (fig.1:a(Ol) and its hydroxy metabolites (fig.1: b( + ) , c U ) , d ( » ) and 
e(v)), as measured by the in vitro competition-binding assay (Materials and Methods). Data-
points are mean values of duplicate incubations. Relative ,25l-T4-thyroxine-binding globulin or 
125l-T4-transthyretin binding (% of control value) is plotted against the log concentration (nM) of 
competitor or T4 added. 
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Figure 3 Structures of hydroxylated PCBs, PCDDs and PCDFs tested in the T4-transthyretin or 
T4-thyroxine-binding globulin competition binding assay and synthesized as described in 
Materials and Methods. 
I: (hydroxylated) polychlorobiphenyls with substituents R (OH or CI). 
2,3,3',4,4'-pentaCB (CB 105) (A), 2-OH-2',3,3',4,4'-pentaCB (B), 4-OH-2',3,3',4',5-pentaCB 
(C), 5-OH-2',3,3',4,4'-pentaCB * (D), 4-OH-3,3',4'-triCB (E), 4-OH-2,3,3',4'-tetraCB (F), 4-0H-
2,2',3,3',4'-pentaCB (G), 4,4'-(OH)r2,3,3',5,5'-pentaCB (H), 4,4'-(OH)2-3,3',5,5'-tetraCB (I), 
4-OH-3,3',4',5,5'-pentaCB (J) and 5-OH-3,3',4,4'-tetraCB (K). 
II: hydroxylated PCDFs with substituents R (OH or CI). 
2-OH-7,8-diCDF (L), 8-OH-2,3,4-triCDF (M), 3-OH-2,6,7,8-tetraCDF (N). 
Ill: hydroxylated PCDDs with substituents R (OH or CI). 
8-OH-2,3-diCDD (O), 7-OH-2,3,8-triCDD (P) and 2-OH-1,3,7.8-tetraCDD (Q). 
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Table 1 ^-transthyretin binding inhibition potencies (IC60), relative potencies of transthyretin-
binding (Lans et a/., 1993) and 125I-T4 binding to thyroxine-binding globulin (% bound of control 
at 250 nM competitor added) of parent and hydroxylated polychlorobiphenyls (PCBs). Com-
pounds are numbered as in fig. 2. Relative potency is given as the ratio of IC50(T4)/IC50(com-
pound). Results shown are means ± S.D. of triplicate measurements. Values that differ signifi-
cantly (Student's t-test) from the natural ligand thyroxine (T4), are indicated: "p < 0.05. 
No 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
K 
Structure 
Thyroxine 
2,3,3',4,4'-pentaCB 
2-OH-2',3,3',4,4'-pentaCB 
4-OH-2',3,3',4',5-pentaCB 
5-OH-2',3,3',4,4'-pentaCB 
4-OH-3,3',4'-triCB 
4-0H-2,3,3',4'-tetraCB 
4-OH-2,2'3,3',4'-pentaCB 
4,4'-(OH)2-2,3,3',5,5'-pentaCB 
4,4'-(OH)2-3,3',5,5'-tetraCB 
4-OH-3,3',4',5,5'-pentaCB 
5-OH-3,3',4,4'-tetraCB 
TTR IC60 
(nM) 
88.3 
>1000 
950 
15.0 
19 
10.5 
8.8 
17.5 
6.5 
16.5 
10.3 
25 
TTR 
relative 
potency 
1 
< < 1 
0.09 
5.9 
4.6 
8.4 
10.2 
5.0 
13.6 
5.4 
8.5 
3.5 
TBG 
% 125I-T 
17.0 ± 
96.0 ± 
94.2 ± 
99.2 ± 
95.2 ± 
93.9 ± 
95.6 ± 
99.7 ± 
97.7 ± 
97.9 ± 
96.1 ± 
94.1 ± 
4 bound 
2.0 
1.3* 
2.5a 
2.0a 
5.6a 
8.1a 
1.7a 
2.6a 
4.3a 
3.7a 
3.6a 
6.8a 
Effects of different hydroxylated PCDFs and PCDDs on T4 binding to TTR 
and TBG 
Consistent with the hydroxylated PCB metabolites, the hydroxylated PCDFs and PCDDs 
tested on thyroxine-binding globulin (Table 2) did not inhibit T4 binding to thyroxine-
binding globulin. Only 3-OH-2,6,7,8-tetraCDF, 7-OH-2,3,8-triCDD and 2-OH-l,3,7,8-
tetraCDD (Fig. 3, N, P and Q) (Table 2) inhibited T4-transthyretin binding. 
Effects of T4-derived structures on T4 binding to TTR and TBG 
The T4-derived structures tyrosine (Tyr), mono-iodotyrosine (MIT) and di-iodotyrosine 
(DIT) (Fig. 4) have been tested on competition of T4 binding to transthyretin and 
thyroxine-binding globulin to further investigate the difference in binding characteristics 
of T4. Tyrosine and mono-iodotyrosine did not inhibit binding of T4 to transthyretin 
(Fig. 5b) nor thyroxine-binding globulin (Fig. 5a). However, tri-iodophenol and to a 
lesser extent di-iodotyrosine, inhibited T4 binding to transthyretin (Fig. 5b) but not to 
thyroxine-binding globulin (Fig. 5a). 
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Discussion 
The tested hydroxylated PCBs, PCDDs and PCDFs that inhibited ^-transthyretin 
binding, did not inhibit T4 binding to thyroxine-binding globulin. Moreover, the parent 
compounds 3,3',4,4'-tetraCB (TCB) and 2,3,3',4,4'-pentaCB (CB 105) did not show T4 
binding competition with transthyretin nor thyroxine-binding globulin. The T4-derived 
structures, tyrosine, mono-iodotyrosine, di-iodotyrosine and tri-iodophenol did not 
interact with thyroxine-binding globulin, while tri-iodophenol and to some extent di-
iodotyrosine competed with T4 for transthyretin. 
These data indicate that thyroxine-binding globulin, unlike transthyretin, is not a 
target protein for hydroxylated metabolites of PCBs, PCDDs and PCDFs. Furthermore, 
there are remarkable differences in ligand-protein interactions which may reflect 
different structural organisation of the T4 binding pockets of transthyretin and thyroxine-
binding globulin. The following features of thyroid hormones are important for optimal 
binding to thyroxine-binding globulin: (a) the L-alanine side chain conformation, (b) the 
presence of a 4'-hydroxyl group, (c) the presence of two substituents on the phenolic 
outer ring and the amino-phenyl inner ring (positions 3, 5, 3' and 5') and (d) the 
presence of either bromine or iodines on the inner amino-phenyl ring and iodines on the 
outer phenolic ring (Snyder et ah, 1976). Especially the inner ring iodines seem to be 
important for T4 binding to thyroxine-binding globulin. This suggests the structural need 
for a second halogenated phenyl-ring of compounds inhibiting T4 binding to thyroxine-
binding globulin. Binding to thyroxine-binding globulin also requires the L-configurated 
ammonium-ion and the negative charged carboxylate ion of the amino-sidechain of T4 
(Snyder et ah, 1976). Of lesser importance is the presence of an oxygen atom in the 
ether position of T4. 
Table 2 T„-transthyretin binding inhibition potencies (IC50), relative potencies of transthyretin 
binding (Lans et a/., 1993) and 125I-T4 binding to thyroxine-binding globulin (% bound of control 
at 250 nM competitor added) of hydroxylated polychlorodibenzo-p-dioxins (PCDDs) and 
polychlorodibenzofurans (PCDFs). Compounds are numbered as in fig. 2. Relative potency is 
given as the ratio of IC50(T4)/IC50(compound). Results shown are means ± S.D. of triplicate 
measurements. Values that differ significantly (Student's t-test) from the natural ligand 
thyroxine (T4), are indicated: "p < 0.05 
No 
L 
M 
N 
0 
P 
Q 
Structure 
Thyroxine 
2-OH-7,8-diCDF 
8-OH-2,3,4-triCDF 
3-OH-2,6,7,8-tetraCDF 
8-OH-2,3-diCDD 
7-OH-2,3,8-triCDD 
2-OH-1,3,7,8-tetraCDD 
TTR IC50 
(nM) 
138 
> 1 0 0 0 
> 1 0 0 0 
30.2 
> 1 0 0 0 
136 
31.6 
TTR rela-
tive poten-
cy 
1 
< < 1 
< < 1 
4.5 
< < 1 
1.0 
4.37 
TBG 
% 125I-T4 bound 
17.0 ± 2.0 
113.4 ± 4.8a 
105.3 ± 0.5a 
98.1 ± 3.0" 
102.1 ± 1.1" 
105.9 ± 8.3a 
95.3 ± 10.3a 
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The halogen substitutions on the outer phenolic ring appear to have two roles in binding 
to thyroxine-binding globulin: one is to increase the ionization of the 4 '-hydroxyl group 
and the other is to contribute directly to hydrophobic bonding. According to Snyder et 
al. (1976) substitution of a smaller halogen (like bromine) for iodine on the inner 
amino-phenyl ring (positions 3 and 5) allows a closer approximation of this ligand to its 
binding site on thyroxine-binding globulin while bromines on the outer phenolic ring 
(positions 3 ' and 5') results in a marked decrease in thyroxine-binding globulin binding 
potency. Chlorine or bromine instead of iodine substitutions on ligands give weaker 
interactions with thyroxine-binding globulin due to the aromatic character of the binding 
site (Terry and Blake, 1992). So the tested (hydroxylated) PCBs, PCDDs and PCDFs 
may be unable to compete for T4 binding to thyroxine-binding globulin as is shown in 
this study due to the chlorine substituents and the absence of a charged amino-sidechain 
and a tyrosine ring. 
Additional experiments on thyroxine-binding globulin and transthyretin with 
thyroid hormone derived structures showed that tri-iodophenol and to a lesser extent di-
iodotyrosine competively inhibited T4-transthyretin binding, but not the binding of T4 to 
thyroxine-binding globulin. These binding studies using mono-aromatic ring derivatives 
of T4 indicate the importance of the phenolic ring with iodine atoms adjacent to the OH-
group for binding to transthyretin but not to thyroxine-binding globulin. This explains 
why transthyretin is a target protein for the OH-metabolites of PCBs, PCDDs and 
PCDFs, while thyroxine-binding globulin is not; e.g. these compounds do contain a phe-
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Figure 4 Thyroxine (T4) and derived structures: tyrosine (Tyr), mono-iodotyrosine (MIT), di-
iodotyrosine (DIT) and 2,4,6-triiodophenol (TIP), as tested in the in vitro competition binding 
assays, described in Materials and Methods. 
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Figure 5 A) Competitive binding to thyroxine-binding globulin and B) competitive binding to 
transthyretin of T4( + ), tyrosine(O), mono-iodotyrosine(D), di-iodotyrosine(T) and tri-iodophe-
no l ( * ) (fig. 4) as measured by the in vitro competition binding assay (Materials and Methods). 
Datapoints are mean values of duplicate incubations. Relative 125l-T4-thyroxine-binding globulin 
or m l-T4-transthyretin binding (% of control value) is plotted against the log concentration (nM) 
of competitor or T4 added. 
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nolic ring with halogen atoms adjacent to the OH-group. T4-transthyretin binding 
competition is also found with other phenolic compounds like chlorophenols (Vanden-
Berg, 1990, Den Besten et al., 1991). 
The increase in T4-transthyretin binding competition, as found with increasing 
numbers of iodines adjacent to the hydroxyl group (di-iodotyrosine and tri-iodophenol) 
confirm the importance of the outer phenolic ring iodines of T4 for transthyretin binding 
as found by Andrea et al. (1980). The inability of tyrosine and mono-iodotyrosine to 
bind to transthyretin may be explained by the lack or inadequate number of iodine 
substitutions. 
The presence of the amino acid side chain in addition to the phenolic ring does 
not suffice for binding of the mono-cyclic aromatic analogues of T4 to thyroxine-binding 
globulin, indicating the need for other structural characteristics of compounds for 
binding to thyroxine-binding globulin. Major differences in binding to transthyretin or 
thyroxine-binding globulin are also found for various acidic drugs which had structural 
similarity to T4 (Munro et al., 1989), the drugs being more potent inhibitors of T4-
transthyretin than T4-thyroxine-binding globulin binding. 
The binding of T4 to thyroxine-binding globulin or transthyretin is accomplished 
through diverse mechanisms with different structural elements of the natural ligand T4. 
In addition there seems to be a major difference in the role of transthyretin and 
thyroxine-binding globulin in rodents and man with regard to T4 transport in blood. 
Interaction of hydroxylated PCBs, PCDDs and PCDFs with thyroid hormone transport 
proteins will be limited to T4-transthyretin binding inhibition according to the results 
from this study. Some, especially lower chlorinated PCB, PCDD or PCDF congeners 
can be metabolized to hydroxylated compounds in rats and mice (Klasson-Wehler et al., 
1989, Klasson-Wehler et al., 1993, Koga et al, 1990, Mason and Safe, 1986, Ramsey et 
al., 1982). Metabolites of 2,3,3',4,4'-pentachlorobiphenyl have been found in the blood 
of different environmentally exposed species like seal, polar bear and man (Klasson-
Wehler et al, 1992). These hydroxylated metabolites of PCBs, PCDDs and PCDFs may 
be partially involved in the observed plasma reductions in thyroid hormone levels in 
several laboratory species exposed to these compounds. 
The differences in T4 plasma transport in rodents and man may cause less 
extensive disturbances in T4 homeostasis after exposure to PCBs, PCDDs or PCDFs in 
man compared to rat. However, since T4 transport to the brain is thought to be mediated 
specifically by transthyretin (Herbert et al, 1986, Dickson et al, 1985), the ^-transthy-
retin binding inhibition or the specific retention of hydroxylated PCB, PCDD and PCDF 
metabolites due to transthyretin binding may be of relevance to the neurotoxic effects of 
PCBs and related compounds in rats (Morse et al, 1993b) and man. 
A ckno wledgements 
We kindly thank prof. dr. S. Safe from the Department of Veterinary Physiology and 
Pharmacology, A & M University, College Station Texas for providing us the hydroxy-
lated PCDDs and PCDFs and dr. E. Klasson-Wehler from the Department of Environ-
mental Chemistry, Wallenberg Laboratory, Stockholm University, S-10691 Stockholm, 
Sweden for providing us the hydroxylated PCBs. 
CHAPTER 4 
In vitro inhibition of thyroxine type 1 deiodinase by 
hydroxylated polychloro-biphenyls, -dibenzo-p-dioxins and 
-dibenzofurans 
Abstract 
In earlier studies hydroxylated metabolites of polychloro-biphenyls (PCBs), dibenzo-p-
dioxins (PCDDs) and dibenzofurans (PCDFs) were found to competitively inhibit 
thyroxine (T4) binding to transthyretin (TTR) but not to thyroxine-binding globulin 
(TBG), both plasma thyroid hormone transport proteins. In this study we investigated 
the possible inhibition of thyroxine type-1-deiodinase (ID-1), another T4 binding protein 
involved in the enzymic conversion of T4 to T3 and/or reverse T3 (rT3), by several 
hydroxylated PCBs, PCDDs and PCDFs. Rat hepatic microsomes were used in an in 
vitro ID-1 activity assay, with labeled rT3 as the substrate and increasing amounts of 
hydroxylated PCBs, PCDDs and PCDFs were added as inhibitors. The formation of free 
labeled iodide by the conversion of rT3 to T2 in hepatic microsomal incubations was 
used as a measure for outer ring ID-1 activity. Only the dihydroxylated metabolites 
(4,4'-(OH)2-3,3',5,5'-tetraCB, 4,4'-(OH)2-2,3,3',5,5'-pentaCB and 4,4'-(OH)2-3,3'-
dibromobiphenyl strongly inhibited ID-1 activity. The inhibition constants (Kj) of these 
compounds (3.7*10* - 2.7*10"7 M) were in the same order of magnitude as the K^ value 
for the preferred natural substrate rT3 (6.4* 10'8 M). Monohydroxylated metabolites of all 
classes of compounds inhibited ID-1 activity only at concentrations 10 to 100 times 
higher. The inhibition of ID-1 activity by these hydroxylated PCB metabolites was of 
competitive nature as was shown for 5-OH-3,3',4,4'-tetraCB and 4,4'-(OH)2-3,3',5,5'-
tetraCB. The data presented in this study indicate that the structural requirements for ID-
1 inhibition by metabolites of PCBs, PCDDs and PCDFs are preferentially dihydroxy-
lation and halogen substitution adjacent to (at least) one hydroxy-group. The observed 
inhibition of ID-1 activity by hydroxylated PCBs, PCDDs and PCDFs with this in vitro 
system suggests that hydroxylated metabolites may play a role in the decrease in hepatic 
ID-1 activity found in rats after exposure to PCBs and related compounds. 
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Introduction 
Polychloro-biphenyls (PCBs), -dibenzofurans (PCDFs) and -dibenzo-p-dioxins (PCDDs) 
are contaminants ubiquitously present in the environment. Due to their lipophilic 
character these compounds bio-accumulate through the foodchain, resulting in relatively 
high levels in top-predators like fish-eating birds, marine mammals and man. Toxic 
effects observed in animals and man after exposure to these compounds include 
developmental and reproductive toxicity, dermal lesions, hepatotoxicity, carcinogenesis, 
endocrine effects and induction of various drug-metabolizing enzymes (McConnell, 
1980; Safe, 1992). 
Disturbances in thyroid hormone levels and metabolism are among the endocrine 
effects observed in animals following exposure to PCBs and related compounds. 
Exposure of rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Bastomsky, 1977; 
Lucier et al., 1975; Potter et al, 1983; Lans et al, 1990), 3,3',4,4'-tetrachlorobiphenyl 
(TCB) (Beetstra et al, 1991; Brouwer and Van den Berg, 1986), 3,3',4,4',5,5'-hexa-
chlorobiphenyl (Morse et al, 1993a), Aroclor 1254 (Bastomsky, 1974), Kanechlor 400 
(Saito et al., 1991) and several polybrominated biphenyls (Byrne et al., 1987; Gupta et 
al., 1983; Spear et al., 1990) resulted in increased glucuronidation and biliary clearance 
of thyroxine (T4) and decreased plasma T4 levels. TCDD and TCB are also reported to 
decrease thyroxine ID-1 activity in rat liver in vivo (Adams et al., 1990, Eltom et al., 
1992). 
In addition to the effects of these compounds on thyroid hormone metabolism, a 
hydroxylated TCB-metabolite (4-OH-3,3',4',5-TCB) was found to interact with transthy-
retin (TTR), a thyroid hormone binding transport protein in the blood, after exposure of 
rats to TCB (Brouwer and Van den Berg, 1986; Brouwer, 1989). In vitro studies showed 
that several different hydroxylated PCB, PCDF and PCDD metabolites but not the 
parent compounds could displace T4, the natural ligand, from TTR (Brouwer et al., 
1990; Lans et al., 1993). This was explained by the striking structural resemblance of 
these hydroxylated metabolites with T4. However, the same hydroxylated metabolites did 
not interact with thyroxine-binding globulin (TBG), the major thyroid hormone plasma 
transport protein in man (Lans et al., 1994). 
Another T4-binding protein, type-1-deiodinase (ID-1), present in rat liver was 
inhibited in vitro by hydroxy-metabolites of TCB, but not by TCB itself (Adams et al, 
1990). The potency of the different TCB-metabolites was considerably lower for 
inhibition of the ID-1 activity as compared to the inhibition of T4 binding to TTR. 
Kohrle et al. (1986) and Aufmkolk et al. (1986) however showed strong correlations 
between the structural requirements for inhibition of T4 binding to TTR and inhibition of 
rat liver ID-1 activity by thyronine analogues without iodines on the phenolic ring and 
aurone derivatives. 
ID-1 is one of three known thyroid hormone deiodinases, present in animals and 
man, with different substrate specificities and organ distribution. ID-1 is mainly present 
in liver, kidney and brain, prefers reverse T3 (3,3',5'-triiodothyronine, rT3) as a substrate 
over T4 and requires reduced dithiols as cofactor for deiodination in vitro. ID-1 can 
deiodinate the inner and outer ring of T4, resulting in the biologically active T3 or the 
inactive rT3, respectively (Leonard, 1990; Visser, 1991). Due to these important charac-
teristics of ID-1 activity, possible inhibition by hydroxylated PCB, PCDD and PCDF 
metabolites could play a role in the disturbances in thyroid hormone levels and metabo-
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lism found in animals exposed to PCBs and related compounds. 
When comparing the various thyroid hormone binding proteins, e.g. TTR, TBG 
and ID-I, inhibitors of ligand binding or enzyme activity apparantly seem to require 
different structural characteristics. Due to the structural resemblance of hydroxylated 
PCB, PCDD and PCDF metabolites with T4, we continued to focus our attention on T4 
binding proteins as possible target proteins for these compounds that may mediate toxic 
responses. The reported effects of TCB and TCDD on the ID-1 activity in rat liver in 
vivo, and the in vitro effects of hydroxylated TCB-metabolites, prompted us to inves-
tigate the inhibitory potency of different hydroxylated PCB, PCDD and PCDF metabo-
lites on ID-1 activity in an in vitro system. 
Materials and methods 
Materials 
The hydroxylated PCBs and PBB (Fig. 1) used in the present study: 2-OH-2',3,3',4,4'-
pentaCB (A), 4-OH-2',3,3',4',5-pentaCB (B), 5-OH-2',3,3',4,4'-pentaCB* (C), 2-OH-
3,3',4,4'-tetraCB (D), 4-OH-3,3',4',5-tetraCB (E), 5-OH-3,3',4,4'-tetraCB* (F), 4-OH-
3,3',4'-triCB (G), 4-OH-2,3,3',4'-tetraCB (H), 4-OH-2,2',3,3',4'-pentaCB (I), 4,4'-
(OH)2-3,3',5,5'-tetraCB (J), 4,4'-(OH)2-2,3,3',5,5'-pentaCB (K) and 4,4'-(OH)2-3,3'-
diBB (L) were obtained by demethylation of the corresponding methoxy-PCBs or PBB 
(Klasson-Wehler et al., 1990). The methoxy-PCBs were prepared and structures verified 
as described elsewhere (Lans et al., 1993). *The numbering of the hydroxy-substituents 
on the biphenyl does not follow IUPAC rules but has been chosen in order to facilitate 
comparison of the structures.) 
The tested hydroxylated chlorodibenzo-p-dioxins and chlorodibenzofurans 2-OH-
1,3,7,8-tetraCDD (N), 7-OH-2,3,8-triCDD (O), 8-OH-2,3-diCDD (P), 3-OH-2,6,7,8-
tetraCDF (Q), 8-OH-2,3,4-triCDF (R) and 2-OH-7,8-diCDF (S), shown in Figure 1, 
were synthesized as previously described (Mason and Safe, 1986; Denomme et al., 
1985; Denomme et al., 1986) and kindly provided by prof. S. Safe of the Department of 
Veterinary Physiology and Pharmacology, Texas A&M University, College Station, 
Texas, U.S.A.. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) (M) was commercially ob-
tained from Schmidt B.V., Amsterdam, The Netherlands. 
Methanol (HPLC grade) was obtained from Merck Chemical Company (Darm-
stadt, Germany). Reverse T3 was obtained from Henning (Berlin, Germany); Sephadex 
LH-20 was purchased from Pharmacia (Woerden, The Netherlands). 3,3',5'-'25I-triiodo-
thyronine (['25I]rT3) was purchased from Amersham, Aylesbury, Buckinghamshire, 
United Kingdom, (specific activity 1200 uCi/|xg rT3). 
Microsomal preparations 
Microsomal preparations were made according to Visser et al. (1979) from livers of 2 
female Wistar rats (16 weeks old). Livers were perfused with 0.9 % (w/v) NaCl, 
homogenized in 10 mM Tris, pH 7 with 0.25 M sucrose and 1 mM DTT and centri-
fuged at 9000g for 30 minutes. The supernatant was collected and centrifuged at 
105.000g for 90 minutes. The resulting pellet was resuspended in 10 mM Tris, pH 7.4, 3 
mM EDTA, 1 mM DTT and microsomes were stored at -80 °C until further use. 
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Hepatic microsomal type 1 rT3 deiodinase assay 
Hepatic type 1 deiodinase (ID-1) activity was determined in triplicate in microsomal 
preparations by the formation of l25I" from [125I]rT3 according to Mol et dl. (1985). 50 ul 
of 100 u.g microsomal protein/ml in 200 mM phosphate-buffer pH 7.4, containing 4 raM 
EDTA and 2 mM DTT was incubated for 30 minutes at 37 °C with 50 ul 0.2 uM 
[125I]rT3, 50 ul incubation buffer and 50 ul of the test compounds (0-40 uM) stock 
solutions dissolved in methanol, or methanol as control to the reaction mixtures 
(methanol concentration in incubation mixture was 1%). The reaction was started by 
adding the microsomal protein and stopped by addition of 750 ul 0.1 M HC1. The 125I" 
produced was separated from the reaction mixture by Sephadex LH-20 chromatography 
according to Otten et dl. (1984) and counted on a Cobra Auto Gamma counter (Canber-
ra-Packard). Microsomes boiled for 10 minutes were used as blanks. The percentage of 
deiodination was determined by dividing the number of counts from the 125P fraction by 
the total number of counts in the incubation. Controls were used to determine 100 % 
ID-1 activity. Inhibition curves indicate the % of ID-I activity inhibition compared to 
controls against the log concentration of competitor added (means + standard deviations 
of triplicates). 
To determine competitive or non-competitive inhibition by 4,4'-(OH)2-3,3',5,5'-
tetraCB and S-OH-S.S'^^'-tetraCB increasing amounts of rT3 (0 - 3.2 uM in the 
incubation) were used in the in vitro ID-1 activity assay, with constant amounts of 4,4'-
(OH)2-3,3',5,5'-tetraCB and 5-OH-3,3',4,4'-tetraCB or no inhibitor and 25 |xg/ml 
microsomal protein in the final incubation. In order to determine a good inhibitor 
concentration, the inhibition of ID-1 activity by 5-OH-3,3',4,4'-tetraCB and 4,4'-(OH)2-
3,3',5,5'-tetraCB metabolite was again tested using higher concentrations (0-20 uM) 
than in the inhibition studies described earlier. A constant inhibitor concentration of 2 
uM was chosen for the incubations with increasing amounts of substrate (rT3). ID-1 
activity was calculated in nmol I7min/mg protein. Lineweaver Burk plots were plotted 
with l/[rT3] in uM"1 on the X-axis and 1/V (nmol1 *min*mg) on the Y-axis. In the plots 
of the incubations without inhibitor the Y-axis intercept represents 1/Vmax, while the X-
axis represents -1/Km. In the plots of the incubations with an inhibitor the Y-axis 
intercept also represents 1/Vmax, while the X-as intercept represents -l/Km(K/(Ki+[I])). 
So Vmax, K,,, and K( can be calculated from these Lineweaver Burk plots. 
Analysis of inhibition potency 
Curve-fitting of the inhibition curves using non-linear regression, using Graphpad Inplot, 
was performed and IC50 and IC80 values (molar concentrations of competitor which 
inhibit ID-1 activity to 80% and 50% of control) were calculated using the fitted curve. 
K( values were calculated using the rT3 concentration of 50 nM (L) and the K,„ value for 
rT3 of 64 nM (K) (33) with the formula: K, = EC50/(1+L/K) 
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Figure 1 Structures of hydroxylated PCBs, PCDDs and PCDFs tested in the ID-1 activity assay 
and synthesized as described in Materials and Methods; 2-0H-2',3,3',4,4'-pentaCB (A), 4-OH-
2',3,3',4',5-pentaCB (B), 5-OH-2',3,3',4,4'-pentaCB (C), 2-OH-3,3',4,4'-tetraCB (D), 4-OH-
3,3',4',5-tetraCB (E), 5-OH-3,3',4,4'-tetraCB' (F), 4-OH-3,3',4'-triCB (G), 4-OH-2,3,3',4'-
tetraCB (H), 4-OH-2,2',3,3',4'-pentaCB (I), 4,4'-(OH)2-3,3',5,5'-tetraCB (J), 4,4'-(OH)2-
2,3,3',5,5'-pentaCB (K), 4,4'-(OH)2-3,3'-diBB (L), TCDD (M), 2-OH-1,3,7,8-tetraCDD (N), 7-OH-
2,3,8-triCDD (O), 8-OH-2,3-diCDD (P), 3-OH-2,6,7,8-tetraCDF (Q), 8-OH-2,3,4-triCDF (R) and 
2-OH-7,8-diCDF (S). 'The numbering of the hydroxy-substituents on the biphenyl does not 
follow IUPAC rules but has been chosen in order to facilitate comparison of the structures.) 
Results 
The inhibition of ID-1 activity by the tested hydroxylated PCBs, PCDDs and PCDFs 
(Fig. 1) is summarized in Table 1. For most compounds an IC80 value was calculated, 
IC50 values were only available for the most potent inhibitors (compounds F, J, K, L). 
Compounds B, C, I, M, P, R and S did not inhibit ID-1 activity to 80% of control at the 
highest concentration added (1*10"5 M), therefore no IC50 or IC80 could be calculated. 
The dihydroxylated PCB compounds (J, K, L) strongly inhibited ID-1 activity 
(Table 1). 4,4'-(OH)2-2,3,3',5,5'-PentaCB (K) had the strongest inhibitory potency (IC50: 
6.44*10"8 M), followed by 4,4'-(OH)2-3,3',5,5'-tetraCB (J, ICS0: 1.92*10"7 M) and 4,4'-
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(OH)2-3,3'-diBB (L, IC50: 5.95* 10"7 M). The inhibition curves are shown in Figure 2. In 
Table 2 the calculated inhibition constants (K )^ of the dihydroxylated PCB compounds 
are listed. All K;'s found are between 3.7* 10"8 M and 2.7* 10"7 M, which is in the range 
of the K,,, for rT3 (6.4*10"8 M) (Visser et al, 1984). 
Table 1 Inhibition of ID-1 activity by tested hydroxylated PCBs, PCDDs and PCDFs. 
Compound 
2-OH-2',3,3',4,4'-pentaCB 
4-OH-2',3,3' ,4' ,5-pentaCB 
5-OH-2',3,3',4,4'-pentaCB 
2-OH-3,3',4,4'-tetraCB 
4-OH-3,3',4',5-tetraCB 
5-OH-3,3',4,4'-tetraCB 
4-OH-3,3',4'-tr iCB 
4-OH-2,3,3',4'- tetraCB 
4-OH-2,2' ,3,3' ,4 '-pentaCB 
4,4'-(OH)2-3,3',5,5'-tetraCB 
4,4'-(OH)2-2,3,3',5,5'-pentaCB 
4,4'-(OH)2-3,3'-diBB 
2,3,7,8-tetraCDD 
2-OH-1,3,7,8-tetraCDD 
7-OH-2,3,8-triCDD 
8-OH-2,3-diCDD 
3-OH-2,6,7,8-tetraCDF 
8-OH-2,3,4-triCDF 
2-OH-7,8-diCDF 
Code 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
K 
L 
M 
N 
0 
P 
Q 
R 
S 
IC80 (M) 
5.16 10"6 
-
-
1.25 10'6 
3.12 10"7 
8.25 10"7 
1.17 10"5 
1.10 10"5 
-
3.57 10"8 
1.47 1 0 8 
1.31 10'7 
-
1.29 10"6 
4.11 10"6 
-
2.42 10"6 
-
-
IC50 (M) 
-
-
-
-
-
3.63 10-6 
-
-
-
1.92 10"7 
6.44 10 s 
5.95 1 0 7 
-
-
-
-
-
-
-
Note: IC80 and IC50 values (molar concentrations of inhibitor resulting in inhibition of ID-1 
activity to 80% and 50% of control (no inhibitor)) are calculated by non-linear regression curve 
fitting of inhibition curves (not shown). The compounds are coded as in Figure 1. (- = no 
calculation of IC80 or IC50 possible due to little or no inhibition of ID-1 activity). 
Chapter 4 55 
Of the mono-hydroxylated 2',3,3',4,4'-pentaCB metabolites, only 2-OH-2',3,3\4,4'-
pentaCB (A) inhibited ID-1 activity to 80% of control at a high concentration (5.16*10"* 
M). The 4-OH-2',3,3\4\5-pentaCB (B) and 5-OH-2',3,3',4,4'-tetraCB (C) showed no 
inhibitory potency. The hydroxylated 3,3',4,4'-tetraCB metabolites all inhibited ID-1 
activity with different potencies (Fig. 3); 5-OH-3,3',4,4'-tetraCB (F) was the strongest 
inhibitor (IC50: 3.63*10"* M) followed by 4-OH-3,3',4',5-tetraCB (E) and 2-OH-
3,3',4,4'-tetraCB (D) with IC80s of 3.12*10"7 and 1.25*10"* M, respectively (Table 1). 
The non- and mono-ortfio-chlorine substituted 4-OH-PCB metabolites 4-OH-3,3',4'-
triCB (G) and 4-OH-2,3,3',4'-tetraCB (H) weakly inhibited ID-1 activity (IC80: 1.17*10"5 
and 1.10*10"5 M) while the di-ortfjo-chlorine 4-OH-pentaCB, 4-OH-2,2',3,3',4'-pentaCB 
(I), did not inhibit ID-1 activity (Table 1). 
Of the tested hydroxylated PCDDs only the two hydroxylated metabolites of 
TCDD, 2-OH-l,3,7,8-tetraCDD (N) and 7-OH-2,3,8-triCDD (O), weakly inhibited ID-1 
activity with IC80s of 1.29*10* and 4.11*10"* M (Table 1). The parent compound TCDD 
(M) and 8-OH-2,3-diCDD (P) showed no inhibitory action on type 1-D activity. 3-OH-
2,6,7,8-tetraCDF (Q) had an IC80 of 2.42*10* M, whereas the other hydroxylated 
PCDFs, 8-OH-2,3,4-triCDF (R) and 2-OH-7,8-diCDF (S) did not inhibit ID-1 activity 
(Table 1). 
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Figure 2 Inhibition of ID-1 activity by dihydroxylated compounds 4,4'-(OH)2-3,3',5,5'-pentaCB 
(J, A ) , 4,4'-(OH)2-2,3,3',5,5'-pentaCB (K, O), 4,4'-(OH)2-3,3'-diBB (L, • ) . Datapoints are mean 
values of triplicates with standard deviation. Control ID-1 activity was 60.15 ± 0.44 pmol 
l/min/mg. Percentage of ID-1 inhibition compared to control is plotted against log concentration 
of inhibitor (nM). 
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Figure 3 Inhibition of ID-1 activity by hydroxylated metabolites of 3,3',4,4'-TCB; 2-OH-
3,3',4,4'-tetraCB (D, • ) , 4-OH-3,3',4',5-tetraCB (E, A) , 5-OH-3,3',4,4'-tetraCB (F, O). 
Datapoints are mean values of triplicates with standard deviation. Control ID-1 activity was 
60.15 ± 0.44 pmol l/min/mg. Percentage of ID-1 inhibition compared to control is plotted 
against log concentration of competitor (nM). 
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Figure 4 Inhibition of ID-1 acitivity by the hydroxylated PCB metabolites of 5-OH-3,3',4,4'-
tetraCB (F, A) and 4,4'-(OH)2-3,3',5,5'-tetraCB (J, • ) . Datapoints are mean values of triplicates 
with standard deviation. Control ID-1 activity was 60.45 pmol l/min/mg. Percentage of ID-1 
inhibition compared to control is plotted against log concentration of competitor (nM). 
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To determine whether the inhibition of ID-1 activity by the hydroxylated PCBs 
and related compounds was of competitive or non-competitive nature, additional 
experiments were carried out in incubations using a constant amount of the inhibitors 
4,4'-(OH)2-3,3\5,5'-tetraCB or 5-OH-3,3',4,4'-tetraCB and increasing amounts of rT3 as 
the substrate. In order to determine a good inhibitor concentration, the inhibition of ID-1 
activity by 5-OH-3,3',4,4'-tetraCB and 4,4'-(OH)2-3,3',5,5'-tetraCB metabolite was 
again tested in an in vitro ID-1 activity assay, using higher concentrations (0-20 uM) 
than in the inhibition studies described earlier. The inhibition curve is shown in figure 4. 
Using curve-fitting by non-linear regression the Kj's and ICS0 values were calculated for 
5-OH-3,3',4,4'-tetraCB (K;: 1.39 10"6 M"1; IC50: 3.05 10"6 M) and 4,4'-(OH)2-3,3',5,5'-
tetraCB (Kf: 0.41 10"6 M1; IC50: 0.84 10"6 M), which were in the same range as the Kj's 
and IC50 listed in Table 1 and 2 for these two compounds. In figure 5A the double 
reciprocal Lineweaver Burk plots determined by linear regression are shown of the ID-1 
activity assay incubations using constant amounts of inhibitors. Vmax's, determined from 
the y-axis intercept, are almost identical for the incubations with 5-OH-3,3',4,4'-tetraCB, 
4,4'-(OH)2-3,3',5,5'-tetraCB and without inhibitor (respectively 0.59, 0.69 and 0.80 
nmol/min/mg), indicating a competitive inhibition of ID-1 activity. The K/s calculated 
using the X-intercepts of the Lineweaver-Burk plots were 1.80 and 0.57 * 10"6 M"1 for 5-
OH-3,3',4,4'-tetraCB and 4,4'-(OH)2-3,3',5,5'-tetraCB, respectively. When linear 
regression was performed on the Lineweaver-Burk plots using the average Vmax (1/Y-
axis intercept: 0.71 * 10"6 M"'), assuming competitive inhibition, the Kj's found were 
1.31 and 0.51 * 10"6 M1, for 5-OH-3,3',4,4'-tetraCB and 4,4'-(OH)2-3,3',5,5'-tetraCB, 
respectively (Fig. 5B). 
Discussion 
Of all hydroxylated PCBs, PCDDs and PCDFs tested only 4 were strong inhibitors of 
ID-1 activity, namely 4,4'-(OH)2-3,3',5,5'-tetraCB, 4,4'-(OH)2-2,3,3',5,5'-pentaCB, 4,4'-
(OH)2-3,3'-diBB and 5-OH-3,3',4,4'-tetraCB. All other compounds were not able to 
inhibit ID-1 activity by 50% at concentrations up to 10 uJvl. TCDD was not able to 
inhibit ID-1 activity and its major metabolite in vivo, 2-OH-l,3,7,8-tetraCDD (Mason 
Table 2 Inhibition constants (K,) of tested dihydroxylated PCBs (Fig. 1: J,K,L). 
Compound 
4,4'-(OH)2-2,3,3',5,5'-pentaCB (K) 
4,4'-(OH)2-3,3',5,5'-tetraCB (J) 
4,4'-(OH)2-3,3'-diBB (L) 
MM) 
3.70 10'8 
1.13 10"7 
2.69 TO"7 
Note: Ki's are calculated by non-linear regression curve fitting of the inhibition curves shown in 
Figure 2, using the formula Kj = EC60/(1 +L/K), with L = 50 nM (rT3 concentration) and K = 64 
nM (Km of rT3). 
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Type-1 -delodinase 
Lineweaver-Burk plot 
Type-1-delodinase 
Lineweaver-Burk plot 
1/[rT3] (1/uM) 
Figure 5 Double reciprocal Lineweaver-Burk plots of inhibition of ID-1 activity using increasing 
concentrations of substrate rT3 (0-3.2 //M) in the presence of 2 /JM 5-OH-3,3',4,4'-tetraCB (F, 
A) , 2 /vM 4,4'-(OH)2-3,3',5,5'-tetraCB (J, O) or without inhibitor ( + ). 1 /ID-1 activity (min/mg/n-
mol I) is plotted against 1/[rT3] substrate concentration (1///M) without average Vmax (A) and 
with average Vmax (B). Y-axis intercept represents 1 A/max, while X-axis intercept represents -
1/Km. Datapoints are means of triplicates. 
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and Safe, 1986; Ramsey et al., 1982), only weakly inhibited ID-1 activity at concen-
trations above 0.1 uM. Lineweaver-Burk plots showed a competitive inhibition of ID-1 
activity by 5-OH-3,3',4,4'-tetraCB and 4,4'-(OH)2-3,3',5,5'-tetraCB. 
The dihydroxylated 4,4'-(OH)2-2,3,3',5,5'-pentaCB was the strongest inhibitor of 
ID-1 activity, followed by 4,4'-(OH)2-3,3',5,5'-tetraCB and the 4,4'-(OH)2-diBB. The 
bromine substituted dihydroxy-congener was as potent as the chlorine substituted 
dihydroxylated PCBs for ID-1 inhibitors, indicating no major influence of chlorine or 
bromine substitutions on inhibitory potency. The K;'s calculated for the dihydroxylated 
compounds have values ranging between the K,,, for rT3 (64 nM), the preferred natural 
substrate for ID-1, and the K^ for T4 (1.9-2.3 uM), another natural substrate (Visser et 
al., 1984; Visser, 1990). The presence of two hydroxyl group substitutions appears to be 
important for the strong inhibitory action, because related mono-hydroxymetabolites (4-
OH-3,3',4',5-TCB and 4-OH-2,3,3',4',5-PeCB) are only weak inhibitors of ID-1 activity. 
Ort/zo-chlorine substitution does not influence inhibitory action for dihydroxylated 
metabolites; the (OH)2-pentaCB is the most potent inhibitor. However, for the monohy-
droxylated PCB metabolites, ort^o-chlorination seemed to decrease inhibitory potency of 
these metabolites. 
In an earlier in vitro study by our laboratory on the effects of TCB and its 
hydroxylated metabolites on ID-1 activity (Adams et al., 1990), the same structure 
activitity relations as in this study were found for the 2-OH-3,3',4,4'-, 4-OH-3,3',4',5-
and 5-OH-3,3',4,4'-tetraCB metabolites. In both studies 5-OH-3,3',4,4'-tetraCB was 
found to be a stronger inhibitor than the 4-OH-3,3',4',5- and 2-OH-3,3',4,4'-tetraCB 
metabolites. The 6-OH-3,3',4,4'-tetraCB, not tested in this study, also inhibited ID-1 
activity, so or^o-hydroxylated compounds could also act as inhibitors as was found for 
the 2'-OH-2,3,3',4,4'-pentaCB metabolite in this study. Adams et al. (1990) found no 
inhibition of ID-1 activity by TCB, while in this study no inhibition by TCDD was 
found. This confirms the requirement of hydroxylation of the inhibitor, with chlorine(s) 
substituted adjacent to the hydroxyl group. The inhibition of ID-1 by the tested monohy-
droxylated compounds is of competitive nature as was found in this and other studies 
(Adams et al., 1990; Rickenbacher et al., 1989), with an inhibition constant in the 
micromolar range for 5-OH-3,3',4,4'-tetraCB which equals the Km for T4 (1.9-2.3 uM), 
but is higher than the Km of rT3 (64 nM) (Visser et al, 1984, Visser, 1990), both 
physiological substrates for ID-1. 
The differences in inhibition potencies of the hydroxylated PCDDs and TCDD 
suggest that at least one hydroxyl group is necessary for (weak) inhibitory action on ID-
1 activity. TCDD did not inhibit ID-1 activity, but the hydroxylated tetraCDD and 
triCDD, metabolites of TCDD in vivo, did. The hydroxylated PCDDs and PCDFs that 
had no chlorines next to the hydroxyl group, had no inhibitory potency indicating that 
halogen-substitution adjacent to the hydroxyl group may increase inhibition of ID-1 
activity. 
Several structural requirements for the competitive inhibitory action on ID-1 
activity by these halogenated aromatic compounds are suggested in this study. At least 
one hydroxyl group substitution is essential, while adjacent chlorine substitution seems 
to increase inhibitory potency on ID-1 activity by these compounds. Dihydroxylated 
poly-halogenated biphenyls with hydroxyl groups on both para-positions were very 
potent inhibitors, suggesting that the polarity or high degree of hydroxylation of these 
compounds may attribute to the inhibitory action. 
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Other halogenated dioxin and biphenyl derivatives were tested on inhibition of 
ID-1 activity in vitro by Rickenbacker et al. (1989), showing substrate competitive 
inhibition. 4,4'-(OH)2-3,3',5,5'-TetraCB was also tested in their study and was the 
strongest competitive inhibitor with an IC50 of 0.07 uM, comparable to the IC50 of the 
same compound found in this study (0.19 uM). Other hydroxylated PCB compounds 
tested by Rickenbacher et al. were 4,4'-(OH)2-2,3,5,6-tetraCB, 4-OH-3,4',5-triCB, 4'-
OH-2,4,6-triCB. Like the structural requirements found for ID-1 inhibitors in this study, 
Rickenbacher et al. (1989) found that the hydroxylated PCBs inhibited ID-1 with 
different potencies, suggesting an important role for dihydroxylation and chlorine 
substitution next to the hydroxyl group for good inhibitory action. Ortho chlorine 
substitutions on one phenyl ring resulted in low inhibitory potency for the monohy-
droxylated 4'-OH-2,4,6-triCB, but did not decrease inhibitory action of the dihydroxyla-
ted 4,4'-(OH)2-2,3,5,6-tetraCB. Thus, like in this study, orrto-chlorination only seemed 
to influence the inhibition potency of mono-hydroxylated PCB metabolites. The dibenzo-
p-dioxin-adipamide and 3,7,8-trichlorodibenzo-p-dioxin-adipamide derivates tested by 
Rickenbacher et al. (1989) also showed that chlorine substitutions and a polarizable 
group on these TCDD related compounds were necessary for inhibition of ID-1 activity, 
like was found for TCDD and its hydroxylated metabolites in this study. 
The ligand binding site of ID-1 is described by Kohrle et al. (1986), who 
determined the ligand binding characteristics of ID-1 by dose response inhibition of T4 
deiodination using iodothyronine analogues. The optimal structural requirements for a 
ID-1 substrate or inhibitor were a negatively charged side chain, a 4'-substituent with a 
phenolic pKa or hydrogen bonding capacity, at least one halogen on the tyrosyl ring and 
at least one polarizable group on the phenolic ring. These structural characteristics 
resemble the requirements of the presence of strong polarizable and at least one hydroxy 
group with adjacent halogenation on the hydroxylated PCBs and related compounds for 
ID-1 inhibition potency. However, it was not strictly necessary for the hydroxylated 
PCBs to have a hydroxyl group on the 4 (para)-position on the phenolic ring. Ortho 
(2')-iodine substituents of iodothyronine analogues were found to increase ID-1 in-
hibition, while ortho chlorination of monohydroxylated PCBs was found to decrease 
inhibitory potency in this study. Kohrle et al. (1986) found inhibition of ID-1 by 
thyronine analogues without iodines on the phenolic ring. This would mean that no 
halogen substituents are necessary for ID-1 activity inhibition. 
In another study by Auf mkolk et al. (1986) the interaction of aurone derivatives 
with the ID-1 binding site were evaluated by inhibition studies. Two mechanisms of ID-
1 activity inhibition were suggested, a cofactor competitive mechanism where hydroxy-
lated, non-halogenated aurones can bind to to the oxidized form of the deiodinase and 
prevent enzyme regeneration by the reduced dithiol cofactors. Another mechanism is the 
inhibition of ID-1 activity by iodinated aurones that compete with the substrate binding 
site of the native reduced enzyme. Iodination of ID-1 inhibitors seem to enhance their 
potency as substrate competitive inhibitors. The hydroxylated PCB, PCDD and PCDF 
metabolites tested in this study seem to inhibit ID-1 activity by a substrate competitive 
mechanism as was shown in the Lineweaver Burk plots, confirming the enhancing effect 
of the presence of halogen groups next to the hydroxyl group on ID-1 inhibitory action 
of these compounds. 
Other substrate or cofactor specific inhibitors of ID-1 activity are iodinated 
phenols and aniline derivatives like the X-ray contrast reagent iopanoic acid and ipodate, 
Chapter 4 61 
(halogenated) dyes like bromophenol blue, erythrosine and rose-bengal, thiourea 
derivatives and catecholamine (antagonists, usually all aromatic substances with halogen 
substituents adjacent to hydroxyl or amino-groups (Leonard and Visser, 1986). In 
addition to these known inhibitors of ID-1 activity, this study shows that OH-metabolites 
of PCBs, PCDDs or PCDFs are also capable of inhibiting ID-1 in a substrate competiti-
ve manner. 
The compounds tested on ID-1 inhibitory action in this study have also been 
tested on inhibition of T4 binding to transthyretin (TTR) and thyroxine binding globulin 
(TBG) in in vitro binding competition studies (Lans et al., 1993, 1994). The major 
differences found were the almost essential requirement of dihydroxylation for ID-1 
inhibitory action, while monohydroxylated PCBs could be potent inhibitors of T4-TTR 
binding. The influence of ortfco-chlorine substitution of monohydroxylated PCBs, which 
seemed to decrease ID-1 inhibition, did not affect T4-TTR binding inhibition potency of 
the compounds. Kohrle et al. (1986) found that ID-1 showed no stereospecificity when 
D-T4 and L-T4 are used as substrates, whereas for the TTR binding site stereoselectivity 
has been found. Also the binding affinities of the naturals ligand are different for type 1-
D (rT3 » T4) and TTR (T4 » rT3). Moreover, it is difficult to compare inhibition of 
enzymic activity with ligand binding, as two modes of enzyme activity inhibition are 
suggested. Thus one should be careful using the TTR binding site as a model for the ID-
1 active site in order to design or model other deiodinase inhibitors (Kohrle et al., 1986, 
Auf mkolk et al, 1986). It is clear however, that the binding site of ID-1 is more related 
to the TTR binding site than the TBG binding site, because hydroxylated PCBs, PCDDs 
and PCDFs showed no inhibition at all of T4-TBG binding in in vitro studies (Lans et 
al, 1994). 
ID-1 activity is important for the metabolism of rT3 and the activation or 
inactivation of T4 to resp. T3 or rT3 in the liver. The choice of rT3 as a substrate for ID-1 
activity in these inhibition studies with hydroxylated PCBs, PCDDs and PCDFs directs 
the enzyme to only perform outer ring deiodination (ORD) of the substrate. Exposure to 
PCBs and related compounds may result in metabolite formation in the liver in vivo 
(Darnerud et al, 1986; Klasson-Wehler et al, 1993, Abdel-Hamid et al, 1981; Koga et 
al., 1990). These metabolites could then inhibit ID-1 ORD activity, so rT3 may not be 
metabolized to T2 which can lead to increasing amounts of rT3. Because rT3 is the most 
potent ID-1 substrate, T4 may not be deiodinated to T3 because of the lowered ID-1 
activity and the increasing amount of rT3 present in the liver. In parallel these data can 
indicate that the conversion of T4 to T3, which also involves ID-1 ORD, may directly be 
reduced resulting in a decrease of T3 formation. Both pathways could lead to decreased 
amounts of bioactive T3 in the liver, affecting metabolism and T3 regulated processes. 
On the other hand, conversion of rT3 to T2 may not be inhibited due to the high affinity 
of rT3 for ID-1. This could imply that the physiological function of ID-1 in liver to 
eliminate extrahepatically formed rT3 from circulation is not influenced by these 
metabolites. 
Exposure of rats to TCDD and TCB leads to inhibition of ID-1 activity in the 
liver (Adams et al., 1990; Eltom et al., 1992). This could be due to the metabolites 
formed from these compounds in the liver, directly inhibiting ID-1 activity. In addition 
the exposure to PCBs and related compounds can decrease thyroid hormone levels in 
blood, which may also explain the observed reduction in ID-1 activity due to the 
modulating physiological effects of thyroid hormone levels in blood on hepatic ID-1 
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activity (Kaplan, 1986). Further experiments are necessary to distinguish between those 
causes that may lead to the decreased ID-1 activity in liver after exposure of rats to 
PCBs and related compounds. 
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CHAPTER 5 
In vivo alterations in thyroxine metabolism and plasma 
transport by Aroclor 1254 in rats 
Abstract 
Previous studies in our laboratory indicated that hydroxylated polychlorinated biphenyls 
(PCBs), -dibenzo-p-dioxins (PCDDs) and -dibenzofurans (PCDFs) could specifically inhibit 
thyroxine (T4) binding to transthyretin (TTR), a plasma thyroxine transport protein, and 
decrease type 1 thyroxine deiodinase activity in rat liver microsomes in vitro. In the present 
study the in vivo effects of exposure to Aroclor 1254 on plasma transport and hepatic 
metabolism of T4 was investigated in adult Wistar rats. Rats were exposed to a single i.p. 
dose of 50, or 500 mg Aroclor 1254/kg b.w. and killed and dissected after 3 or 8 days, 
while part of the pretreated rats were i.p. injected with 125I-T4 one day before section on day 
3 or 8, to determine thyroid hormone binding capacities of plasma proteins by 
polyacrylamide gelelectrophoresis (PAGE). Plasma total and free T4 levels were decreased 
in the high dosed, but not in the low dosed group, while total T3 levels were not changed 
by either treatment. Hepatic EROD activity was increased in the low and high dosed group, 
but cytochrome P450 levels and relative liver weight were only increased in the high dose 
group. No clear changes were found in hepatic type 1 T4 deiodinase (ID-I) activity. T4 
glucuronidation was increased in the high dosed groups at day 3 and 8 after Aroclor 1254 
administration. Ratios of l25I-T4 binding to TTR vs. albumin were significantly decreased 
in the high dosed group at day 8. In this treatment group a hydroxylated PCB-metabolite, 
4-OH-2,3,3',4',5-pentaCB, present in high concentrations in plasma, could interact with 
TTR in the blood and competitively inhibit T4 binding to TTR. In conclusion, both 
reduction of T4 binding to the plasma transport protein TTR and increased hepatic T4 
glucuronidation appeared to play a role in the decrease in plasma T4 levels by Aroclor 1254. 
In addition, selective plasma accumulation was shown of a specific hydroxylated PCB 
metabolite, e.g. 4-OH-2,3,3',4',5-pentaCB in rats exposed to the commercial PCB mixture 
Aroclor 1254. 
Martine C. Lans, Ingeborg Brouwer, Menrike Beukers, Eva Klasson-Wehler" and Abraham 
Brouwer 
'Environmental Chemistry, Wallenberg Laboratory, Stockholm University, 10691 Stockholm, 
Sweden 
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Introduction 
Polychlorinated biphenyls (PCBs) are a group of widespread and persistent environmental 
contaminants (McConnell, 1980; McFarland and Clarke, 1989; Safe, 1990, 1994). Due to 
their chemical stability and widespread use they have bioaccumulated in the foodchain 
during the last decades. The commercial PCB mixtures, which have been banned from 
industrial use since the early 1980s, contain PCB-congeners with a different degree of 
chlorination. The various congeners present in these mixtures can cause a broad range of 
adverse effects, such as alterations of epithelial differentiation, embryonal development, 
energy metabolism, reproduction and endocrine function (Ahlborg et al., 1992; Safe, 1994). 
These effects are highly dependent on age, sex, species and strain of animal used and the 
composition of the PCB-mixture, or the individual PCB-congener. 
Effects of PCBs on thyroid hormone metabolism are extensively described. Exposure 
to Aroclor 1254, a commercial PCB mixture containing 54 % chlorine (by weight), 
decreased plasma thyroxine (T„) levels (Gray et al., 1993; Byrne et al., 1987; Brouwer, 
1989) and increased T4 glucuronidation and bile flow in rats while plasma 3,3,5-
triiodothyronine (T3) levels were not decreased (Bastomsky, 1974; Beetstra et al., 1991). 
In addition, effects of Aroclor 1254 on thyroid function and morphology are described by 
Collins and Capen (1980a,b,c). Saito et al. (1991) found that Kanechlor 400, another 
commercial PCB mixture, also increased T4 glucuronidation in rats. Chronic exposure of 
rats to commercial PCB and polybrominated biphenyls (PBB) mixtures caused decreases 
in serum T3 and T4 levels and a decrease in the rate of T4 production which led to 
hypothyroidism (Byrne et al., 1987). Commercial PBB mixtures have also been reported 
to cause hypothyroidism in the mouse (Gupta et al., 1983). Moreover, changes in human 
serum T4 levels following exposure to PCBs or PBBs are described in several studies 
(Emmett et al, 1988, Murai et al, 1987, Bahn et al, 1980, Kreiss et al, 1982). 
Decreased plasma T4 levels in rodents after PCB exposure are commonly explained 
as the result of increased excretion and metabolism (increased glucuronidation and bile 
flow) or decreased synthesis (thyroid damage) of thyroid hormones. Brouwer and Van den 
Berg (1986), suggested a third mechanism for the decrease in plasma T4 levels in rats 
exposed to 3,3',4,4'-tetrachlorobiphenyl (TCB), a coplanar PCB-congener. A hydroxylated 
TCB metabolite (4-OH-3,3',4',5-TCB) interacted with transthyretin (TTR), the major 
thyroid hormone plasma transport protein in rodents, in vivo and in vitro (Brouwer, 1989). 
Other hydroxylated PCB metabolites also inhibited T4 binding to TTR in vitro (Lans et al., 
1993). Due to the structural resemblance of these metabolites with T4, they could 
competitively inhibit T4 binding to TTR. In addition, type 1 iodothyronine deiodinase (ID-
I), which converts T4 to active T3 or inactive reverse T3 in liver, could be inhibited by 
hydroxylated PCB metabolites in vitro using rat hepatic microsomes (Adams et al, 1990, 
Rickenbacher et al, 1989, Lans et al, 1994). The parent PCBs themselves did not inhibit 
T4-TTR binding or ID-I activity in these in vitro studies. 
In the environment most species, including man, are not exposed to single PCB 
congeners but to complex PCB-mixtures (Safe, 1994). In this study the contribution of 
decreased plasma transport and increased metabolism of thyroid hormones to alterations in 
plasma thyroid hormone levels was investigated by in vivo exposure of rats to a commercial 
PCB mixture, Aroclor 1254, which resembles the real life exposure situation. 
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Materials and methods 
Materials 
Aroclor 1254 was kindly donated by Dr. M. van den Berg of the Research Institute for 
Toxicology, University of Utrecht, The Netherlands. 4-OH-2,3,3',4',5-pentachlorobiphenyl 
was synthesized by Dr. E. Klasson-Wehler of the Wallenberg Laboratory, Stockholm 
University, Sweden, according to the methods described in Lans et ctl. (1993). 125I-T4 (1500 
uCi/(ig T4), ,25I-rT3 (1200 nCi/|ag rT3) and TT4, FT4 and TT3 Amerlite kits were obtained 
from Amersham (Amersham, Aylesbury, Buckinghamshire, United Kingdom). T4, T3, 6-
propyl-2-thiouracil (PTU), uridine-5'-diphosphoglucuronic acid (UDPGA), (3[{3-
cholamidopropyl} dimethylammonio]-l -propane sulphonate) (CHAPS) and dithiotreitol 
(DTT) were purchased from Sigma (St. Louis, MO, USA); rT3 was obtained from Henning 
(Berlin, Germany); Sephadex LH-20 was purchased from Pharmacia (Woerden, The 
Netherlands). Biorad protein reagent was obtained from Biorad Laboratories (Bio-rad, 
Richmond, CA, USA). 125I-T4 and 125I-rT3 were purified on Sephadex LH-20 immediately 
before each assay according to Beetstra et al. (1991). Pure human TTR and BSA were 
obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
Experimental design 
42 Female wistar rats (16 weeks old) were dosed once i.p. with 0, 50 and 500 mg Aroclor 
1254/ kg b.w. in corn oil (14 rats per dose, 5 ml/kg b.w.). After 2 and 7 days 3 rats of each 
dose-group were i.p. injected with 25 uCi 125I-T4 (21 pmol T4). Blood samples were 
collected by tail bleeding at 3, 6 and 24 hours after l25I-T4-injection. Plasma was prepared 
from blood by centrifugation at lOOOg and stored at -20 °C. At 24 hours after 125I-T4 
injection the rats exposed to Aroclor 1254 (for 3 and 8 days in total) were killed and 
dissected and blood, plasma, livers and brain were collected and stored at -80 °C. At day 
3 and 8, four other, non ,25I-T4 treated rats per dose-group were killed and plasma, liver and 
brains were collected and stored at -80° C. Of all non 125I-T4 treated rats per dose-group 
blood samples were collected on day 1 and 6 of Aroclor 1254 exposure. 
Sample preparations of non 125I-T4 treated rats 
Livers were divided in two for preparation of microsomes in two different buffers e.g. for 
EROD-activity and T4-glucuronidation and for hepatic type 1 deiodinase (ID-I) activity. 
Microsomes for EROD/T4 glucuronidation were prepared by homogenizing liver on ice in 
a Potter-tube in 0.1 M Tris-HCl buffer, pH 7.5 containing 0.25 M sucrose (2 ml/g liver), 
followed by centrifugation at 9000g for 30 min. The resulting supernatant was centrifuged 
at 105,000g for 90 min. and the pellet was resuspended in 0.1 M phosphate buffer, pH 7.5. 
Microsomes for ID-I activity were prepared by homogenizing liver in 10 mM Tris-HCl, pH 
7.4, containing 0.25 M sucrose and 1 mM DTT. After differential centrifugation at 9000 
and 105,000g the microsomal pellet was resuspended in 10 mM Tris-HCl, pH 7.4, 
containing 1 mM DTT and 3 mM EDTA. All hepatic microsomes were stored at -80 °C 
until further use. Protein concentrations were determined using the Bio-rad coomassie blue 
assay. 
Cytochrome P-450 levels 
Hepatic cytochrome P450 levels were measured using the method of Omura and Sato 
(1964) with modifications according to Rutten et al. (1987). Briefly hepatic microsomes 
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(used for EROD and T4 glucuronidation) were diluted in 980 ul of 0.1 M phoshate-buffer, 
pH 7.4 to a final concentration of 1 mg/ml. Carbon-monoxide gas was run through the 
incubation. An absorption spectrum from 400 - 500 nm was collected before and after 
addition of 20 ul saturated sodium-dithionite solution in phosphate buffer to the incubation. 
The difference spectrum showed a peak at 450 nm from which cytochrome P450 content 
could be calculated in nmol/mg microsomal protein. 
Ethoxyresorufin-O-deethylase activity 
Ethoxyresorufin-O-deethylase (EROD) activity was determined in hepatic microsomes using 
a modified method of Burke et al. (1977). In short the reaction mixture, containing final 
concentrations of 2 uM ethoxyresorufin and 100 ng/ml microsomal protein in 0.1 M Tris-
HC1 buffer, pH 7.8, was pre-incubated for 2 minutes at 37 °C. The reaction was started by 
adding 0.1 mM NADPH to the incubation mixture. To detect the deethylation product, 
resorufin (RR), the excitation and the emission wavelength of the fluorimeter were 530 and 
586 nm, respectively. The results are expressed as nmol RR formed per minute per 
milligram of microsomal protein. 
Hepatic T4-UDP-glucuronyltransferase activity (T4-UGT) 
Hepatic microsomal T4-UGT activity was determined in duplicate according to Beetstra et 
al. (1991) by the formation of 125I-T4-glucuronide from 125I-T4. The final concentrations in 
the reaction mixture were 0.1 M Tris-HCl buffer, pH 7.8, 5 mM UDPGA, 3.75 mM MgCl2, 
0.25 % (w/v) CHAPS , 0.125% (w/v) BSA, 1 uM T4 with 50,000 cpm 125I-T4, and 0.2 mg 
micosomal protein in a total volume of 200 ul. The reaction mixture was incubated at 37 
°C for 30 min. The reaction was stopped with 200 ul ice-cold methanol and after 
centrifugation 200 ul of supernatant was added to 750 ul 0.1 M HC1. The amount of 125I-T4 
glucuronide (T4G) in the supernatant was isolated using Sephadex LH-20 chromatography 
and quantified using a Cobra AutoGamma counting system (Canberra-Packard, USA) 
(Rutgers et al., 1989). Boiled microsomes were used as blanks. The results are expressed 
as nmol T4G formation per minute per mg of microsomal protein. 
Hepatic type 1 rT3 deiodinase (ID-I) activity 
Hepatic ID-I activity was determined in duplicate in microsomal preparations by the 
formation of ,25T from l25I-rT3 according to Mol and Visser (1985). A sample of 100 ul of 
50 ug microsomal protein/ml in 200 mM phosphate-buffer pH 7.4, containing 4 mM EDTA 
and 2 mM DTT was incubated for 30 minutes at 37 °C with 100 ul of 0.2 uM rT3 and 
100,000 cpm 125I-rT3 in 4 mM NaOH, which did not affect the pH of the reaction mixture. 
The reaction was started by adding the microsomal protein. The reaction was stopped by 
addition of 750 ul 0.1 M HC1. The l25I" produced was separated from the reaction mixture 
by Sephadex LH-20 chromatography according to Otten et al. (1984) and counted on a 
Cobra Auto Gamma counting system (Canberra-Packard, USA). Boiled microsomes were 
used as blanks. The percentage of deiodination was determined by dividing the amount of 
counts from the 125I" fraction by the total amount of counts in the incubation. 
Thyroid hormone analysis 
Plasma total T4 (TT4), total T3 (TT3) and free T4 (FT4) were measured with the Amerlite 
chemiluminescence system (Amersham, U.K) using the standard protocol from the supplier, 
with minor modifications. For TT4 measurements the standard curve ranged from 0 to 120 
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nM TT4 and the assay buffer was diluted five times with demineralized water. 
In vivo thyroxine binding inhibition study (T4 binding capacity of plasma 
proteins) 
At several time points after 125I-T4 injection, blood was collected from the rats by tail-
bleeding. Aliquots of 25 \i\ serum were mixed 1:1 with electrode buffer 5 mM Tris, 38 mM 
glycine buffer, pH 8.3 containing 10 % glycerol. These samples were subjected to native 
polyacrylamide gelelectrophoresis (PAGE) using a 10% separating gel and run during 5 
hours at a constant current of 50 mA at 4 °C according to the method of Brouwer and Van 
den Berg (1986). The acrylamide gel was cut into 1 mm pieces, which were counted for 
125I-radioactivity in a Cobra Auto Gamma counter (Canberra-Packard). PAGE gel-profiles 
were made by plotting the l25I-radioactivity against the migration distance on the gel. 125I-
Radioactivity (cpm) bound to the different serum proteins on the gels was used to calculate 
I25I-T4 binding ratios between transthyretin (TTR) and albumin. Pure human TTR and BSA 
and control rat serum were used to identify the plasma proteins on PAGE by comparing 
migration distances. 
TTR levels 
Radioimmunochemical analyses of TTR were performed at the laboratory of Dr. W.S. 
Blaner, Institute of Human Nutrition (Columbia University, New York, USA) according to 
the method of Muto et al. (1972) and Brouwer (1987), using immunosorbent purified, 
mono-specific rabbit anti-rat TTR (Navah et al., 1977). The antibody was radiolabeled with 
l25I via the Chloramine-T method. Samples of serum (25 times diluted in 50 mM Tris buffer 
pH 8.6, with 1% BSA (w/v)) were incubated with the specific TTR antibody . After 
precipitation with polyethylene-glycol buffer, the tubes were centrifuged for 30 minutes and 
the amount of TTR was determined by counting ,25I-radioactivity. The limit of detection 
was 20 ng/ml. 
Analysis of hydroxylated Aroclor 1254 metabolites in plasma 
PCBs and hydroxylated PCB metabolites (OH-PCBs) were analysed according to the 
method of Bergman et al. (1994). Plasma samples were diluted with one volume of 
methanol and one volume of water. After acidification, PCBs and OH-PCBs were extracted 
with hexane:methyl /ert-butyl ether (MTBE). The extract was partitioned with 1 M KOH 
(in 50 % ethanol). The alkaline phase was acidified and the OH-PCBs were re-extracted in 
hexane:MTBE. The OH-PCBs were methylated with diazomethane and co-extracted lipids 
removed by treatment with concentrated sulphuric acid (%). The PCB fraction was similarly 
treated with concentrated sulphuric acid, while the hexane phase contained PCBs. 
The samples were analyzed by GC, a Varian 3400 equipped with an electron capture 
detector (ECD) and a fused silica capillary column DB5+, 30 m by 0.25 mm i.d. with a 
film thickness of 25 uM (J&W Scientific Inc.), with a temperature program of 80 °C(2 
min.)-10 °C/min-300 °C(10 min.), injector temperature was 250 °C and detector temperature 
was 360 °C. The individual congeners were identified by comparison of relative retention 
time to the internal standards (2,3,3',4,4',5,5'-heptaCB (PCB 189) and 4-OH-
2,3,3',4',5,5',6-heptaCB, respectively) with authentic standards. The quantifications were 
done individually using the internal standard and comparing with a standard also containing 
the internal standard. The OH-PCB was quantified only for the 4-OH-2,3,3',4',5-pentaCB. 
A comparison was made of amount of the 4-OH-pentaCB metabolite with the amount of 
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Figure 1 Plasma levels of total thyroxine in control and Aroclor 1254 exposed rats (50 and 500 
mg/kg b.w.) on day 0 before i.p. injection with corn-oil (control) or Aroclor 1254, and on exposure 
day 1, 3, 6 and 8. Results are means ± SEM. "Indicates values significantly different from controls 
(p < 0.05). 
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Figure 2 Plasma levels of free thyroxine in control and Aroclor 1254 exposed rats (50 and 500 
mg/kg b.w.) on day 0 before i.p. injection with corn-oil (control) or Aroclor 1254, and on exposure 
day 1, 3, 6 and 8. Results are means ± SEM. 'Indicates values significantly different from controls 
(p < 0.05). 
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2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) present in the plasma and a ratio was 
calculated. 
In vitro T4 competition-binding assays on TTR 
The gel-filtration procedure as decribed by Somack et al. (1982) with minor modifications 
as described in Lans et al. (1993) was used for the in vitro T4 competition-binding assay. 
The assay, using human TTR, was performed as follows: TTR (30 nM, dissolved in 0.1 M 
Tris-HCl, 0.1 mM NaCl, 1 mM EDTA buffer, pH 8) was incubated with a mixture of l25I-
T4 and unlabeled T4 (70.000 cpm, 55 nM) in Tris-HCl buffer, and competitors (T4 or 
hydroxylated 4-OH-2,3,3',4',5-pentaCB) were added in increasing concentrations (dissolved 
in methanol, volume added was 5 uL). Control incubations were made by adding 5 ul 
methanol instead of competitor. Total ,25I-radioactivity added to each of the incubation 
mixtures (200 ul total volume) was checked by gamma-counting. The incubations were 
allowed to reach binding equilibrium overnight at 4 °C. Protein-bound 125I-T4 and free 125I-
T4 were separated on 1 ml Biogel P-6DG columns (prepared in a 1 ml disposable syringe, 
equilibrated in Tris-HCl buffer) that were equilibrated with 300 ul 10 % (W/V) saccharose-
Tris-HCl buffer) and centrifuged for 1 min at 1000 rpm (100 g) in a precooled centrifuge 
(Difuge, Hereaus). The columns were spin-forced eluted with an additional 200 ul Tris-HCl 
buffer. The first 2 eluate fractions, containing the protein bound 125I-T4 fraction, were 
combined; radioactivity was counted and compared to the control incubations. Free T4 was 
bound to the Biogel matrix and therefore was not present as a contaminant in the fractions 
eluted. Competition binding curves were made by plotting relative ,25I-T4-protein binding 
(% of control) against added inhibitor concentration. Competition binding assays with 
unlabeled T4 were used as reference assays to make comparisons between different 
experiments. 
Statistics 
Data were analysed, after testing for homogeneity and normality, with one way analysis of 
variance (ANOVA) and the least significant difference test (LSD; p <0.05 or 0.005) for 
differences to controls. A significant difference of p < 0.05 or p < 0.005 is indicated in the 
figures and tables, showing means and standard errors of means (SEM) or standard 
deviations (S.D.). All data analysed are results of duplicate, or triplicate measurements. 
Results 
Effects on plasma thyroid hormone levels 
Total thyroxine (TT4) levels were significantly decreased to 41, 38, 35 and 41 % of 
controls, in the high dose Aroclor 1254 group (500 mg/kg b.w.) on respectively day 1, 3, 
6, and 8 after exposure (Fig. 1). The low total T4 level (14.9 ± 6.9 nM) found at day 1 after 
exposure in the high dose Aroclor 1254 group did not further decrease but leveled off at 
day 3, 6 and 8. No decrease of plasma total T4 was found in the low dose Aroclor 1254 
group (50 mg/kg b.w.). Exposure to 500 mg Aroclor 1254/kg b.w. also resulted in 
reductions in plasma free T4 concentrations to 9.7 nM (53 % of control), 8.4 nM (51 % of 
control), 7.9 nM (49 % of control) and 9.6 nM (73 % of control) at day 1, 3, 6 and 8 after 
exposure (Fig. 2), while no reduction of free T4 was found after exposure to 50 mg Aroclor 
1254/kg. 
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Plasma T3 levels (not shown) were not changed significantly in the low and high dose 
group at either timepoint of analysis. 
Effects on plasma protein binding of T4 
Polyacrylamide gel-electrophoresis (PAGE) was used to determine the amount of l25I-T4 
derived radioactivity bound to plasma proteins. Examples of PAGE profiles of 125I-T4 
binding proteins in plasma from the control, low and high dose groups are shown in Figures 
3a-c. Two peaks of 125I-T4 derived radioactivity could be identified on the gels that co-
migrated with the reference samples of purified TTR and albumin, respectively. 
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Figure 3 Examples of PAGE profiles of 125I-T4 derived radioactivity bound to plasma proteins as 
described in Materials and Methods. Transthyretin (TTR) and albumin (ALB) were identified by 
comparison of migration distances, using pure human TTR and BSA and rat serum proteins. PAGE 
profile of serum of control, corn-oil treated rats (A), 50 mg Aroclor 1254/kg b.w. (B) and 500 mg 
Aroclor 1254/ kg b.w. (C) treated rats, on exposure day 7, 6 hours after i.p. injection with 126I-T4 
(25/yCi). 
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In control rats the amount of 125I-T4 derived radioactivity bound to TTR was approximately 
2.5 fold higher on day 2/3 (data not shown) and 5.5 fold higher on day 7/8 than the 125I-T4 
derived radioactivity associated with albumin. On day 2 and 3 after Aroclor 1254 exposure 
the ratio of 125I-radioactivity bound to TTR over albumin, was not significantly different 
between the control and Aroclor 1254 groups (Fig. 4). On day 7 and 8 after Aroclor 1254 
administration the high dose Aroclor 1254 group had significantly (3.5-4.1 fold) lower 
TTR/albumin ratios of bound l25I-T4 radioactivity than controls, while the level of 
radioactivity associated to albumin remained essentially the same (Fig. 4). The low dose 
Aroclor 1254 group showed no significant differences in TTR/albumin ratios on day 7/8. 
The control TTR/albumin ratios of bound 125I-T4 radioactivity were higher in the group 
injected with 125I-T4 on day 2/3 when compared with the group treated on day 7/8. 
Plasma TTR levels 
Analysis of plasma TTR concentrations using specific anti-TTR antibodies indicated that 
the TTR levels were decreased significantly on day 3 in the low dose Aroclor 1254 group 
to 48% (22.9 mg TTR/dl plasma; 4.2 \M) of control and in the high dose group to 63 % 
(29.9 mg TTR/dl; 5.4 u.M) of control (47.5 mg TTR/dl; 8.6 uM) (Fig. 5). On day 8 of 
Aroclor 1254 exposure, however, TTR levels were not different from controls (38.0 mg 
TTR/dl; 6.9 uM) in high (35.9 mg TTR/dl; 6.5 uM) and low dosed Aroclor 1254 groups 
(38.9 mg TTR/dl; 7.1 uM), but were increased with 20 % and 70 %, respectively, compared 
to day 3 of exposure. Levels of plasma TTR were slightly lowered to 80 % at day 8 
compared to day 3 in corn-oil treated controls. 
a 
lO 
CM s 
2 4 
5. 3 
DC 
t 2 
13 1 
2/3 2/6 3/24 7/3 7/6 8/24 
Day/hour after [125JI-T4 administration 
Figure 4 Ratio of 125I-T„ radioactivity bound to TTR over albumin, calculated as described in 
Materials and Methods, in rat serum of control and Aroclor 1254 exposed rats (50 and 500 mg/kg 
b.w.) on different exposure days 2 and 7, at 3, 6 and 24 hours after 125I-T4 injection (day after 
Aroclor 1254 exposure/hour after 125I-T4 injection). Results shown are means ± SEM of triplicate 
measurements. 'Indicates values significantly different from controls (p < 0.05). "Indicates values 
significantly different from controls [p < 0.005) 
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Presence of hydroxylated PCB-metabolites in plasma 
In the Aroclor 1254 treated rats, GC analysis of plasma extracts indicated the presence of 
relatively large amounts of hydroxylated PCB-metabolites at exposure day 3 and 8. GC-MS 
analysis using synthetically prepared OH-PCB-metabolite reference compounds revealed the 
presence of mainly one major metabolite e.g. 4-OH-2,3,3',4',5-pentachlorobiphenyl (4-OH-
pentaCB) metabolite (data not shown), which can be formed by para-hydroxylation of 
2,3,3',4,4'-pentaCB (PCB 105) or 2,3,3',4',5-pentaCB (PCB 118), both present in Aroclor 
1254. Quantification of the amount of 4-OH-pentaCB is represented in Figure 6. High 
levels of 4-OH-pentaCB up to respectively 758 + 110 and 1020 ± 17 ppb (fresh weight), 
corresponding to 2.22 + 0.32 and 2.98 ± 0.05 uM, were observed in the plasma of 500 mg 
Aroclor 1254/kg dosed rats at day 3 and 8 after Aroclor 1254 administration. About 6-fold 
lower (on day 3: 133 ± 102 ppb, 0.39 ± 0.30 uM) and 17-fold lower concentrations (on day 
8: 62 ± 66 ppb, 0.18 ± 0.18 uM) of 4-OH-pentaCB were observed in the 50 mg Aroclor 
1254/kg dosed rats. The molar ratios of TTR levels over the amount of 4-OH-pentaCB 
metabolites were 10.8 on day 3 and 40 on day 8 for the low dosed group, while for the 
high dosed group ratios were 2.4 on day 3 and 2.2 on day 8. 
In addition the amount of PCB 153 (2,2',4,4',5,5'-hexachlorobiphenyl) was 
quantified and ratios were calculated of levels of metabolite vs. PCB 153 in plasma, which 
ranged from 7.5 to 12 for the low dosed group and 3.1 to 12.7 for the high dosed group, 
indicating that relative large amounts of metabolite compared to the persistent PCB 153 
congener were present in the blood of both low and high Aroclor 1254 exposed rats. PCB 
153 is almost always present in ca. 20 % (15-25%) of the total PCBs in biological samples. 
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Figure 5 Plasma TTR levels of control rats and Aroclor 1254 exposed rats (50 and 500 mg/kg b.w.) 
on exposure day 3 and 8. Results are means ± SEM of duplicate measurements. "Indicates values 
significantly different from controls (p < 0.05). "Indicates values significantly different from 
controls (p < 0.005). 
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In vitro competition of T4 binding to TTR by the hydroxylated PCB metabolite 
The 4-OH-2,3,3\4',5-pentaCB
 metabolite as was present in the plasma of the Aroclor 1254 
exposed rats, was synthesized and used in an in vitro T4-TTR binding competition study. 
The competition curves of the 4-OH-pentaCB metabolite and T4 are shown in Figure 7. The 
IC50's (the concentration inhibiting 50 % of T4-TTR binding) of 4-OH-PentaCB and T4 
(resp. 15.5 nM and 101.6 nM) show that 4-OH-pentaCB inhibits T4-TTR binding 6.5 times 
more potent than T4, the natural ligand, itself. 
Effects on hepatic thyroid hormone metabolism 
Hepatic T4-glucuronidation was significantly increased to 2.9 and 6.1 times control values 
in the high dose Aroclor 1254 group at day 3 and 8 after Aroclor 1254 administration, 
respectively (Table 1). A slight, but not significant increase in hepatic T4-UGT activity was 
observed on day 3 (1.4 times control value) in the low dose Aroclor 1254 group. Hepatic 
type 1 reverse T3 deiodinase (ID-I) activity was not significantly different between controls 
and the low and high dosed Aroclor 1254 groups at either day 3 or day 8 after exposure 
(Table 1), except for the low dose group at day 3. 
Hepatic cytochrome P450 levels and EROD activity 
Cytochrome P450 levels were increased in the high dose group at day 3 and 8 after Aroclor 
1254 administration (1.4 and 1.5 times control values) but not in the low dose group (Table 
2). Hepatic microsomal EROD-activity, however, was markedly increased at day 3 (not 
significantly) and 8 after exposure in both 50 mg Aroclor 1254/kg (13.1 and 6.3 
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Figure 6 Plasma concentrations of 4-OH-2,3,3',4',5-pentachlorobiphenyl (ppb of fresh plasma 
weight) in 50 and 500 mg Aroclor 1254/kg b.w. exposed rats, on exposure day 3 and 8. Results 
are means ± SEM of duplicate measurements. "Indicates values significantly different from 50 mg 
Aroclor 1254/kg dose group {p < 0.005). 
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Table 1 Hepatic T4 glucuronidation (T4-UGT) activity and hepatic type 1 deiodinase (ID-I) activity 
in control, 50 and 500 mg Aroclor 1254/kg b.w. exposed rats (n = 4) on day 3 and 8 after 
administration. 
Enzyme activity Day Control 
(corn oil) 
Aroclor 1254 
(50 mg/kg) 
Aroclor 1254 
(500 mg/kg) 
T4-UGT activity 3 0.82 ± 0.09 
(pmol T4/min/mg) 8 0.78 ± 0.20 
ID-I activity 3 60 ± 5.5 
(pmol rTj/min/mg) 8 72 ± 4.0 
1.11 
0.85 
85 ± 
78 ± 
± 0.27 
± 0.23 
6.0a 
5.0 
2.36 
4.79 
60 ± 
60 ± 
± 0.47ab 
± 1.31ab 
5.5 
7.5 
Note: Results are means ± SEM of duplicate measurements. "Indicates values significantly different 
from controls {p < 0.05). "Indicates values significantly different from 50 mg Aroclor 1254/kg dose 
group (p < 0.05). 
Table 2 Cytochrome P450 levels and EROD activity in hepatic microsomes of control and Aroclor 
1254 exposed rats (50 and 500 mg Aroclor 1254/kg b.w., n = 4) on day 3 and 8 after exposure. 
Day Control 
(corn oil) 
Aroclor 1254 
(50 mg/kg) 
Aroclor 1254 
(500 mg/kg) 
Cytochrome P450 
(nmol/mg) 
EROD activity 
(nmol RR/min/mg) 
Rel. liver weight 
(g/100 g b.w.) 
3 
8 
3 
8 
3 
8 
1.77 ± 0.33 
1.65 ± 0.30 
0.036 ± 0.001 
0.035 ± 0.001 
3.13 ± 0.14 
3.13 ± 0.06 
1.84 ± 0.47 
1.18 ± 0.13 
0.469 ± 0.231 
0.221 ± 0.074 
3.25 + 0.15 
3.19 ± 0.06 
2.43 + 0.14 
2.43 ± 0 .31 ' 
2.336 ± 0.513a'b 
2.241 ± 0.328 
3.72 ± 0.14ab 
3.70 + 0.21a b 
Note: Relative liver weights are given as ratio of liver weight per 100 g b.w.. Results are means 
± SEM of duplicate measurements. "Indicates values significantly different from controls (p < 
0.05). "Indicates values significantly different from 50 mg Aroclor 1254/kg dose group (p < 0.05). 
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times control) and 500 mg Aroclor 1254/kg group (65.2 and 63.8 times control) (Table 2). 
The increased EROD activity in the high dose Aroclor 1254 group was also significantly 
different from the low dose Aroclor 1254 group at day 3 and 8 after exposure (resp. 5 and 
10 fold increased compared to low dose group). 
No changes in body weights were observed in the low and high exposed Aroclor 
1254 group compared to controls. Relative liver weights were only significantly increased 
in the high dose group (1.2 times) at day 3 and 8 compared to controls and low dose group 
(Table 2). 
Discussion 
Exposure of Wistar rats to Aroclor 1254 (50 and 500 mg Aroclor 1254/kg b.w.) resulted 
in decreased plasma total and free thyroxine (T4) levels. Both reduced binding of T4 to TTR 
in plasma and increased hepatic glucuronidation of T4 were observed in this study, 
suggesting the participation of both mechanisms of action in the reduction of circulating T4 
levels. In addition, selective accumulation of the 4-OH-2,3,3',4',5-pentaCB metabolite was 
found in this study, i.e. a PCB-metabolite that has the structural requirements to bind to 
TTR in vitro and strongly displace T4 from TTR as found in this study and by Lans et al. 
(1993). The observed diminished T4 binding capacity to TTR (as demonstrated on PAGE 
by the low ratio of T4 binding to TTR over albumin) may indicate that the decrease in 
plasma T4 found at day 8 in highly exposed rats in this study, may partially be caused by 
inhibition of T4 binding to TTR by the 4-OH-pentaCB metabolite present in plasma. 
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Figure 7 In vitro competition of T4 binding to TTR by 4-OH-2,3,3',4',5-pentaCB ( • ) and T4 ( + ). 
Competition curves show the percentage (means ± S.D.) of radiolabeled T4 bound to TTR 
compared to control (no inhibitor) at different inhibitor concentrations (nM). 
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Like the decreased T4 binding to TTR after Aroclor 1254 exposure found in this 
study, Brouwer and Van den Berg (1986) found a comparable selective decrease of 
radiolabeled T4 bound to TTR in plasma after exposure of rats to 3,3',4,4'-
tetrachlorobiphenyl (TCB). In both studies the amount of labeled T4 bound to albumin 
remained unaltered and TTR levels were not decreased. Exposure of rats to radiolabeled 
TCB resulted in TCB-derived radioactivity, later identified as the 4-OH-3,3',4',5-tetraCB 
metabolite, which was selectively bound to TTR in the plasma and displaced T4 from TTR 
(Brouwer, 1989). Consistent findings of high blood concentrations of TCB derived 
radioactivity, mainly in the form of a TCB-metabolite, were described after exposure to 
radioactive TCB for mice by Lucier et al. (1978b) and for rats and monkeys by Abdel 
Hamid et al. (1981). Also in pregnant rats exposed to TCB, a selective accumulation of the 
4-OH-3,3',4',5-tetraCB metabolite was found in the fetus and fetal plasma (Morse et al., 
1995b). 
In this study the 4-OH-2,3,3',4',5-pentaCB metabolite was identified as the major 
PCB-metabolite in the plasma of Aroclor 1254 exposed rats. This metabolite can 
theoretically be formed by para-hydroxylation of 2,3,3',4,4'-pentaCB (PCB 105), or 
2,3,3',4',5-pentaCB (PCB 118). Both CB 105 and 118 are present in Aroclor 1254 mixtures 
in relatively high amounts (resp. 4 and 6 % by weight) (Schulz et al., 1989). As shown by 
the T4-TTR inhibition study, the 4-OH-pentaCB was a potent inhibitor structurally 
resembling T4. As found for other hydroxylated PCB metabolites (Lans et al., 1993, 1994) 
the potency of inhibiting T4-TTR binding in vitro was even stronger than T4, the natural 
ligand. The difference in 4-OH-pentaCB levels on day 3 and 8 in the high dosed Aroclor 
1254 group may be enough for reaching a threshold level for displacement of T4 from TTR. 
In combination with the high T4 glucuronidation on day 8 this may explain the decrease in 
the ratio of T4 bound to TTR/albumin at day 8 and the lack of effect on the ratio on day 
3 in the high dosed group. 
Hydroxylated Aroclor 1254 metabolites were also found in adult rats in vivo in 
another study (Bergman et al., 1994) where rats were dosed with Aroclor 1254 at lower 
levels (25 mg/kg for 3 subsequent days) and plasma and tissues like lung, kidney, liver and 
adipose tissue were analysed by GC-MS. In plasma 12 hydroxylated PCB metabolites were 
found, the major peak was identified as the 4-OH-2,3,3',4',5-pentaCB metabolite. 
Hydroxylated PCB metabolites were found in rat lung and liver, whereas no hydroxylated 
PCB metabolites were detected in adipose tissue. Selective retention of several hydroxylated 
PCB metabolites in plasma of environmentally exposed species, like man and seal, was 
described by Bergman et al. (1994), showing the presence of the 4-OH-2,3,3',4',5-pentaCB 
metabolite and a hydroxylated hexaCB in seal blood and the 4-OH-2,3,3',4',5-pentaCB and 
4-OH-2',3,3',4',5,5'-hexaCB (a PCB 156 metabolite) in human serum. So the 4-OH-
pentaCB found in rat plasma after Aroclor 1254 exposure in this study, can also be present 
in plasma after background exposure to PCBs present in environment. 
TTR plasma levels measured in this study were decreased in the low and high dosed 
Aroclor 1254 group on day 3. However, a direct effect of the PCB congeners present in the 
Aroclor mixture on TTR synthesis is not likely because no clear dose-dependent response 
was found. Moreover, TTR synthesis in the liver is not changed by differences in thyroid 
hormone status (Blay et al., 1994). On day 2/3 after Aroclor 1254 exposure, the low dosed 
group showed the lowest TTR levels, while on day 3 the TTR/albumin ratio of bound ,25I-
T4 was elevated in the low dose group compared to control. Opposite effects are found in 
the control group of day 3 which shows high TTR levels, but a low ratio of TTR/albumin 
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bound 125I-T4. No clear mechanism can be found explaining these contradicting results. On 
the contrary, high TTR levels would suggest a concommitant high ratio of TTR/albumin 
bound 125I-T4. Plasma TTR levels at day 8 were equal in all exposure groups, while the 
strongest reduction in the ratio of TTR/albumin bound l25I-T4 was observed at this time 
point in the high dose group. This clearly suggests that Aroclor 1254 exposure interfered 
with T4 binding to TTR, most likely by competitive displacement of T4 by the 4-OH-
pentaCB metabolite present in the blood. 
The other mechanism studied in this paper that is possibly involved in plasma T4 
reduction is hepatic T4 metabolism (glucuronidation and deiodination). T4 glucuronidation 
was significantly increased in the high dose group on day 3 and 8 after Aroclor 1254 
administration, suggesting a concomittantly increased biliary T4 excretion. In the low dosed 
Aroclor 1254 group no changes in plasma in T4 levels were observed while T4-UGT activity 
was not increased either. Changes in total T4 as found on day 1 and 3 in the high dosed 
Aroclor 1254 group, are probably caused by increased T4 glucuronidation, because no 
effects on plasma T4 transport was found in the high dose group at day 3. Several other 
studies on Aroclor 1254 exposure in rats have shown increased T4 glucuronidation and 
excretion (Bastomsky, 1974; Barter and Klaassen, 1992). Kanechlor 400, another 
commercial PCB mixture increased T4 glucuronidation to the same extent as other inducers 
like 3-methylcholanthrene and beta-naphtoflavone, but TT4 levels in plasma were decreased 
more (Saito et al., 1991). The authors suggest that decreased T4 binding to plasma proteins 
could be causing this difference. T4 glucuronidation is also increased after exposure to other 
halogenated aromatic compounds, like hexachlorobenzene (HCB), TCB, TCDD (Visser et 
al, 1993), 2,3,3',4,4',5-hexachlorobiphenyl (PCB 156) (Van Birgelen et al, 1994a), 
polybromobiphenyl (PBB, Byrne et al., 1987), 3,3',4,4',5-hexabromobiphenyl (Spear et al., 
1990) and 3,3',4,4',5,5'-hexachlorobiphenyl (Morse et al., 1993a), compounds which 
simultaneously decrease plasma T4 levels. 
Hepatic type 1 reverse T3 deiodinase (ID-I) activity was not affected in this study. 
Inhibition of ID-I activity by hydroxylated PCB and TCB metabolites has been found in in 
vitro studies (Adams et al., 1990; Rickenbacher et al., 1989; Lans et al., 1994). 
Hydroxylated PCB metabolites apparently do have the capacity to inhibit ID-I activity. 
However, in this study even the high dose Aroclor 1254 group, with relatively high levels 
of hydroxylated PCB metabolites in plasma, did not show inhibition of ID-I in vivo. On the 
other hand, in vivo inhibition of ID-I activity (to 50%) has been observed following 
treatment of rats with several Ah-receptor agonists, such as 3-methylcholantrene, TCB and 
TCDD (Visser et al., 1993). Likewise, Adams et al. (1990) found a decrease in hepatic ID-I 
activity in rats after exposure to 50 mg TCB/kg in vivo. This decrease in ID-I activity could 
be caused by direct inhibiting effects of the parent compound PCBs and TCDD, or as a 
secondary effect of hypothyroidism caused by these compounds (Kaplan, 1986). Hence 
inhibition of ID-I activity by both hydroxylated PCB metabolites and parent compounds 
may occur. The lack of effect by Aroclor 1254 suggests that there may be antagonists 
present in the PCB mixture that obscure effects of parent compounds or hydroxylated 
metabolites on ID-I activity, or that the exposed rats have no functional hypothyroid status. 
In conclusion, in this study a hydroxylated PCB metabolite selectively accumulated 
in blood of rats exposed to Aroclor 1254 and inhibited T4 binding to TTR. In addition T4 
glucuronidation was strongly increased. Consequently decreases in plasma thyroid hormone 
levels after Aroclor 1254 exposure are most likely caused by a combined effect of different 
mechanisms e.g. disturbances in thyroid hormone metabolism and selective inhibition of 
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thyroid hormone plasma transport in rodents. We cannot exclude that a direct effect on the 
thyroid gland by Aroclor 1254 has also occurred, similar to results discussed by Collins and 
Capen (1980a,b,c) that may additionally contribute to the reductions in circulating thyroid 
hormone levels. 
The presence and selective retention of a specific major hydroxy-PCB metabolite, 
4-OH-2,3,3',4',5-pentaCB, in plasma given the exposure of rats to a complex PCB mixture, 
deserves further attention in terms of occurence of hydroxylated PCB metabolites in human 
and wildlife and its potential toxic effects, especially on brain or neurologic development 
and reproduction through thyroid hormone disturbances (Morse et al., 1993b). 
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CHAPTER 6 
In vivo alterations in thyroxine metabolism and plasma 
transport by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in 
rats 
Abstract 
Polyhalogenated aromatic hydrocarbons such as polychlorobiphenyls (PCBs) and 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) are potent environmental goitrogens, that 
cause marked reductions in plasma thyroid hormone levels. In earlier studies at our 
laboratory hydroxylated polychloro-dibenzo-p-dioxin (PCDD), polychloro-dibenzofuran 
(PCDF), and PCB-metabolites inhibited thyroxine (T4) binding to transthyretin (TTR), 
the major thyroid hormone plasma transport protein in rodents, in vitro. In vivo, 
hydroxylated PCB metabolites were found to inhibit T4 binding to TTR after exposure 
of rats to 3,3',4,4'-tetrachlorobiphenyl or Aroclor 1254, thereby decreasing plasma T4 
levels. In vivo exposure of rats and mice to TCDD has been described to cause major 
changes in plasma T4 levels. In this study the contribution of distinct modes of interac-
tion of TCDD with thyroid hormone metabolism and plasma transport, i.e. changes in 
hepatic glucuronidation and deiodination and inhibition of T4-TTR binding, to the 
observed plasma T4 reductions were investigated. Female Wistar rats were dosed with a 
single i.p. injection of TCDD (25 ug/kg) or cornoil (vehicle control). Four days after 
TCDD exposure part of the control and TCDD-exposed rats were injected with 125I-T4 
(25 uCi). Blood samples were taken after 3, 6, and 24 hours after 125I-T4 injection. All 
rats were killed at t=24 h after 125I-T4 injection (day 5 after TCDD exposure) and liver 
and brains were collected. 
Plasma total T4 levels were significantly decreased with 56 % and 46 % in 
TCDD-treated rats at resp. 4 (non 125I-T4 injected rats) and 5 days after exposure, plasma 
free T4 levels were non-significantly decreased at 4 and 5 days after exposure. No 
alterations were observed in plasma total T3 levels. Polyacrylamide gelelectrophoresis 
(PAGE) revealed two peaks of 125I-T4-derived radioactivity in plasma which were 
identified as TTR and albumin. The ratio of 125I-T4 binding to TTR over albumin was 
calculated for PAGE plasma profiles of control and TCDD exposed rats as an indication 
of T4-TTR binding capacity. This ratio was the same in control and TCDD treated rats 3 
hours after 125I-T4 injection, but was decreased at 6 hours and significantly at 24 hours 
after ,25I-T4 injection. However, no hydroxylated TCDD-metabolites, which could inhibit 
T4 binding to TTR in vitro, were detected in plasma, while plasma TTR levels were not 
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changed either after TCDD exposure. The parent compound TCDD was present in 
plasma, but is not likely to inhibit T4 binding to TTR. Hepatic cytochrome P450 levels 
and cytochrome P4501A1 (EROD) activity were significantly induced resp. 1.8 and 212 
fold in TCDD exposed rats. In addition, TCDD exposure resulted in an increased hepatic 
T4 glucuronidation (3.9-fold) while hepatic type 1 deiodinase activity was decreased to 
82% of control values. Brain type 2 deiodinase activity was increased 2-fold following 
TCDD exposure indicating a hypothyroid status of the rats. Based on these results one 
can conclude that reduced T4-TTR binding by hydroxylated TCDD-metabolites does not 
play a role in the decreases of plasma T4 levels, while enhanced hepatic elimination of 
thyroid hormone may be the major cause of the plasma thyroid hormone reductions 
found in rats after TCDD exposure. 
Introduction 
Polychlorinated dibenzo-p-dioxins (PCDDs) and related compounds, like polychlorinated 
dibenzoftirans (PCDFs) and biphenyls (PCBs), are ubiquitous environmental contami-
nants. In contrast with the commercially produced PCBs, PCDDs and PCDFs are 
unwanted byproducts of waste-combustion and the production of diverse chlorinated 
aromatics, like PCBs and hexachlorobenzene in the past, and chlorinated phenoxybenze-
nes and phenols (Safe, 1990; Van den Heuvel and Lucier, 1993; Van den Berg et al, 
1994). 
The 2,3,7,8-substituted congeners of PCDDs and PCDFs are selectively bioaccu-
mulated in the foodchain, and are especially abundant in higher trophic levels like fish 
eating birds, marine mammals and man (Ahlborg et al, 1992). PCDDs and PCDFs 
cause a wide range of toxic responses including teratogenic, reproductive, immunotoxic, 
hepatotoxic and neuro-endocrine effects and are known carcinogens in experimental 
animals (Safe, 1990). These toxic responses are congener-, dose-, species- and tissue 
specific (Peterson et al, 1993). The lateral substituted congeners (2,3,7,8-substituted) 
PCDDs and PCDFs are causing most if not all their effects via a specific cytosolic 
receptor, the Ah-receptor. The most toxic congener is 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD). 
Effects of TCDD on plasma thyroid hormone levels and metabolism in liver have 
been described by several authors. TCDD markedly increased the biliary excretion of 
thyroxine (T4) (Bastomsky, 1977). The increase in T4 excretion was most likely due to 
induction of T4 glucuronyltransferase (T4-UGT) activity by TCDD (Beetstra et al., 1991; 
Lucier et al., 1975). Administration of TCDD to rats or mice resulted in reduced plasma 
T4 levels (Potter et al., 1983; Lans et al., 1990; Potter et al, 1986; Roth et al, 1988). 
Plasma 3,3',5-triiiodothyronine (T3) levels, however, increased (Bastomsky, 1977; Potter 
et al., 1986), did not change (Potter et al., 1983; Henry and Gasiewicz, 1987; Lans et 
al, 1990; Muzi et al, 1989; Gorski and Rozman, 1987; Jones et al, 1987) or decreased 
(Pazdernik and Rozman, 1985) after exposure of rodents to TCDD. 
Induction of T4 glucuronidation by certain PCDDs, PCDFs and PCBs may partly 
explain the decrease in plasma T4 levels. A second mechanism that may be involved in 
this decrease is the inhibition of T4 transport in plasma after exposure to these com-
pounds. In in vitro studies in our laboratory, hydroxylated PCDD, PCDF and PCB 
metabolites could inhibit T4 binding to transthyretin (TTR), the plasma T4 transport 
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protein in rodents (Lans et al., 1993). This was confirmed by in vivo studies where 
plasma thyroid hormone transport via TTR was inhibited by hydroxylated PCB-metab-
olites of 3,3',4,4'-tetrachlorobiphenyl (TCB or CB77) and Aroclor 1254 in rats and mice 
(Brouwer, 1989; Lans et a/.,1994). However, hydroxylated PCDD, PCDF and PCB 
metabolites did not inhibit in vitro T4 binding to thyroxine-binding globulin (TBG), the 
major plasma thyroid hormone transport protein in man (Lans et al., 1994). Another 
possible pathway of interference in thyroid hormone levels is through modulation of 
hepatic type 1 deiodinase (ID-I) activity, another thyroxine binding protein which 
converts T4 to T3 or 3,3',5'-triiodothyronine (rT3) in the liver. Conversion of T4 by ID-I 
was competitively inhibited in vitro by hydroxylated PCDD, PCDF and PCB metabolites 
(Lans et al., 1994; Rickenbacher et al, 1989). Moreover, TCDD exposure decreased 
ID-I activity in rats in vivo (Eltom et al., 1992; Rickenbacher et al., 1986). 
All of these interactions of TCDD with thyroid hormone metabolism have been 
studied and reported separately. The present study was carried out to investigate the 
contribution of the various interaction pathways to the reduction of plasma T4 by TCDD 
in the same experiment. Corn oil or TCDD-pretreated rats were injected with 125I-T4 to 
determine the T4 binding capacity of the various plasma proteins, like TTR and albumin. 
TCDD and hydroxylated TCDD metabolites were analysed in plasma by GC/MS 
analysis. In addition, parameters of hepatic T4 metabolism, eg. T4-UGT and ID-I activity 
were measured. Moreover, brain type 2 deiodinase (ID-II) activity was measured as an 
indication of functional hypothyroidism. 
Materials and methods 
Materials 
2,3,7,8-Tetrachlorodibenzo-jo-dioxin (>99 % pure) was obtained from Promochem, 
Wesel, Germany. The hydroxylated TCDD metabolites, 2-OH-3,7,8-TriCDD and 2-OH-
1,3,7,8-TCDD were kindly donated by Dr. S.H. Safe of the Department of Veterinary 
Physiology and Pharmacology, Texas A&M University, College Station, Texas, USA. 
I25I-T4 (1500 |aCi/ng T4), l2SI-rT3 (1200 \iCil\ig rT3) and TT„, FT4 and TT3 Amerlite kits 
were obtained from Amersham (Amersham, Aylesbury, Buckinghamshire, United 
Kingdom). T4, T3, 6-propyl-2-thiouracil (PTU), uridine-5'-diphosphoglucuronic acid 
(UDPGA), (3[{3-cholamidopropyl} dimethylammonio]-l-propane sulphonate) (CHAPS) 
and dithiotreitol (DTT) were purchased from Sigma (St. Louis, MO, USA); rT3 was 
obtained from Henning (Berlin, Germany); Sephadex LH-20 was purchased from 
Pharmacia (Woerden, The Netherlands). Biorad protein reagent was obtained from 
Biorad Laboratories (Bio-rad, Richmond, CA, USA). Pure human TTR and BSA were 
obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
Experimental design 
Female wistar rats (16 weeks old) were dosed with a single i.p. injection of 0 or 25 \ig 
TCDD/kg b.w. in corn oil (8 rats per dose, 5 ml/kg b.w.). After 4 days four rats of each 
dose-group were injected i.p. with 25 uCi 125I-T4 (21 pmol). Blood samples were 
collected by tail bleeding at 3, 6 and 24 hours after 125I-T4 injection. Plasma was 
prepared from blood by centrifugation at lOOOg and stored at -20 °C. At 24 h after 125I-
T4 injection (day 5 after TCDD exposure) the rats were killed and dissected and blood 
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plasma, livers and brain were collected and stored at -80 °C. At day 5 after TCDD 
exposure four other, non 125I-T4 treated rats per dose-group were killed and plasma, liver 
and brains were collected and stored at -80 °C. Of all non 125I-T4 treated rats per dose-
group blood samples were collected by tail-bleeding on day 1, 4 and 5 after TCDD 
exposure. 
Sample preparations of non 125I-T4 treated rats 
Livers were divided in two pieces for preparation of microsomes in two different buffers 
e.g. for EROD-activity and T4-glucuronidation and for hepatic type 1 deiodinase (ID-I) 
activity. Microsomes for EROD/T4 glucuronidation were prepared by homogenizing liver 
in a Potter-tube on ice with 2 ml/g liver of 0.1 M Tris-HCl buffer, pH 7.5 containing 
0.25 M sucrose, followed by centrifugation at 9000g for 30 min. The resulting superna-
tant was centrifuged at 105,000g for 90 min. and the pellet was resuspended in 0.1 M 
phosphate buffer, pH 7.5. Microsomes for ID-I activity were prepared by homogenizing 
liver in 10 mM Tris-HCl, pH 7.4, containing 0.25 M sucrose and 1 raM DTT. After 
differential centrifugation at 9000 and 105,000g the microsomal pellet was resuspended 
in 10 mM Tris-HCl, pH 7.4, containing 1 mM DTT and 3 mM EDTA. All hepatic 
microsomes were stored at -80 °C until further use. For brain type 2 iodothyronine 
deiodinase (ID-II) measurements, brains were homogenized on ice in a Potter-tube with 
8 ml/gram of 100 mM phosphate-buffer, pH 7.4, containing 4 mM EDTA and 25 mM 
DTT and stored at -80 °C until further use. Protein concentrations were determined using 
the Bio-rad coomassie blue assay. 
Cytochrome P-450 levels 
Hepatic cytochrome P450 levels were measured using the method of Omura and Sato 
(1964) with modifications according to Rutten et al. (1987). Briefly hepatic microsomes 
(used for EROD and T4 glucuronidation) were diluted in 980 ul of 0.1 M phoshate-
buffer, pH 7.4 to a final concentration of 1 mg/ml. Carbon-monoxide gas was run 
through the incubation. An absorption spectrum from 400 - 500 nm was collected before 
and after addition of 20 ul saturated sodium-dithionite solution in phosphate buffer to 
the incubation. The difference spectrum showed a peak at 450 nm from which cytochro-
me P450 content could be calculated in nmol/mg microsomal protein. 
Ethoxyresorufin-O-deethylase activity 
Ethoxyresorufin-0-deethylase (EROD) activity was determined in hepatic microsomes 
using a modified method of Burke et al. (1977). In short the reaction mixture, contai-
ning final concentrations of 2 uM ethoxyresorufin and 100 ug/ml microsomal protein in 
0.1 M Tis-HCl buffer, pH 7.8, was pre-incubated for 2 minutes at 37 °C. The reaction 
was started by adding 0.1 mM NADPH to the incubation mixture. To detect the 
deethylation product, resorufin (RR), the excitation and the emission wavelength of the 
fluorimeter were 530 and 586 nm, respectively. The results are expressed as nmol RR 
formation per minute per milligram of microsomal protein. 
Hepatic T4-UDP-glucuronyltransferase activity (T4-UGT) 
l25I-T4 was purified on Sephadex LH-20 immediately before each assay according to 
Beetstra et al. (1991). Hepatic microsomal T4-UGT activity was determined in duplicate 
according to Beetstra et al. (1991) by the formation of 125I-T4-glucuronide from ,25I-T4. 
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The final concentrations in the reaction mixture were 0.1 M Tris-HCl buffer, pH 7.8, 5 
mM UDPGA, 3.75 mM MgCl2, 0.25 % (w/v) CHAPS , 0.125% (w/v) BSA, 1 uM T4 
with 50,000 cpm 125I-T4, and 0.2 mg micosomal protein in a total volume of 200 ul. The 
reaction mixture was incubated at 37 °C for 30 min. The reaction was stopped with 200 
ul ice-cold methanol and after centrifugation 200 ul of supernatant was added to 750 ul 
0.1 M HC1. The amount of 125I-T4 glucuronide (T4G) in the supernatant was isolated 
using Sephadex LH-20 chromatography and quantified using a Cobra AutoGamma 
counting system (Canberra-Packard, USA) (Rutgers et ctl., 1989). Boiled microsomes 
were used as blanks. The results are expressed as nmol T4G formation per minute per 
mg of microsomal protein. 
Hepatic type 1 rT3 deiodinase (ID-I) activity 
l25I-rT3 was purified on Sephadex LH-20 immediately before each assay according to 
Beetstra et al. (1991). Hepatic ID-I activity was determined in duplicate in microsomal 
preparations by the formation of 125I" from 125I-rT3 according to Mol and Visser (1985). 
A sample of 100 ul of 50 jig microsomal protein/ml in 200 mM phosphate-buffer pH 
7.4, containing 4 mM EDTA and 2 mM DTT was incubated for 30 minutes at 37 °C 
with 100 ul of 0.2 uM rT3 and 100,000 cpm ,25I-rT3 in 4 mM NaOH, which did not 
affect the pH of the reaction mixture. The reaction was started by adding the micro-
somal protein. The reaction was stopped by addition of 750 ul 0.1 M HC1. The 125I" 
produced was separated from the reaction mixture by Sephadex LH-20 chromatography 
according to Otten et al. (1984) and counted on a Cobra Auto Gamma counting system 
(Canberra-Packard, USA). Boiled microsomes were used as blanks. The percentage of 
deiodination was determined by dividing the amount of counts from the l25I" fraction by 
the total amount of counts in the incubation. 
Brain type 2 thyroxine deiodinase activity (ID-II) 
l25I-T4 was purified on Sephadex LH-20 immediately before each assay according to 
Beetstra et al. (1991). Brain ID-II activity was determined in duplicate as described by 
Visser et al. (1982) by the formation of 125I" from l25I-T4. Briefly the final concentrations 
in the reaction mixture were 100 mM phosphate buffer, pH 7.2, 25 mM dithiotreitol 
(DTT), 1 mM 6-propyl-2-thiouracil (PTU), 1 mM EDTA, 2 nM T4 with 100,000 cpm 
125I-T4, 500 nM T3 and 0.4 mg protein (brain homogenate) in a final volume of 200 ul. 
The addition of T3 was necessary to inhibit inner-ring deiodination of T4 by brain type 3 
deiodinase (ID-III) (Kaplan et al., 1983). Reaction mixtures were incubated at 37 °C for 
one hour. The reaction was stopped on ice by the addition of 100 ul 70 mg/ml BSA in 
order to bind the remaining substrate and T3, followed by adding 500 ul of 10 % TCA 
(w/v) to precipitate the protein. The tubes were then centrifuged at 4000 rpm for 5 min., 
and 500 ul supernatant was removed, containing the free l2T liberated from the 125I-T4. 
The amount of 125I" present in the supernatant was determined using Sephadex LH-20 
chromatography (Otten et al. 1984). Boiled brain homogenates were used as blanks. 
Results are expressed as fmoles T4 deiodinated per hour per mg of protein. 
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Thyroid hormone analysis 
Plasma total T4 (TT4), total T3 (TT3) and free T4 (FT4) were measured with the Amerlite 
chemilurninescence system (Amersham, U.K) using the standard protocol from the 
supplier, with minor modifications. For TT4 measurements the standard curve ranged 
from 0 to 120 nM TT4 and the assay buffer was diluted five times with demineralized 
water. 
In vivo T4 binding capacity of plasma proteins 
At several time points after l25I-T4 injection, blood was collected from the rats by tail-
bleeding. Aliquots of 25 ul serum were mixed 1:1 with electrode buffer 5 mM Tris, 38 
mM glycine buffer, pH 8.3 containing 10 % glycerol. These samples were subjected to 
native polyacrylamide gelelectrophoresis (PAGE) using a 10% separating gel and 
chromatographed during 5 hours at a constant current of 50 mA at 4 °C according to the 
method of Brouwer and Van den Berg (1986). The acrylamide gel was cut into 1 mm 
pieces, which were counted for 125I-T4-radioactivity in a Cobra Auto Gamma counter 
(Canberra-Packard). PAGE gel-profiles were made by plotting the 125I-T4-radioactivity 
against the migration distance (relative to the free T4 peak used as front) on the gel. 125I-
T4-Radioactivity (cpm) bound to the different serum proteins on the gels was used to 
calculate 125I-T4 binding ratios between transthyretin (TTR) and albumin. Pure human 
TTR and BSA and control rat serum were used to identify the plasma proteins on PAGE 
by comparing migration distances. 
TTR levels 
Radioimmunochemical analyses of TTR were performed at the Institute of Human 
Nutrition (Columbia University, New York, USA) according to the method of Muto et 
dl. (1972) and Brouwer (1987) using immunosorbent purified, mono-specific rabbit anti-
rat TTR (Navah et al, 1977). The antibody was radiolabeled with 125I via the Chlorami-
ne-T method. Samples of serum (25 times diluted in 50 mM Tris buffer pH 8.6, with 
1% BSA (w/v)) were incubated with the specific TTR antibody . After precipitation with 
polyethylene-glycol buffer, the tubes were centrifuged for 30 minutes and the amount of 
TTR was determined by counting 125I-radioactivity. The limit of detection was 20 ng/ml. 
GC/MS analysis of hydroxylated TCDD metabolites 
Clean-up and GC/MS procedures of rat plasma were performed according to the 
methods used by Dr. M. Van den Berg (Research Institute of Toxicology, University of 
Utrecht, The Netherlands). Serum was mixed with H20 and methanol (2:1:1), acidified to 
pH 3 with H2S04 and 13C-labeled 2,3,7,8-TCDD (Cambridge Isotope Laboratories, 
Woburn, MA, U.S.A.) was added as an internal standard. This mixture was extracted 
three times with hexane:tert-butyl ether (1:1) by mixing and centrifugation. The organic 
phase was collected, concentrated and dissolved in aceton. The putative TCDD-metaboli-
tes were methylated by adding K2C03 and CH3I, and refluxing during 15 hours. K2C03 
was filtered and the remaining aceton was evaporated, hexane was added next and 
concentrated. The extract was run through an hexane pre-eluted aluminium-oxide 
column, eluted with dichloromethane CH2C12, and concentrated by evaporation. The 
standard hydroxylated metabolites, 2-OH-3,7,8-TriCDD and 2-OH-l,3,7,8-TCDD were 
methylated (to Cl3-DD-OCH3 and Cl4-DD-OCH3, respectively) using the described 
method. 
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GC-MS procedure 
A J&W deltaB5 60m*0.22mm column was used, on a QMD 1000 high resolution gas 
chromatography/low resolution mass spectrometer, operating in electron impact mode. 
The temperature program used was T,=120 °C, 1 min. to T2=250 °C; rate 30 °C/min. 
First a full scan of 2,3,7,8-TCDD, Cl3-DD-OCH3 and Cl4-DD-OCH3 was made to obtain 
retention times and full mass-spectra. Next a multiple ion run (MI) was carried out 
scanning: 2,3,7,8-[13C]/[12C]-TCDD on M+ and M+ +2; Cl3-DD-OCH3 and Cl4-DD-OCH3 
on M+, M+ +2, M+ -15 and (M+ +2)-15. Cl3-DD-OCH3 mass were 315.9; 317.9; 302.9; 
300.9, and Cl4-DD-OCH3 mass were 351.9; 349.9; 336.9; 334.9. 
Statistics 
Data were analysed, after tesing for homogeneity and normality, with one way analysis 
of variance (ANOVA) and the least significant difference test (LSD; p <0.05 or 0.005) 
for differences to controls. A significant difference of p < 0.05 or p < 0.005 is indicated 
in the figures and tables, showing means and standard errors of means (SEM). All data 
analysed are results of duplicate or triplicate measurements. 
Results 
Effects on plasma thyroid hormone levels 
Total plasma T4 levels were significantly reduced in TCDD treated rats at day 4 and 5 
after exposure to respectively 43.8 % and 53.6 % of their controls at the respective days 
(Fig. la). TT4 levels at day 1 of exposure showed a tendency of reduction, but this was 
not significant at this time point. Plasma FT4 levels showed a similar decrease at day 4 
and 5 to 55.2 % and 63.3 % of controls, respectively (Fig. lb), but this did not reach the 
level of significance. No changes were observed in plasma TT3 levels following 
exposure of rats to 25 ng/kg TCDD at either time point of sampling (Fig. lc). 
Effects on plasma protein binding of T4 
l25I-T4 binding proteins in plasma of control and TCDD pretreated rats were separated 
by gel electrophoresis (Figs. 2a-f). Three peaks of radioactivity were identified on 
PAGE, the first two representing albumin and transthyretin (TTR), the last one represen-
ted free T4. The identification was based on co-migration with purified albumin and 
TTR. The amount of T4 radioactivity bound to TTR or albumin was determined by 
gamma-counting and, subsequently the TTR/albumin ratio of 125I-T4 binding was 
determined. At 3 hrs after the l25I-T4 injection the TTR/albumin 125I-T4 binding ratio was 
equal in TCDD exposed and control rats (Table 1). This ratio decreased with time at 6 
hrs (79 % of control), and was significantly lower that controls on 24 hrs (54 % of 
control) after 125I-T4 injection in the TCDD exposed rats (Table 1). In order to exclude 
that the decreased TTR/albumin 125I-T4 binding ratio was caused by reduced TTR levels 
following TCDD treatment, TTR was quantified by a specific radioimmuno-assay for rat 
TTR. TTR levels were not significantly decreased compared to controls after 4 days of 
TCDD exposure (resp. 69.65 ± 6.38 and 55.94 ± 7.00 mg TTR/dl plasma). 
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Figure 1 Total plasma thyroid hormone levels of control and TCDD treated rats. Blood samples 
were collected on 1 day before dosing (day 0), and 1, 4 and 5 days after dosing rats with 25 
fjg TCDD/kg b.w. or corn oil (n = 4). A) total T„ (nmol/l); B) free T4 (pmol/l); C) total T3 (nmol/l). 
Results are means ± SEM of duplicate measurements. 'Indicates values significantly different 
from controls (p<0.05). 
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Presence of hydroxylated TCDD metabolites in plasma 
The decrease in the ratio of TTR/albumin l25I-T4 ratio may be explained by the presence 
of compounds in TCDD treated rats, e.g. hydroxy metabolites of TCDD, that can inhibit 
T4 binding to TTR in vitro (Lans et al, 1993). GC-MS analysis of plasma aliquots of 
TCDD treated rats revealed the presence of TCDD but no hydroxylated TCDD metab-
olites in the plasma (data not shown). The Mi-scan revealed only TCDD in plasma in a 
concentration of 0.843 ng/g plasma (ppb). The detection limit for the internal standard 
2,3,7,8-[,3C]-TCDD was 75 pg, corresponding to 40 pg/g plasma (ppt). If the electron 
impact response of the Cl4 and Cl3 TCDD-metabolites (2-OH-3,7,8-TriCDD and 2-OH-
1,3,7,8-TCDD) are assumed to be equal to 2,3,7,8-[13C]-TCDD, the absolute detection 
limit was 50-100 pg, corresponding to 25-50 pg/g plasma (ppt). Thus the detection limit 
was low enough to be able to detect levels of TCDD-metabolites if present, representing 
5 % of 2,3,7,8-[12C]-TCDD present in plasma. 
Hepatic cytochrome P450 levels and EROD activity 
Total cytochrome P450 levels were significantly increased in livers of TCDD treated rats 
to 1.8 times control levels on a mg protein basis and to 2.5 times control values on a 
total liver content basis (Table 2). Cytochrome P450 1A1 isoenzyme (EROD) activity 
was concurrently highly induced in TCDD treated rats compared to controls, both on 
basis of activity/mg protein (212 times control), per nmol total cytochrome P450 (182 
times control) and per total liver (497 times control) (Table 2). Liver weight was 
significantly increased with 28 % in TCDD rats compared to controls (9.71 ± 0.99 vs. 
7.59 ± 0.41 g, respectively; p<0.0l) while body weights were not significantly changed 
after TCDD exposure: 205.1 ± 11.5 g in controls vs. 198.2 ± 14.2 g in the TCDD 
treated group. 
Table 1 Relative binding of 125I-T4 to TTR and albumin in plasma of control and TCDD treated 
rats. 
Ratio of 125I-T4-TTR / ,25l-T4-albumin 
Time after 125I-T4 Control TCDD 
injection (hr) (corn-oil) (25 //g/kg) 
3 4.2 ± 0.8 4.4 ± 1.0 
6 3.9 ± 0.6 3.1 ± 0.3 
24 4.6 ± 0.7 2.5 ± 0.4" 
Note: for each time point of blood sampling after 125I-T4 injection, t = 3, 6 and 24 hours, gel 
profiles were made from plasma of control (n = 4) or TCDD-treated rats (n = 4). Ratios were 
calculated as described in Materials and Methods, using 125I-T4 radioactivity measured on gel 
profiles as shown in figure 1. Results are means ± SEM. 'Indicates values significantly different 
from control (p < 0.05) 
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Figure 2 PAGE profiles of 125I-T4 derived radioactivity bound to plasma proteins as described in 
Materials and Methods. Transthyretin (TTR) and albumin (Alb) were identified by comparison of 
migration distances using pure human TTR and BSA and rat serum proteins. Rf values were 
calculated using the free 125I-T4 peak as front, Rf is the ratio of migration distance of 125I-T4 
peak vs. front. PAGE profiles are shown of plasma of control, corn-oil treated rats (A: 3hrs, B:6 
hrs, C:24 hrs after 12SI-T„ injection) and TCDD-treated (25 /yg/kg b.w.) rats (D:3 hrs, E:6 hrs, 
F:24 hrs after 125I-T4 injection). 
Chapter 6 89 
Effects on thyroid hormone metabolism 
Hepatic T„-glucuronidation (T4-UGT) was significantly increased 3.9 fold control levels 
(Table 3) on the basis of specific activity. On the contrary hepatic type 1 deiodinase 
(ID-I) activity was significantly reduced to 82% of control activities (per mg protein) 
(Table 3). Brain type 2 deiodinase (ID-II) activity was significantly increased to about 2-
fold control levels indicating a status of functional hypothyroidism in TCDD treated rats 
(Table 3). 
Table 2 Hepatic cytochrome P450 levels and EROD-activity of control (corn-oil) and TCDD-
treated rats (25;vg TCDD/kg). 
Cytochrome P450 parameters Control (n = 4) TCDD (n = 4) 
Cytochrome P450 level (nmol/mg protein) 0.552 ± 0.031 0.991 ± 0 . 0 9 7 " 
Cytochrome P450 level (nmol/total liver) 64 ± 3 161 ± 35" 
EROD activity (nmol RR/min/mg protein) 0.016 ± 0.003 3.390 ± 0 . 7 3 1 " 
EROD activity (nmol RR/min/nmol P450) 0.022 ± 0 .004 4 .000 ± 0 . 8 6 4 " 
EROD activity (nmol RR/min/total liver) 1.31 + 0 . 1 5 651 ± 2 6 4 " 
Note: results are means ± SEM of duplicate measurements. 'Indicates values significantly 
different from control (p < 0.05), "Indicates values significantly different from control 
(p < 0.005). 
Table 3 Thyroid hormone metabolism enzyme activities of control (corn-oil) and TCDD-treated 
rats (25//g TCDD/kg). 
Thyroid hormone metabolism parameters Control (n = 4) TCDD (n = 4) 
T4-UGT-activity (pmol T„/min/mg) 1.732 ± 0 . 1 2 5 6.782 ± 1 . 1 7 2 * 
ID-l-activity (nmol rT3/min/mg) 97 ± 5 80 ± 6" 
ID-ll-activity (fmol T4/hour/mg) 28.90 ± 9 . 1 4 57.57 ± 1 4 . 7 9 * 
Note: hepatic microsomal T4-UGT activity (pmol/min/mg); hepatic microsomal type-1-deiodinase 
(ID-I) activity (nmol/min/mg) and brain type-2-deiodinase (ID-II) activity (fmol/hour/mg protein 
from whole homogenate) are shown. Results are means ± SEM of duplicate measurements. 
"Indicates values significantly different from control (p <0.05). 
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Discussion 
Exposure of rats to TCCD resulted in distinct decreases in total and free plasma T4 
levels, while T3 levels were not changed. These plasma thyroid hormone reductions were 
accompanied by an increased hepatic T4-glucuronidation which may result in enhanced 
excretion and a decreased hepatic type 1 (ID-I) deiodination, presumably lowering the 
conversion of T4 to active T3 or inactive rT3. In addition the TTR/albumin ratio of 125I-T4 
binding in plasma of TCDD exposed rats showed a decrease, which is suggestive for an 
interference of hydroxylated metabolites of TCDD on T4 transport by plasma TTR. 
However, GC/MS analysis revealed that no hydroxylated TCDD-metabolites were 
present in plasma, despite the highly induced cytochrome P450IAI activities in livers of 
TCDD exposed rats. TTR plasma levels were not changed by TCDD exposure either, 
excluding the possibility that plasma T4 levels were decreased due to disruption of 
plasma thyroid hormone transport by TCDD exposure. 
The decrease in plasma thyroid hormone levels as found in this study has been 
described in several other studies in which rodents were exposed to TCDD. Administra-
tion of TCDD to rats or mice resulted in reduced plasma T4 levels (Bastomsky, 1977, 
Potter et al., 1983, Lans et al, 1990, Potter et al, 1986, Roth et al, 1988, Jones et al, 
1987, Henry and Gasiewicz, 1986, 1987, Pohjanvirta et al, 1989). Gorski and Rozman 
(1987) found decreases in total and free T4 and rT3 while plasma T3 and TSH levels did 
not change in Sprague-Dawley rats exposed to different doses of TCDD, including the 
dose used in this study (25 ug/kg). Likewise, Henry and Gasiewicz (1987) found a 
decrease in serum T4 but not tri-iodothyronine (T3) in rats. Plasma T3 levels were 
reported to be increased (Bastomsky, 1977, Potter et al., 1986), unchanged (Potter et al., 
1983, Henry and Gasiewicz, 1987, Lans et al, 1990, Muzi et al, 1989, Gorski and 
Rozman, 1987, Jones et al., 1987, Roth et al, 1988) or decreased (Pazdernik and 
Rozman, 1985) after TCDD exposure. These conflicting results on plasma T3 levels may 
be attributed to differences in TCCD dose, exposure time and species differences. 
The decreased TTR/albumin ratio of 125I-T4 binding suggests an interference in 
plasma T4 transport by TCDD exposure. However we could not find any evidence for 
the presence of hydroxy metabolites of TCDD in plasma of rats in this study. Therefore 
the mechanism of interference in plasma T4 transport is not caused by hydroxy-TCDD 
metabolites. TCDD, however, was detected in the plasma of exposed rats. Although 
McKinney and coworkers (1985) suggested that TCDD could be associated to TTR on 
the basis of structural resemblance to T4, TCDD did not inhibit T4 binding to TTR in in 
vitro binding studies (Lans et al., 1993). Hence TCDD is not expected to interfere with 
plasma T4 transport in this study. Another possibility would be that TCDD exposure 
may have enhanced TTR-binding metabolite formation from endo- or exogenous com-
pounds (PCBs, pesticides) already accumulated in the body via diet. The conditions for 
accelerated metabolite formation are present, since cytochrome P4501A1 activity 
(EROD), an isozyme known to be involved in hydroxy-metabolite formation of several 
polyhalogenated arylhydrocarbons, was markedly increased in the TCDD treated rats. 
This does not, however, explain the lack of difference in the TTR/albumin l25I-T4 
binding ratio at 3 hrs. after 125I-T4 injection in control and TCDD treated rats. 
Since plasma TTR levels were not decreased, the reduced TTR/albumin 12SI-T4 
binding ratio seems to indicate some other mechanism of interference with T4 binding to 
TTR. No difference was found between control and TCDD rats in the TTR/albumin l25I-
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T4 binding ratio at 3 hrs. after l25I-T4 injection, while the ratio decreased at 6 hours and 
significantly at 24 hours after 125I-T4 injection, suggesting an increased clearance of 125I-
T4 from blood. One possibility would be that the increased hepatic T4 metabolism and 
subsequent excretion may have an influence on the bound/free equilibrium of T4 to its 
plasma binding proteins. Such a mechanism would have to account for a more rapid 
dissociation of T4 from TTR than from albumin, which is not likely to happen, because 
TTR has an 10-fold higher binding affinity for T4 than albumin. Since the I-T4 
radioactivity in plasma 24 hours after 125I-T4 injection is much lower than after 3 hrs., 
and just above detection level, the observed decrease may also be the result of inaccura-
cy. 
Despite the highly induced EROD activity, no metabolites of TCDD could be 
detected in the plasma. Several reports however, demonstrated that 2,3,7,8-tetrachlorodi-
benzo-p-dioxin is metabolized in mammals to yield a number of hydroxylated products 
which include, 2-OH-3,7,8-TriCDD, 2-OH-l,3,7,8-TCDD, l-OH-2,3,7,8-TCDD, other 
hydroxylated chlorinated dibenzo-p-dioxins and diphenylethers and 4,5-dichlorocatechol 
(Van den Berg et al, 1994, Neal et al, 1984, Poiger and Buser, 1984, Sawahata et al, 
1982, Weber et al, 1982, Mason and Safe, 1986). Most of these hydroxylated TCDD 
metabolites, however, are excreted in bile and faeces as glucuronide conjugates (Ramsey 
et al, 1982, Weber et ah, 1982). Increased UGT activities were also observed in this 
study, which could have resulted in effective glucuronidation of TCDD-metabolites 
explaining the absence of these metabolites in plasma in this study. 
Hepatic metabolism of T4 was clearly affected in rats by TCDD treatment in this 
study. The glucuronidation pathway of T4 was significantly induced after TCDD 
exposure. T4 is glucuronidated by different UDP-glucuronyl-transferase (UGT) isoen-
zymes, like the bilirubin- and phenol-UGT isoenzymes, while T3 is glucuronidated by 
the androsterone-UGT isoenzyme (Visser et al., 1993). It has been reported that TCDD 
induced UGT activities in the rat 4-7 fold toward p-nitrophenol (Rozman et al., 
1985b,1987), 1-naphtol (Eltom et al, 1992) and T4 (Henry and Gasiewicz, 1987) but not 
or weakly toward testosterone or estrone as substrates (Umbreit et al., 1989, Lucier et 
al., 1975). In another study exposure of rats to TCDD selectively induced the phenol-
UGT activities, but did not change the bilirubin- and androsterone-UGT activity, 
resulting in increased T4 glucuronidation, but no change in T3-glucuronidation (Visser et 
al., 1993). These findings are similar to the earlier observations of Bastomsky (1977), 
using the same dose as in this study, who found an increase in biliary excretion of T4 
(mostly T4-glucuronide) but not T3, indicating an induction of T4 but not T3 glucuronida-
tion. This increase in T4 glucuronidation could explain the decrease of T4 plasma levels 
after TCDD exposure of rats. The in tandem induction of phenol-UGT and cytochrome 
P450 1A1 activities suggests that both isozymes are regulated via the Ah-receptor 
(Sutter and Greenlee, 1992). 
A second enzyme involved in hepatic T4 metabolism, type 1 deiodinase (ID-I), 
was weakly but significantly inhibited by TCDD in this study. Using reverse T3 as a 
model substrate for ID-I, only the outer ring deiodination (which converts T4 into T3) by 
ID-I was selectively measured (Kohrle et al., 1991). Inhibition of outer ring deiodination 
may presumably lower the amount of active T3 in liver in vivo and if severe enough may 
also result in reduced plasma T3 levels. This may partly explain why in some studies 
plasma T3 is lowered and in others not. Inhibition of ID-I activity by several Ah-receptor 
agonists, including TCDD, has been reported before (Visser et al, 1993, Eltom et al, 
92 Alterations in thyroxine metabolism and plasma transport by TCDD 
1992, Rickenbacher and McKinney, 1986). Neonatal rats, exposed to TCDD via 
lactation, showed a significant and sharp decrease in ID-I activity (Adams et ctl., 1990). 
In addition exposure of adult rats to 3,3',4,4'-tetrachlorobiphenyl (TCB) resulted in 
inhibition of ID-I activity (Adams et al., 1990) while it was also observed that hydroxy-
lated TCB metabolites inhibited ID-I activity, in vitro. Therefore it was suggested that 
hydroxylated metabolites of related compounds could also play a role in the in vivo 
inhibition of ID-I activity. Other in vitro studies showed only moderate inhibition of ID-
I activity by hydroxylated TCDD metabolites (Rickenbacher et al., 1989, Lans et al., 
1994). One cannot exclude the possibility that in addition to TCDD also the hydroxyla-
ted TCDD metabolites, which may have been formed in the liver, could be partly 
responsible for the decrease in hepatic ID-I activity in vivo. 
Decreased hepatic ID-I activity can also be a physiological response to hypothy-
roidism or low T4 plasma levels in rats (Kaplan, 1986). Likewise brain type-2-deiodinase 
(ID-II) activity was increased in this study, suggesting a physiological response to 
decreased plasma T4 levels to keep T3 levels in brain constant (Kohrle et al., 1991). 
Increased brain ID-II has also been reported in fetal and neonatal rats exposed to 
3,3',4,4',5,5'-HCB, that showed severely reduced plasma T4 levels (Morse et al, 1993a). 
In this study TCDD exposure of rats caused a decrease in hepatic ID-I activity, an 
increase in brain ID-II activity and concommitant decreases in plasma TT4 and FT4 
concentrations, which may indicate that in the TCDD treated rats compensatory 
mechanisms keep T3 concentrations in tissue sufficiently high in order to maintain a 
functional euthyroid status in the rats. 
No conclusive evidence on the thyroid status of TCDD-treated rats can be found 
in the conflicting results reported in in vivo studies so far. Effects that indicate a 
hypothyroid status after TCDD treatment in rats are decreases in serum T4 levels, free T4 
index, feed intake, growth and increased serum cholesterol concentrations (Bastomsky, 
1977, Potter et al, 1983; Potter et al, 1986, Rozman et al, 1985a,b; Moore et al, 1985; 
Christian et al, 1986; Seefeld et al, 1984; Albro et al, 1978). Hypothyroidism in rats 
after exposure to TCDD was also suggested by elevated TSH plasma levels and goiters 
(Bastomsky, 1977). Furthermore Gupta et al. (1973) and Rozman et al. (1986) found 
histological changes in the thyroid which may be interpreted as thyroid activation in 
TCDD treated rats, probably due to lowered plasma T4 levels. On the other hand effects 
suggesting an euthyroid state in TCDD-exposed rats are described also by Potter et al. 
(1983, 1986) and Pohjanvirta et al. (1989), while Kelling et al. (1987) and Roth et al. 
(1988) found contradicting effects on thyroid hormone regulated enzyme activities in rat 
liver after TCDD exposure. 
In conclusion the decreases in plasma T4 concentrations as found in rats after 
TCDD exposure in this study, are mainly caused by increased thyroid hormone metabo-
lism. No evidence is found for reduction in binding of T4 to TTR in plasma by hydroxy-
lated TCDD metabolites or TCDD itself. The changes in plasma thyroid hormone 
concentrations, with concurrent changes in hepatic and brain deiodination, suggest that 
compensatory mechanisms in the thyroid hormone regulatory system probably maintain 
an euthyroid status in the liver and brain tissues of rats exposed to TCDD. The effects 
of TCDD on the thyroid hormone regulatory system may also be of importance for man, 
since effects on plasma thyroid hormone concentrations were also found in pregnant 
woman and newborn infants exposed to background concentrations of PCDDs, PCDFs 
and PCBs (Koopman-Esseboom et al., 1994). 
CHAPTER 7 
Structural basis for the binding of hydroxylated poly-
chlorobiphenyl (PCB) metabolites to human transthyretin 
Abstract 
This is the first detailed description of the binding of a hydroxylated polychlorinated 
biphenyl (OH-PCB) metabolite to transthyretin (TTR), both by X-ray analysis of a crystal 
of the OH-PCB-TTR complex and computer assisted graphics modelling studies. The crystal 
structure of the complex of 4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl (diOH-TCB) with 
human TTR, a plasma thyroid hormone transport protein, was determined and refined for 
data to 2.7 A resolution. In vitro the diOH-TCB molecule is a potent inhibitor of thyroxine 
(T4) binding to TTR (Lans et al., 1993) as well as an inhibitor of type-1 thyroxine 
deiodinase activity (Lans et al., 1995a). The crystal of the TTR-diOH-TCB complex was 
isomorphous to native TTR crystals. Interpretation of the difference Fourier electron density 
maps revealed the mode of binding of diOH-TCB in the T4 binding site of the TTR 
tetramer. The molar ratio of diOH-TCB to TTR was between 1:1 and 2:1 as based on the 
electron densities present in the two independent T4 binding sites of the TTR tetramer. The 
diOH-TCB molecule bound deep in the binding channel near the Serine 117 residue. This 
allowed the 4-OH group of the diOH-TCB molecule to form a hydrogen bond with the 
oxygen present on the sidechain of the Ser 117 residue, as was clearly shown by the 
electron dense bridge between the 4-OH group of diOH-TCB and the two paired Ser 117 
residues in the channel centre. The diOH-TCB molecule binds in a non-planar 
conformation, as was expected on the basis of the minimum energy rotation angle of the 
molecule (McKinney and Singh, 1988). Comparison with the earlier described interaction 
of T4 with TTR, showed that the diOH-TCB molecule was bound deeper into the binding 
channel than T4. The mode of diOH-TCB binding observed in this cocrystal TTR complex 
confirms the results from computer assisted graphics modelling studies on the interactions 
of hydroxylated PCB metabolites with TTR also described in this study. 
In these studies it was also shown that hydroxyl groups on the meta-positions of 
PCB metabolites have the potential to form hydrogenbonds with the Ser 117 residues, 
explaining the similar binding TTR affinities of para- or /weta-hydroxylated PCB 
metabolites. 
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In addition, the computer modelling studies predicted no structural changes of the TTR 
molecule after binding of either hydroxy-PCB metabolites or pentachlorophenol (PCP). This 
did not explain the ability of hydroxylated PCB metabolites but not PCP to disrupt the 
TTR-retinol binding protein complex as found in vivo and in vitro. 
Introduction 
Exposure to the environmental pollutants polychlorinated biphenyls (PCBs), can lead to 
changes in plasma transport and hepatic metabolism of thyroid hormones in experimental 
animals. One mechanism to explain the PCB-induced decrease in plasma thyroxine (T4) 
levels is by competition of hydroxylated PCB metabolites for T4 binding to transthyretin 
(TTR), the major plasma thyroid hormone transport protein in rodents (Brouwer et al., 
1989, Lans et al., 1995b). The close structural resemblance of these hydroxylated PCB 
metabolites with T4 has been shown to result in competition for the T4 binding site on TTR 
in in vitro binding studies (Rickenbacher et al., 1986, McKinney et al., 1985, Lans et al, 
1993, 1994). In these studies structural requirements of hydroxylated PCB metabolites for 
T4-TTR binding competition were determined. Para- or meta-hydroxylation with at least 
one adjacent chlorine substitution was necessary for strong inhibition of T4-TTR binding. 
Ort/jo-hydroxylated PCB metabolites were poor inhibitors of T4-TTR binding while di-
ort^o-chlorination only weakly decreased the inhibitory potency of para-hydroxylated PCB 
metabolites, probably due to the non-planar conformation. The tested parent PCB 
compounds did not inhibit T4-TTR binding in vitro (Lans et al., 1993, Lans et al., 1994). 
In vivo exposure of rats and mice to TCB or Aroclor 1254, showed a selective retention of 
para-hydroxy-substituted PCB metabolites in the blood, bound to TTR (Brouwer 1989, 
Bergman et al., 1994, Morse et al., 1995b). In addition, selective retention of para- or 
weto-hydroxylated PCB metabolites were detected in human and seal blood, exposed to 
environmental levels of PCBs (Bergman et al., 1994). 
TTR not only transports thyroid hormones in plasma of rats and mice, but also forms 
a complex with retinol binding protein (RBP), which transports retinol, eg. vitamin A (Raz 
and Goodman, 1969). Binding of the hydroxylated 4-OH-3,3',4',5-tetraCB metabolite to 
TTR in plasma of rats exposed to 3,3',4,4'-tetraCB, diminished RBP-TTR binding which 
in turn caused decreases in plasma RBP and retinol (Brouwer and Van den Berg, 1986, 
Brouwer et al, 1988). The interference of this hydroxylated PCB metabolite with TTR-RBP 
binding may be explained by conformational changes in the TTR molecule upon binding 
of the PCB metabolite. However, exposure of rats to a related halogenated phenolic 
compound, pentachlorophenol (PCP), resulted in decreased plasma T4 levels due to 
competitive T4 displacement from TTR, but not in plasma retinol levels (Den Besten et al., 
1991). These data suggest a dissimilar effect of PCP and hydroxylated PCBs on T4-TTR 
and the TTR-RBP interaction. 
In order to better understand the molecular basis of the structural requirements for 
hydroxylated PCB metabolites to inhibit T4-TTR binding and also to elucidate possible 
differences between PCP and hydroxylated PCB metabolites with respect to TTR-RBP 
dissociation, computer assisted molecular graphics modelling studies were performed and 
described in this paper. The4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl (di-OH-TCB) molecule 
is one of the most potent inhibitors of T4-TTR binding, eg. 5.4 fold more potent than the 
natural ligand T4 (Lans et al., 1993). Thus this di-OH-TCB was suitable as an illustrative 
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model compound for TTR binding of hydroxylated PCB metabolites and related 
compounds. The three-dimensional structures of diOH-TCB and TTR, which were based 
on X-ray crystallographic structure analysis (Blake et al., 1978, McKinney and Singh, 
1988), were used for modelling their interaction. In addition several other hydroxylated 
PCB metabolites and parent compounds were modelled and compared with PCP in order 
to explain the consequences of ligand binding for TTR-RBP interaction and for 
conformational changes of the TTR molecule. 
To obtain more accurate data on the interaction of TTR with hydroxylated PCB 
metabolites and compare these with the data collected from graphics modelling in this 
study, cocrystallisation experiments were performed using human plasma TTR with 
different hydroxylated PCB metabolites including the diOH-TCB. The three dimensional 
structure of a diOH-TCB-TTR complex has been determined in this study by X-ray 
diffraction and is refined for data to a 2.7 A resolution. Comparisons are made between the 
crystal structure data and the graphics modelling data on the interaction of TTR with the 
diOH-TCB molecule. 
Figure 1 Structures of compounds used in computer assisted graphics modelling studies. Atomic 
coordinates as available for A:4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl (4,4'-diOH-TCB) were used 
as a basis for the structure of the other hydroxylated PCB structures, B:4,4'-(OH)2-2,3,3',5,5'-
pentachlorobiphenyl (4,4'diOH-PeCB), C:3,3',4,4'-TCB (TCB), D:4-OH-3,3',4',5-tetrachlorobiphenyl 
(4-OH-TCB), E:2,3,3',4,4'-PeCB (PeCB), F:4'-OH-2,3,3',4,5'-pentachlorobiphenyl (4'-OH-PeCB), 
and G:pentachlorophenol (PCP). 
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Materials and methods 
Modelling 
Modelling compounds 
Atomic coordinates as available for 4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl (diOH-TCB) 
(McKinney and Singh, 1988) were used in the graphics modelling study. From this structure 
other hydroxylated PCB structures, like 4-OH-3,3',4',5-tetrachlorobiphenyl (4-OH-TCB), 
4'-OH-2,3,3',4,5'-pentachlorobiphenyl (4'-OH-PeCB), 4,4'-(OH),-2,3,3\5,5'-
pentachlorobiphenyl (4,4'-diOH-PeCB), the parent compounds 3,3',4,4'-tetrachlorobiphenyl 
(TCB) and 2,3,3',4,4'-pentachlorobiphenyl (PeCB) and pentachlorophenol (PCP) were 
derived and also used in the graphics modelling studies (Fig. 1). To facilitate comparisons 
with the OH-PCB metabolites, the OH-group of PCP was defined to be on a 4-position, 
similar to the para-hydroxyl groups on the OH-PCBs. 
Graphics modelling system 
Graphics modelling was carried out on an Evans and Sutherland PS390 Picture System 
using the FRODO program suite. Coordinates of the native transthyretin (Blake et al., 
1978), obtained from Brookhaven Protein Data Bank were used, while the coordinates of 
4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl (diOH-TCB) were based on previous 
crystallographic measurements as described in McKinney and Singh (1988). Atomic 
distances and contacts of the chlorine and hydroxyl substituents of the modelled compounds 
with important amino acid residue pairs within the TTR binding site were measured using 
the FRODO program. 
Modelling assumptions 
The diOH-TCB molecule has a size of 6.57 by 4.79 by 19.46 A (x,y,z-axis) with a phenyl 
ring-ring bond of 1.5 A. The compound crystallizes in a coplanar state due to intermolecular 
stacking interactions in the crystal. However, on basis of molecular mechanics calculations 
the phenyl-rings have an angle of 36° when no intermolecular interactions are present, as 
was described in McKinney and Singh (1988). This agrees with the minimum energy angles 
of 35-45° between the phenyl-rings of non-ortho substituted biphenyls as found by ab initio 
calculations and gas phase determinations (McKinney et al., 1983, Pedersen et al, 1986). 
The graphics model of the diOH-TCB-TTR interaction served as a basis for models made 
of TTR complexes with the other hydroxylated PCB structures (4-OH-TCB, 4'-OH-PeCB, 
4,4'-diOH-PeCB, the parent compounds TCB and PeCB and pentachlorophenol (PCP). 
Before modelling of diOH-TCB and related test compounds into the binding site of 
TTR, several assumptions were made. The interaction of the test compounds with TTR was 
modelled so that their symmetry matched that of the TTR binding site. The two fold axis 
along the length of a compound were coincident with that of the binding site, while the 
inner phenyl ring near the channel centre was more or less coplanar with the phenolic ring 
of T4. When only one hydroxyl group was present on the compound, it was modelled in a 
"forward" mode of binding, with the hydroxyl group near the channel centre. 
Positions of hydroxyl groups within a distance of ca. 3 A with hydrogen bonding 
groups of the amino-acid residues present in the TTR binding channel, could presumably 
be involved in hydrogen bond formation. Van der Waals interactions could occur between 
atoms of the modelled compounds and the amino acid residues present in the binding 
channel, which are 3-4 A apart. 
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Cocrystallization experiments 
Compounds 
The compounds 4-OH-2',3,3',4',5-tetrachlorobiphenyl, 4,4'-(OH),-2,3,3\5,5'-
pentachlorobiphenyl and 4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl w ere synthesized 
according to the methods described by Bergman et al. (1994) and used in the 
cocrystallisation incubations. Human serum transthyretin was purified according to the 
method described by Saraiva et al. (1983). 
Cocrys tallisa tion 
Human TTR (20 nM) was incubated with the hydroxylated PCB compounds (200 nM, 
molar ratio OH-PCB:TTR = 10:1) in 0.165 M sodium-citrate buffer pH 7.0, in 0.25 % (w/v) 
1,2,3 heptanetriol (Sigma) for 2 days at 4 °C. Using these incubations of TTR and 
hydroxylated PCB metabolites, cocrystals were grown using the hanging drop vapor 
diffusion method, with saturated ammonium sulfate solutions (in 0.165 M sodium-citrate 
buffer) ranging from 43 to 53 % and pHs ranging from 4.5 to 5.5. A crystal was grown in 
conditions of 45 % ammonium sulfate solution, pH 4.5. 
Data collection 
X-ray intensities were collected using an Enraf-Nonius FAST area detector system and 
graphite-monochromated Cu-koc radiation (k 1.5418 A), with a focal spot size of 0.3 x 0.3 
mm, from a Nonius FR-571 rotating anode generator operating at 45 kV and 99 mA. A 
total of 1303 frames 0.15° wide in § were measured with an exposure time of 120 seconds 
per frame, at two orthogonal crystal orientations from the same crystal. These frames were 
then processed with the software package MADNES to produce a set of integrated 
intensities which were scaled and merged together using the CCP4 (Collaborative 
Computational Project Number 4 (1994), Acta Cryst. D50, 760-763). The crystal diffracted 
to a maximum resolution of 2.7 A. In the resolution 27.4 < d < 3.25 A a total of 12539 
measurements of 3950 independent reflections were obtained, with a merging R-factor (I) 
= 0.155 and an average redundancy of 3.2, corresponding to 97.6 % of the theoretically 
possible within this resolution limit. The total number of observed independent reflections 
was 4761 corresponding to 70 % of the theoretical value for 2.7 A resolution. 
Crystallographic refinement 
The crystals are isomorphous with those of native TTR (Blake et al., 1978) and coordinates 
of the native protein, obtained from Brookhaven Protein Data Bank, were used to calculate 
the phases. The initial model, including only residues 10-123 for each monomer, was 
refined using XPLOR (Brunger, A., 1988, J. Mol Biol. 203, 803-816). First the two 
monomers were refined as rigid groups and then functional refinement using conjugate 
gradient minimization was used. Difference Fourier maps were calculated and analysed 
using FRODO. The major peaks of density were observed in the protein channel along the 
crystallographic twofold axis. Coordinates obtained from the X-ray diffraction studies on 
diOH-TCB (McKinney and Singh, 1988) were used to model the PCB molecule in the 
electron density using FRODO. Conventional positional refinement with two diOH-TCB 
molecules introduced in the protein channel, resulted in R=23.8 %. Refinement of B-factors 
for each residue and improvement of the model, using difference Fourier maps and the 
model-building program FRODO, followed by positional refinement, resulted in R=20%. 
Using the program FRODO interatomic distances were calculated between amino 
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acid residues present in the TTR binding site and the diOH-TCB molecule, in order to 
compare the actual binding of the diOH-TCB molecule in the T4 binding site of TTR with 
the graphics modelling studies of this interaction. 
Results 
Characteristics of T4 binding to the TTR binding site 
Structural data for TTR, as determined by Blake et al. (1978), showed that the TTR 
tetramer contains a channel that is divided in two symmetry related halves (between 
monomers A anc C or B and D), each forming a T4 binding site. Three distinct regions, 
important for ligand interactions, are formed by the side chains of the symmetry related 
pairs of amino-acid residues within the binding site (Fig. 2). A hydrophilic region in the 
centre of the binding channel is formed by the hydroxyl groups of the Ser 112, Ser 115, ser 
117 and Thr 119 pairs of residues. The paired residues Leu 17, Thr 106, Ala 108, Leu 110 
and Val 121 form a hydrophobic region in the middle of the binding site. Finally, a charged 
region near the channel entrance was formed by the paired side chains of Lys 15 and Glu 
54. 
Figure 2 A schematic drawing of the relative positions of the protein side chains and the bound 
hormone T4 in the T4 binding site of TTR. (From De la Paz et al.,1992). 
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The interaction of the natural ligand T4 with TTR is described in detail by De la Paz 
et al. (1992). T4 binds to TTR on a 1:1 molar ratio under physiological conditions. X-ray 
studies showed that T4 bound into the TTR molecule along the long axis of the binding 
channel, with the phenolic hydroxyl group close to the channel centre. The binding site 
matched the hydrophylic-hydrophobic-ionic character of the T4 molecule in this way (Blake 
et al., 1978). In each T4 binding site six pockets, formed by the grooves between 
neighbouring beta-strands, are capable of binding an iodine T4 substituent (Fig. 3); eg. an 
outer pair of pockets (PI and PI') and two inner sets the proximal P2 and P2' and the distal 
P3 and P3'. The 3,5 iodines of the tyrosine ring of T4 bind to the hydrophobic outer pockets 
(PI and PI') while the 3',5' iodines of the phenolic ring bind to the non-symmetry related 
P2 and P3',respectively (Blaney et al, 1982). The phenolic hydroxyl group of T4 may 
interact with the Ser 117 and Thr 119 residues either directly or most probably via a water 
molecule present in the channel centre (De la Paz et al., 1992). At the channel entrance the 
amino acid side chain of T4 can interact with the charged Glu 54 and Lys 15 residues, with 
the carboxylate group playing a more important role than the ammonium group on the T4 
molecule in this interaction (Andrea et al, 1980). In addition to this conventional "forward" 
mode of binding, also a "reverse" mode of T4 binding to TTR is described, with the 
phenolic hydroxyl group of T4 located near the channel entrance and the amino acid side 
chain of T4 located in the channel centre (De la Paz et al., 1992). 
Thr 106 
Thr 119 
Figure 3 Diagram of the T4 hormone binding site in TTR showing the side chains which project into 
the hormone channel. Entry into the channel is on the right. Broken lines represent the three 
symmetry related pairs of iodine binding pockets; P1, P2 and P3. (From De la Paz et al., 1992) 
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Figure 4 Graphics modelling of the binding of hydroxylated PCB metabolites and PCP in the T4 
binding site of TTR formed by monomers A and C. Hydrogen bond formation is represented by the 
dotted line. Only side chains of the amino acid residues present in the binding site are shown. No 
individual hydrogen atoms are drawn. Schematic representations are shown of binding in TTR 
binding site of: A) 4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl (4,4'-diOH-TCB); B) 4,4'-(OH)2-
2,3,3',5,5'-pentachlorobiphenyl in forward binding mode (4,4'-diOH-PeCB); C) 4,4'-(OH)2-
2,3,3',5,5'pentachlorobiphenyl in reverse binding mode (4,4'-diOH-PeCB); D) pentachlorophenol 
(PCP). 
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Table 1 Interatomic distances (A) of 4,4'-(OH)2-3,3',5,5'-tetrachlorobiphenyl with amino acid 
residues of monomers A and C of the TTR tetramer forming a T4 binding site, as collected by 
graphics modelling (Fig. 4a). 
Substituent position 
Residue 
O-Ser 117 
O-Thr 119 
C-Leu 110 
N-Lys 15 
N-Glu 54 
Monomer 
A 
C 
A 
C 
A 
C 
A 
C 
A 
C 
3 4 5 
CI OH CI 
Interatomic distance (A) 
3.41 3.28 
3.27 3.41 
3.40 4.55 
4 .54 3.38 
5.21 3.84 
3.86 5.28 
3 ' 
CI 
4 .36 
4 ' 
OH 
2.20 
2.40 
5.36 
5.23 
5' 
CI 
4 .66 
Table 2 Interatomic distances (A) of 4,4'-(OH)2-2,3,3',5,5'-pentachlorobiphenyl (forward mode of 
binding) with amino acid residues of monomers A and C of the TTR tetramer forming a l t binding 
site, as collected by graphics modelling (Fig. 4b). 
Substituent position 2 3 4 5 3 ' 4 ' 5' 
CI CI OH CI CI OH CI 
Interatomic distances (A) 
Residue 
O-Ser 117 
O-Thr 119 
C-Leu 110 
N-Lys 15 
C-Ala 108 
A 
C 
A 
C 
A 
C 
A 
C 
A 
Monomer 
3.12 
3.35 
5.06 
3.82 
3.15 
3.13 
4 .60 
4.55 
3.78 
3.82 
3.35 
5.07 
3.69 
2.37 
2.35 
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Table 3 Interatomic distances (A) of 4,4'-(OH)2-2,3,3',5,5' 
of binding) with amino acid residues of monomers A and C of the TTR tetramer forming a T4 
binding site, as collected by graphics modelling (Fig. 4c). 
Substituent position 
Residue 
O-Ser 117 
O-Thr 119 
C-Leu 110 
N-Lys 15 
C-Ala 108 
A 
C 
A 
C 
A 
C 
A 
C 
A 
C 
3' 
CI 
4' 5' 
OH CI 
Interatomic distances (A) 
Monomer 
3.41 
3.40 
5.21 
3.28 
3.27 3.41 
4.55 
4.54 3.38 
3.84 
3.86 5.28 
2 
CI 
2.30 
3 
CI 
4.40 
4 
OH 
2.17 
2.31 
5 
CI 
4.28 
Table 4 Interatomic distances (A) of pentachlorophenol (PCP) with amino acid residues of 
monomers A and C of the TTR tetramer forming a T4 binding site, as collected by graphics 
modelling (Fig. 4d). Substituents positions are labeled comparable to OH-PCBs (Table 1,2,3), with 
OH-group on 4-position. 
Substituent position 1 2 3 4 5 6 
CI CI CI OH CI CI 
Interatomic distances (A) 
Residue Monomer 
0 -Se r117 A 3.07 3.04 
C 3.01 2.99 
O-Thr 119 A 4.73 4.59 
C 4.64 4 .84 
C-Leu 110 A 3.91 3.79 
C 3.72 3.79 
C-Ala 108 A 2.93 
C 3.14 
C-Leu 17 A 3.78 
C 4.28 
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Graphics Modelling of OH-PCBs and PCP binding to TTR 
The interatomic contacts of chlorine and hydroxyl substituents of hydroxylated PCBs and 
PCP with amino acid residues in the TTR binding site as found by graphics modelling, are 
listed in Tables 1-4. The interaction of the symmetric 4,4'-(OH)2-3,3',5,5'-
tetrachlorobiphenyl (diOH-TCB) molecule with TTR was used as the reference model, with 
the 4-OH group of the diOH-TCB molecule located in the channel centre (Fig. 4A, Table 
l).The4,4'-(OH)2-2',3,3',5,5'-pentachlorobiphenyl (4,4'-diOH-PeCB) was modelled in both 
possible modes of binding, with the least chlorinated phenyl-ring and 4-OH group in the 
channel centre (forward, Fig. 4B, Table 2) or towards the channel entrance (reverse, Fig. 
4C, Table 3). The monohydroxylated PCB metabolites and PCP (Fig. 4D, Table 4) were 
modelled in the binding site in a forward binding mode, again meaning the OH group was 
directed towards the channel centre. Atomic distances or contacts of chlorine and hydroxyl 
substituents of the other modelled compounds were similar to the analogous substituents on 
the diOH-TCB and diOH-PeCB and not separately stated (data not shown). 
The modelling of the compounds along the binding channel axis and with the inner 
phenyl ring coplanar to the inner ring of T4, allows the diOH-TCB to bind deep in the 
binding pocket of TTR (Fig. 2). This position in the channel centre of the 4-OH group 
present on the di-OH-TCB molecule makes it possible to interact and presumably form a 
hydrogen bond with the O-group of the paired Ser 117 residues (3.27 - 3.28 A, Table 1). 
No interaction is expected of the 4-OH group with the hydrophobic Leu 110 residues 
regardless the close distance (3.84-3.86 A, Table 1). 
The 4'-OH substituent of di-OH-TCB shows very close contacts with the N atom 
of the Lys 15 residue (2.20 - 2.40 A), which may result in hydrogen bond formation (Table 
1; Fig. 4A). The flexible side chain of Lys 15 may assume a different conformation upon 
ligand binding, similar to the conformational change when T4 is bound in the binding site 
(De la Paz et al., 1992). The close contact of 4'-OH group of the OH-PCB compounds can 
only lead to polar interactions between this OH group and the N-group of the Lys 15 
residue if the OH group of diOH-TCB molecule is ionized. No close contact was found 
between the 4'-OH group with the charged GIu 54 residues near the channel entrance (5.23 
A, Table 1). 
The chlorines substituted on the meta (3 and 5) positions of the diOH-TCB molecule 
are within close distance with the oxygen atoms present on Ser 117 (3.41 A) and Thr 119 
residues (3.38-3.40 A) which could result in electrostatic or charge transfer interactions 
(Table 1). The 3 and 5 chlorines fitted well into the T4 iodine binding pockets, also called 
the P3 and P3' pockets, which are surrounded by residues Ala 108, Ala 109, Leu 110, Ser 
117, Thr 118 and Thr 119 (Fig. 4A; Table 1). The chlorine substituents present on the 3' 
and 5' position of the diOH-TCB molecule are not within close distance with the Lys 15 
residue to allow possible interactions (4.36 and 4.66 A, Table 1). 
The chlorines substituted on position 3' and 5' positions of the diOH-TCB and 4,4'-
diOH-PeCB compounds (located near the channel entrance) may fill the PI and PI' T4 
iodine binding pockets of the binding site formed by residues Lys 15, Leu 17, Thr 106, Ala 
108 and Val 121, or will fit into the P2 and P2' T4 binding pockets (Fig. 2). 
The ring-ring bond region of the diOH-TCB is located in the hydrophobic region of 
the TTR binding site formed by the paired residues Leu 17, Thr 106, Ala 108, Leu 110 and 
Val 121 (Fig. 2), however no limiting contacts are made with the residues in this area. 
Like diOH-TCB, the 4-OH group of the 4,4'-(OH)2-2,3,3',5,5'-PeCB molecule can 
interact with the paired Ser 117 residues (3.13-3.15 A) present in the channel centre when 
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bound in forward mode (Fig. 4B, Table 2). Likewise the chlorines on positions 3 and 5 can 
bind into the P3 and P3' T4 binding pockets while the 3' and 5' chlorines may fit in the P2 
and P2\ or PI and PI' T4 binding pockets. The 4'-OH-group present near the channel 
centre when diOH-PeCB is bound to TTR in forward mode may also interact with the Lys 
15 residue (2.35-2.37 A) analogous to the 4'-OH group of diOH-TCB (Fig. 4A). In reverse 
mode of binding similar interactions of the 4-OH and the 4'-OH group can be made as resp. 
the 4'-OH and 4-OH group in forward binding mode (Table 3, Fig. 4C). The ortho-chlorine 
substituent (2-position) of diOH-PeCB bound forwardly shows close contact (3.12 A) with 
the Ala 108 residue, which is also present in the P2 and P2' binding pockets (Table 2, Fig. 
4B). When, in reverse mode of binding, the or/Ao-chlorine substitution is present on the 
outer phenyl ring (2'-position), a very close contact (2.3 A) is made with the Ala 108 
residue, which may result in a repelling force due to steric hindrance and therefore possible 
a lower binding to TTR (Table 3, Fig. 4C). 
Pentachlorophenol also shows the ability for hydrogen bond formation of the 
hydroxyl group with the O atoms of both Ser 117 residues present in the binding channel 
(3.01 - 3.04 A, Table 4, Fig. 4D). Pentachlorophenol does not have close contacts with Lys 
15 or Glu 54 residues near the binding channel entrance, because the axial-length of PCP 
is too short to be positioned close enough to the N-lys 15, or N-Glu 54, when an interaction 
of the 4-OH group with the Ser 117 residue is assumed. In addition the CI substituents of 
PCP would prevent a polar interaction with Lys 15 or Glu 54, even when it would meet the 
minimal distances required. Chlorines substituted on the 1, 2 and 6 position of PCP are in 
Figure 5 Fourier electron density maps (blue) of the two T4 binding sites of TTR as calculated from 
X-ray analysis for the diOH-TCB-TTR cocrystal to a resolution of 2.7 A, showing the presence of 
2 diOH-TCB molecules. The centre of the binding channel is located in the middle of the picture. 
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close contact with Ala 108 (2.93-3.14 A) and Leu 17 (3.78-4.28 A, Table 4), but still 
seemed to fit easily into the T4 binding site. They likely occupy the P3 and P3' and part of 
the P2 and P2' T4 binding pockets, which are surrounded by the Lys 15, Leul7, Ala 108, 
Ala 109 and Leu 110 residues, and the hydrophobic region of the binding site formed by 
residues Leu 17, Thr 106, Ala 108, Leu 110 and Val 121 (Fig. 3; Table 2). 
When parent PCB compounds were modelled into the TTR binding channel (data 
not shown), it was evident that the lack of hydroxyl groups excluded the two interactions 
important for binding to TTR; eg. the possible hydrogen bond formation of the 4-OH group 
with Ser 117 in the channel centre and possible charged interactions of 4'-OH with the Lys 
15 residue near the channel entrance. Although the atomic distance of chlorines on ihspara 
(4) position of PCB molecules to the O atom of Ser 117 will be equal since the chlorine 
and hydroxyl group are almost similar in size, hydrogen bond formation is not expected due 
to the differences in chemical properties of the OH and CI groups. Likewise a close contact 
but no polar interaction will be formed with the Lys 15 or Glu 54 residues when a chlorine 
substituent is present on the 4' position of PCB molecules located near the channel centre. 
The graphics modelling of the hydroxylated PCB metabolites in the T4 binding site 
of TTR, as performed in this study does not clearly reveal the actual conformation of the 
OH-PCBs assumed upon binding to TTR, because modelling is partly based on assumptions 
made beforehand. Especially for the rotational angle of the phenyl-rings, which was 
assumed to be 36°, it cannot be excluded that the compounds may adapt a coplanar state 
or different rotational angle upon binding to TTR. In addition the possible hydrogen-bond 
interaction between the 4-OH group and Ser 117, is a consequence of modelling the OH-
PCB metabolites deep inside the binding channel. For precise information on the 
conformation and location of the OH-PCB metabolites in the TTR binding channel after 
binding, X-ray structure analysis of cocrystallisation experiments was performed. 
X-ray crystallographic structure analysis 
The co-crystallisation experiments resulted in a crystal of the TTR-diOH-TCB complex 
usable for X-ray diffraction analysis. The structure of the diOH-TCB-TTR complex is 
isomorphous to the native TTR structure (Blake et al. 1978). The crystals are orthorombic, 
with space groups P2,2,2 with A=42.73 A, B=85.66 A and C=65.08 A. In this study no 
significant changes in overall TTR and binding site structure were observed upon diOH-
TCB binding. However, the resolution of the complex is not good enough to precisely 
locate all the atoms of the protein side chains, so residues 1-9 and 124-127 were not 
included, analogous to studies on native TTR (Blake et al., 1978), which include only 
residues 10-123. A general view of the TTR molecule is shown on the front cover of this 
thesis, with the two hydroxylated PCB molecules (white) present in the T4 binding sites and 
with the symmetric alpha-helices (red), beta-sheets (green) and connecting peptide chains 
(yellow) that form the tertiary structure of the TTR molecule. In figure 5 the location of the 
calculated and refined electron density maps to a resolution of 2.7 A on the TTR molecule 
are shown in blue. The electron density corresponding to the diOH-TCB was clear so the 
exact location of the molecule in the T4 binding site of TTR (formed by monomers A and 
C or B and D) could be determined. Electron density maps showed the presence of a 
hydroxylated PCB molecule in each T4 binding site of TTR, although in the diffraction data 
the densities were much better for one of the diOH-TCB molecules present in the T4 
binding sites. This indicates that diOH-TCB is bound to TTR in a molar ratio between 1.5:1 
and 2:1 (diOH-TCB:TTR). 
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Table 5 Interatomic distances (< 4 A) of 4,4'-(OH)2-3,3',5,5'-tetrachloro-biphenyl with amino acid 
residues of resp. A and C monomers of the TTR tetramer forming a T„ binding site, as collected 
using FRODO from X-ray crystallographic structure analysis. (— = hydrogen bond formation) 
Monomer A/residue 
Lys 15 -CD 
Lys 1 5 -CD 
Lys 1 5 -CE 
Lys 1 5 -CE 
Lys 1 5 -CE 
Lys 15 -CE 
Leu 17 -CD1 
Ala 108-CB 
Ala 108-CB 
Ala 108-CB 
Ala 109-CA 
Ala 109-C 
Leu 110-N 
Leu 110-CB 
Leu 110-CD2 
Ser 117-OG 
Ser 117-OG 
Ser 117-OG 
Ser 117-OG 
Ser 117-C 
Ser 117-0 
atom 
C4B 
04B 
C4B 
C5B 
04B 
L5B 
C6B 
C6A 
C2B 
CI3B 
CI5A 
CI5A 
CI5A 
CI5A 
04A 
C4A 
C5A 
CI 5 A 
04A— 
CI 5 A 
CI 5 A 
(A) 
3.9513 
3.4472 
3.6410 
3.9152 
3.2417 
3.8046 
3.7495 
3.8237 
3.5678 
3.9522 
3.9854 
3.8343 
3.6431 
3.7363 
3.8161 
3.8207 
3.9446 
2.8846 
-2 .8683 
3.5666 
3.0907 
Monomer C/residue 
Lys 1 5-CD 
Lys 1 5-CE 
Leu 17-CD1 
Leu 17-CD1 
Leu 17-CD1 
Ala 108-CB 
Ala 108-CB 
Ala 108-CB 
Ala 108-C 
Ala 108-0 
Ala 109-N 
Ala 109-CA 
Ala 109-C 
Leu 110-N 
Ser 117-CB 
Ser 117-OG 
Ser 117-C 
Ser 117-0 
Thr 118-N 
Thr 118-CA 
Thr 118-C 
Thr 119-N 
Thr 119-0G1 
Thr 119-0G1 
atom 
04B 
04B 
C1B 
C2B 
C3B 
C2A 
C5B 
C6B 
CI3 
CI3A 
CI3A 
CI3A 
CI3A 
CI3A 
04A 
04A— 
CI3A 
CI3A 
CI3A 
CI3A 
CI3A 
CI3A 
C3A 
CI3A 
(A) 
3.8285 
3.629 
3.9320 
3.3707 
3.9216 
3.5262 
3.9660 
3.4099 
3.6571 
3.1297 
3.9864 
3.8742 
3.9727 
3.6732 
3.7225 
-2 .7815 
3.2700 
2.9324 
3.3829 
3.2137 
3.5246 
3.7994 
3.9583 
3.6128 
A detailed representation in figure 6 clearly shows the hydroxylated diOH-TCB molecule, 
located deep in the T4 binding site of TTR formed by monomers A and C. The 4-OH-group 
of the diOH-TCB undoubtedly forms a hydrogen bond with the oxygen present on the Ser 
117 residues in the centre of the binding channel, as confirmed by the presence of electron 
density between the 4-OH-group and the Ser 117 side chains (Fig. 6). The O atoms from 
the paired Ser 117 residues make close contacts with the O atom of the 4-OH group and 
the 3 and 5 CI atoms on the diOH-TCB molecule (Table 5). The electron density map 
covers the diOH-TCB molecule in a way that verifies the coordinates and size of the diOH-
TCB molecule as described by McKinney and Singh (1988). A view into the T4 binding 
channel towards the centre of TTR, with the non-planar diOH-TCB molecules (white) 
located alongside each other (back cover of thesis) also reveals a non-planar conformation 
of the hydroxylated PCB, although no ortho chlorine-substitutions are present on the diOH-
TCB molecule. The two phenyl-rings of the diOH-TCB are lined up and shown in the 
centre with a rotational angle of ~45°. So upon binding to TTR, the diOH-TCB molecule 
adopts a non-planar conformation as was predicted by molecular mechanics calculations 
(McKinney and Singh, 1988). 
In figure 7 a schematic representation of the diOH-TCB molecule in the T4 binding 
site of TTR shows the most important amino acid residues for ligand binding. The 
interatomic coordinates as calculated from this co-crystal complex structure as stated in 
Table 5, show general agreements with the interatomic coordinates collected from the 
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Figure 6 Fourier electron density map (blue) of a bound diOH-TCB molecule present in the T4 
binding site of TTR, formed by monomers A and C. Hydrogen bonds are present between the 4-0H-
group of diOH-TCB (red) and the O-atom of the paired Ser 117 residues (red) in the form of electron 
dense material (blue). 
Figure 7 Schematic representation of the location of the diOH-TCB molecule, as based on X-ray 
diffraction analysis of a cocrystal, within the binding site of TTR formed by monomers A and C, 
here only showing the peptide backbone and amino acid side chains of the paired amino acid 
residues Lys 15, Leu 17, Leu 110 and Ser 117. 
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Figure 8 Detailed view into the T4 binding channel centre of TTR with both two diOH-TCB 
molecules (white) and the Serine 117 residues of the upper TTR monomers (light blue), and with 
the symmetric alpha-helices (red), beta-sheets (green) and connecting peptide chains (yellow) that 
form the tertiary structure of the TTR molecule. 
graphics modelling study with the diOH-TCB molecule (Table 1, Fig. 4A). Due to the 2.7 
A resolution small differences in interatomic distances collected from the co-
crystallographic experiments and data collected from the graphics modelling studies can 
only be compared with caution. The most notable differences are found in the distances 
between the 4'-OH group of diOH-TCB and the N-Lys 15 residue, which is 2.17-2.40 A 
in the graphics modelling study and ~ 3 A in the crystal complex. In figure 8 a detailed 
view is given into the centre of the binding channel. 
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Discussion 
Computer assisted graphics modelling and co-crystallisation experiments were used to better 
understand the molecular characteristics of the binding of hydroxylated PCB metabolites 
to the T4 binding pocket of TTR. Results from the modelling studies indicate that the tested 
hydroxylated PCB metabolites and the related compound pentachlorophenol fitted in the 
TTR binding pocket accurately. These fits were based on the modelled interaction of 4,4'-
(OH)2-3,3',5,5'-TCB (diOH-TCB) with TTR, using the coordinates of both ligand and 
protein derived from X-ray crystallographic analysis (McKinney and Singh, 1988, Blake 
et al., 1978). In addition X-ray crystallography of a cocrystal revealed the structure of a 
TTR-diOH-TCB complex, confirming the interactions between hydroxyl- and chlorine-
groups present on the diOH-TCB and amino acid residues present in the binding channel 
as found in the graphics modelling studies. 
The tested hydroxylated PCB metabolites which are smaller and more planar than 
the natural ligand T4, were able to bind deeper into the binding channel compared to the 
natural ligand T4 due to the smaller halogen substituents. This resulted in direct hydrogen 
bond formation of the para-hydroxyl (4-OH) group of the diOH-TCB with the O-atom of 
the Ser 117 residues, present in the channel centre. When T4 is bound to TTR, the phenolic 
hydroxyl group of T4 presumably only interacts indirectly with the Ser 117 residue through 
a water molecule (De la Paz et al., 1992). 
Co-crystallisations of milrinone (Wojtczak et al., 1993), 3',5'-dibromo-2',4,4',6-
tetrahydroxybromoaurone (Ciszak et al., 1992) and 3,3'-diiodo-L-thyronine (Wojtczak et 
al., 1992) with TTR, indicated that these ligands were also able to bind deeper in the TTR 
binding site than the natural ligand T4, which allowed hydrogen bond formation of the 4-
OH groups of these compounds with the Ser 117 residue, similar to our modelling studies 
and crystallographic data. 
In earlier studies the structural requirements of hydroxylated PCB metabolites for 
binding to TTR were investigated using in vitro T4-TTR binding competition assays (Lans 
et al., 1994, 1993, Brouwer et al., 1990). Para- or weto-hydroxylation and at least one 
adjacent chlorine substitution on the PCB metabolites were necessary for strong inhibition 
of T4-TTR binding. These requirements are consistent with the important role of the 
hydroxyl and chlorine substitutions on hydroxylated PCB metabolites for close interaction 
with the TTR binding channel as observed in this study using computer assisted graphics 
modelling and X-ray crystallographic structure analysis. .Para-hydroxylation of the phenyl-
rings resulted in possible interactions of the hydroxyl group with resp. Ser 117 near the 
channel centre, or Lys 15 near the channel entrance. Afeta-hydroxylation of the phenyl-ring 
located near the channel centre could also lead to hydrogen-bond interactions with Ser 117 
because short distances were found in this study between wieta-substitutions on the phenyl-
ring and the Ser 117 residue. These findings are in line with the strong T4-TTR 
displacement potency of /weta-hydroxylated PCB metabolites. 
Mefa-chlorine substitutions, adjacent to the hydroxyl group on the phenyl-ring 
located in the channel centre fitted well in the P3 and P3' T4 iodine binding pockets of the 
binding channel. Ort/io-chlorine substitutions on the hydroxylated PCB metabolites tested 
in the graphics modelling studies did not clearly affect the binding in the T4 binding 
channel, although di-orrto-chlorine substitution weakly lowered the TTR binding affinity 
of hydroxylated PCB metabolites (Lans et al., 1993). This could, however, be the result of 
steric hindrance of the orrto-chlorine substitutions on both phenyl-rings with the Ala 108 
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residue in the channel, as was found by graphics modelling of the diOH-PeCB molecule. 
Since the ether bridge of T4 is not required for binding to TTR (Rickenbacher et al., 
1986), the linear polychlorinated biphenyl structures tested in this study could easily bind 
to TTR, with the phenyl-ring bond fitting into the hydrophobic region of the binding site. 
However, the rigid 3,3',5,5'-tetrachloro-diphenoquinone structure showed weaker binding 
(Ka's) than di-OH-TCB (Pedersen et al, 1986), which may indicate that the C-C bond 
which allows rotation of the phenyl-rings, may be important for the high binding affinities 
of the hydroxylated PCBs for TTR. 
The inability of parent PCB compounds to bind to and displace T4 from TTR as 
found by Brouwer et al. (1990) and Lans et al. (1993, 1994) was confirmed by the graphics 
modelling fits because non-hydroxylated, parent compounds like TCB and PeCB lack the 
possibilities for hydrogen bond interactions with the Ser 117 residues present in the binding 
channel centre. This could result in lower binding affinity of parent PCB compounds 
compared to the jwra-hydroxylated PCB metabolites. The increase in binding affinities of 
non-, mono-, and di-para-hydroxylated PCB molecules for TTR with increasing numbers 
of hydroxyl-substituents as found in vitro (Lans et al., 1993), may be caused by the 
additional possibility of interactions of hydroxy 1 groups with N-Lys 15 next to interactions 
with Ser 117 that may strengthen binding to TTR. 
Pentachlorophenol (PCP) was also found to inhibit T4-TTR binding in vitro (Van den 
Berg, 1990; Den Besten et al., 1991), which was confirmed in this study where a close fit 
of the PCP molecule within the TTR binding site was observed, with formation of a 
hydrogen-bond between the hydroxyl group of PCP with the Serine 117 residues and the 
chlorines substituted adjacent to the hydroxyl group of PCP fitting in the P3 and P3' and 
part of the P2 and P2' iodine binding pockets of the T4 binding site of TTR. 
Other graphics modelling studies of the related compounds 3,3',4,4',5,5'-hexaCB and 
2,2',4,4',6,6'-hexaCB by Rickenbacher and coworkers (1986), showed a good fit of these 
molecules in the TTR binding channel. However, by superimposing the inner phenyl ring 
of these compounds on the place of the inner-phenyl ring of T4 in the binding channel, 
these compounds were fitted more towards the channel entrance. The authors concluded that 
the 3,3',4,4',5,5'-hexaCB was able to bind to TTR while 2,2',4,4',6,6'-hexa-CB showed no 
good binding due to steric hindrance in the TTR binding pocket (Rickenbacher et al., 1986). 
However, in the same study it was suggested that /?ara-hydroxylation with adjacent meta-
chlorination of the biphenyls led to the strongest binding to TTR, on basis of in vitro T4-
TTR binding assays with related compounds. In another study 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) and 2,3,7,8-tetrachloro-dibenzofuran (TCDF) were modelled into the 
binding site of TTR (McKinney et al., 1985). Only the adipamide derivatives of TCDD and 
TCDF were tested in in vitro binding assays, showing possible binding to TTR. In a earlier 
study from our laboratory TCDD was found not to inhibit T4-TTR binding, suggesting no 
binding to TTR as was found for the other non-hydroxylated PCBs (Lans et al., 1993). 
Hydrogen-bond interactions may therefore be important requirements for strong binding of 
PCBs and related compounds to TTR, as was found in this study. 
The selective binding of hydroxylated PCB metabolites to TTR has also been 
observed in vivo. Exposure of rats and mice to TCB (Brouwer and Van den Berg, 1986, 
Brouwer, 1989) resulted in the selective retention of the 4-OH-3,3',4',5-TCB metabolite, 
bound to TTR in plasma and was indicated to be at least partly responsible for the decrease 
in plasma T4 levels by inhibition of T4-TTR binding. This metabolite was also found to be 
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selectively retained in rat fetuses after TCB exposure of pregnant rats (Morse et ai, 1995b). 
Another PCB congener 2,3,3',4,4'-PeCB caused a selective retention of a hydroxylated 
metabolite in plasma of rats exposed to this compound (Klasson Wehler et ai, 1993). In 
plasma of rats exposed to Aroclor 1254, a commercial PCB mixture, the para-hydroxylated, 
meta-chlorine substituted PCB metabolite 4-OH-2,3,3',4',5-PentaCB was mainly found 
(Bergman et ai, 1994, Lans et ai, 1994), while this metabolite also accumulated in fetuses 
after Aroclor 1254 exposure of pregnant rats (Morse et al., 1995d). In addition 
environmental exposure to PCBs caused the selective retention of mainly 4-OH-2,3,3',4',5-
pentaCB in seal plasma and both 4-OH-2,3,3',4',5-pentaCB and 4-OH-2,2',3,4',5,5',6-
heptaCB in human plasma (Bergman et al., 1994). It was evident that para- or meta-
hydroxylation and adjacent chlorine substitution was necessary for binding to TTR in 
plasma. No selective retention of the parent compounds by TTR was found in plasma of 
exposed animals. Thus, all structural requirements for binding to TTR as found in in vitro 
studies (Lans et al., 1993, 1994) and by computer assisted graphics modelling and X-ray 
crystallography in this study are confirmed by in vivo findings, following both experimental 
and environmental PCB exposures. 
The selective retention of di- or Xn-ortho chlorinated, non-planar hydroxylated PCB 
metabolites after exposure to commercial PCB mixtures, or environmental exposure 
(Bergman et al., 1994) suggests that a non-planar conformation does not interfere with 
binding to TTR. Since di-ortho highly chlorinated PCBs are present in substantial levels in 
the environment (for review see McFarland and Clarke, 1989, Safe, 1994) marine mammals 
(Kannan et al., 1989) and human milk (Safe et al., 1985), and the metabolism of these 
compounds is slow (Safe, 1989), this may explain the presence of metabolites of di- or tri-
ortho chlorine substituted PCBs in plasma of environmentally exposed organisms. 
In addition to T4-binding and transport, TTR also functions in RBP-retinol transport. 
It was observed by Brouwer et al. (1988) that the affinity of TTR for RBP complex 
formation was reduced by the interaction of the 4-OH-3,3',4',5-TCB metabolite. This 
suggested that binding of a hydroxylated PCB metabolite did not only disturb T4-TTR 
binding but also RBP-TTR binding, probably as a consequence of conformational changes 
of the TTR protein. Competition of 4-OH-TCB for the RBP binding site on TTR was not 
likely because the metabolite competed with T4 for the thyroid hormone binding site on 
TTR (Brouwer et al., 1990, Lans et ai, 1994). The interaction of hydroxylated PCB 
metabolites with TTR as found in this study does not support the hypothesis of a 
conformational change causing the decrease in TTR-RBP binding, because binding of a 
hydroxylated PCB molecule does not seem interfere with the native TTR conformation. 
Only the Lys 15 residues present near the channel entance may assume a different 
conformation. This change is analogous to the conformational change of the Lys 15 residues 
upon T4 binding, which does not interfere with RBP binding, so no interference of TTR-
RBP binding is expected by this mechanism. Recently, the participation of the He 84 
residues, on the outside of the TTR tetramer, with the TTR-RBP interaction is described 
(Berni et al., 1994). Interaction of hydroxylated PCB metabolites with TTR are, however, 
not expected to interfere with this region on the TTR molecule as based on the interaction 
with the T4 binding site of TTR described in this study. 
In vivo studies with PCP-exposed rats showed a decrease in plasma total T4 levels 
that could also be caused by inhibition of T4-TTR binding as found in vitro (Van den Berg, 
1990). However, no decrease in plasma retinol was found, suggesting no interference with 
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RBP-TTR binding (Den Besten et al, 1991). As for the hydroxylated PCB metabolites 
tested in this graphics modelling, no indication was found for a conformational change in 
the TTR molecule after binding of PCP, which seemed to fit well in the binding channel 
of TTR. 
The mechanism of the different effects of hydroxylated PCB metabolites and PCP 
on RBP-TTR interaction is not yet elucidated. Detailed structural information on the PCP-
TTR interaction, as could be derived from X-ray crystallograpic studies on the PCP-TTR 
complex, could help explain the dissimilar effects on RBP-TTR interaction of the related 
PCP and hydroxylated PCB metabolites. 
In addition to disturbances of T4-TTR binding, several hydroxylated PCB metabolites 
could also competitively inhibit type-1-deiodinase activity in vitro (Lans et al., 1995a), 
while no disturbances were found in vitro of T4 binding to thyroxin-binding globulin, the 
major human thyroid hormone transport protein in plasma (Lans et al., 1993), indicating 
differences in the structural requirements of hydroxylated PCB metabolites for binding to 
these thyroxine binding proteins. 
In conclusion, exact and detailed information derived from X-ray analysis of 
cocrystallized complexes of TTR and diOH-TCB and the computer assisted graphics 
modelling of complexes of hydroxylated PCBs with TTR confirmed structural requirements 
of these compounds for TTR binding as found in vitro, and gave insight in the mechanism 
of selective retention of para- or meta-hydroxylated PCB metabolites as found in vivo in 
plasma of mammals after experimental and environmental PCB exposure. These techniques 
can therefore be used for predictions of possible interferences of compounds, structurally 
related to T4, with TTR. In ongoing studies, binding energies of the hydroxylated PCB 
metabolites modelled in the TTR binding site in this study will be calculated using energy 
minimisation calculations in order to compare binding energies derived from graphics 
modelled interactions with binding affinities determined in vitro (Lans et al., 1993). 
Detailed information on subtle changes due to diOH-TCB binding in the binding channel 
of TTR and differences in the binding of T4 and diOH-TCB to TTR will be obtained by 
superimposing the X-ray crystallographic structures. ' 
CHAPTER 8 
Summary and concluding remarks 
Summary 
Some toxic effects caused by polyhalogenated aromatic hydrocarbons (PHAHs) develop 
through alterations in the reproductive and thyroid hormone regulatory systems, thereby 
affecting (brain) development, reproduction and behaviour of several species (Stone, 
1995, Birnbaum, 1994, for review: Brouwer et al, 1995, Peterson et al, 1993). In this 
thesis we have focused on the effects of different classes of PHAHs, eg. polychlorinated 
biphenyls (PCBs), dibenzofurans (PCDFs) and dibenzo-/?-dioxins (PCDDs) and their 
hydroxylated metabolites on thyroid hormone homeostasis. These changes seem to be 
partly caused by Ah-receptor mediated changes in thyroid hormone glucuronidation, and 
effects on the thyroid gland affecting hormone production and secretion. However, 
hydroxylated metabolites of PCBs, PCDFs and PCDDs may have an additional effect on 
thyroid hormone transport. Previous studies (Brouwer, 1987) have shown that exposure 
to 3,3',4,4'-tetrachlorobiphenyl (TCB) can disturb the plasma transport of thyroxine (T4) 
and retinol in rats through specific competition of a hydroxylated metabolite, 4-OH-
3,3',4',5-tetraCB, with T4 for the thyroid hormone binding site of transthyretin (TTR), 
the major thyroid hormone transport protein in rodents. This observation raised the 
question if structurally related hydroxylated PHAH-metabolites could interact with TTR 
in the same way, as well as with other thyroxine binding proteins, like thyroxine binding 
globulin (TBG) and type-1-deiodinase (ID-1), subsequently disturbing thyroid hormone 
transport and metabolism. Special attention was also paid on the structure-activity 
relationships of hydroxylated PHAH metabolites for binding to TTR by using in vitro 
and in vivo studies and X-ray crystallographic structure analysis. 
In vitro studies on interactions of hydroxylated PHAH metabolites 
with thyroxine binding proteins 
In in vitro studies the interactions of several hydroxylated PHAH metabolites with 3 
different T4 binding proteins, eg. TTR, thyroxine binding globulin (TBG) and type-1-
deiodinase (ID-1), were investigated (Chapter 2, 3 and 4). The inhibition of T4 binding 
to TTR by hydroxylated PHAH metabolites was studied using in vitro T4-TTR bin-
dingstudies. These studies revealed the structural requirements for competition of T4 
binding to TTR by hydroxylated PHAH metabolites: para- or /weto-hydroxylation on 
one or both phenylrings, with one or more adjacent chlorine substitutions (Chapter 2). 
PHAH metabolites with these structural characteristics showed a remarkable resem-
blance to T4, the natural ligand for TTR, consequently displacing T4 from the T4 binding 
site of TTR. Both non-planar, ortfio-chlorinated hydroxylated PCB metabolites and rigid, 
planar hydroxylated PCDF or PCDD metabolites could inhibit T4-TTR binding. 
However, the orffto-hydroxylated PHAH metabolites and parent PHAH compounds, like 
TCDD, 2,3,3',4,4'-pentaCB and 3,3',4,4'-tetraCB could not inhibit T4-TTR binding in 
vitro. 
In subsequent in vitro studies, a wide range of hydroxylated PHAH metabolites 
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did not inhibit T4 binding to TBG, the major plasma thyroid hormone transport protein 
in man (Chapter 3). This indicates that ligand interactions with TTR or TBG are clearly 
different. Additional studies with iodothyronine derivatives, showed that tri-iodophenol 
and to a lesser extent di-iodotyrosine could inhibit T4-TTR binding but not T4-TBG 
binding in vitro. Finally, the enzymatic activity of hepatic ID-1, which plays a role in 
the (in)activation of thyroid hormones, could be competitively inhibited mainly by di-
para-hydroxylated, /neta-halogenated PHAH metabolites while mono-hydroxylated 
PHAH metabolites were 10 to 100 times less potent (Chapter 4). The differences 
between the structural requirements of hydroxylated PHAH metabolites for interactions 
with TTR, TBG and ID-1, are in line with previous studies in which related hydroxyla-
ted PHAH compounds or iodothyronine derivatives were used. In conclusion, specific 
hydroxylated PHAH metabolites can disturb T4-TTR interactions, or inhibit ID-1 activity 
in vitro, indicating that hydroxylated PHAH metabolites may play an additional role in 
the observed disturbances in thyroid hormone transport and metabolism after PHAH 
exposure in vivo. 
In vivo studies on effects of Aroclor 1254 and TCDD 
on thyroid hormone transport and metabolism 
Two in vivo experiments were carried out to study role that both disturbances in plasma 
T4 transport and hepatic T4 metabolism caused by hydroxylated PHAH metabolites play 
in the observed decreases in plasma T4 levels. Rats were exposed to Aroclor 1254, a 
commercial mixture containing persistent and metabolisable PCB congeners (Chapter 5) 
or the persistent 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Chapter 6). 
In adult Wistar rats, that were exposed to a high dose of Aroclor 1254, plasma T4 
levels were decreased on day 3 and day 8 (Chapter 5). In addition, high levels of a 
single hydroxylated PCB metabolite, eg. 4-OH-2,3,3',4',5-pentaCB, were detected in 
plasma of the rats on day 8, while lower concentrations of this metabolite were present 
in the blood on day 3. However, the T4 binding capacity in plasma was decreased only 
in the high dosed group on day 8 but not on day 3, indicating a threshold level for the 
hydroxylated PCB metabolite to disturb T4-TTR binding. On both day 3 and 8, hepatic 
cytochrome P450 1A1 levels and activity were induced, which is essential for the 
formation of hydroxylated metabolites. Hepatic T4 glucuronidation was induced 
simultaneously. The decreased plasma T4 levels found in all exposure groups could 
therefore be attributed to both disturbed plasma T4 transport and/or induced T4 glucuro-
nidation. No significant changes in plasma T3 levels were found following Aroclor 1254 
treatment. In addition, hepatic ID-1 activity was not decreased, suggesting that the in 
vitro inhibition by hydroxylated PCB metabolites does not occur in vivo. However in an 
earlier study Adams et ctl. (1990), in vivo exposure to the easily metabolisable 3,3',4,4'-
tetraCB or persistent TCDD could inhibit ID-1 activity. The levels of PCB metabolites 
with the required structure for inhibition of hepatic ID-1 activity were possibly too low 
(Chapter 4) liver after Aroclor 1254 exposure in vivo. 
Another remarkable finding was the selective retention of a single specific 
hydroxylated PCB metabolite, 4-OH-2,3,3',4',5-pentaCB, in plasma of rats exposed to a 
complex mixture of PCB congeners (Fig. 1). This was the result of the presence of 
PCB-congeners that strongly induce cytochrome P4501A1 activity and PCB-congeners 
that could easily form hydroxylated PCB metabolites in the Aroclor 1254 mixture, and 
the strict selectivity of the TTR present in plasma retaining only hydroxylated PCB 
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metabolites that meet the structural requirements as described in Chapter 2. Surprisingly 
the 4-OH-2,3,3\4',5-pentaCB metabolite which was formed and selectively retained in 
plasma, has a hydroxy group on the highest chlorinated ring, in contrast to the expected 
formation of mainly metabolites with a para- or /weta-hydroxy group on the least 
chlorinated ring. However, the inhibition potencies of T4-TTR binding for the 4-OH-
2,3,3',4',5-pentaCB metabolite (Chapter 5) and the structurally related 4'-OH-2,3,3',4,5'-
pentaCB metabolite (Chapter 2) were almost similar. There is no clear indication yet on 
the mechanism of selective retention of the 4-OH-2,3,3',4',5-pentaCB in rat plasma, 
although pharmacokinetics and tissue levels of the presumed parent compounds 
2,3,3',4,4'-pentaCB (CB 105) or 2,3',4,4',5-pentaCB (CB 118) may play a role. 
No detectable levels of hydroxylated metabolites were found by GC-MS analysis 
of plasma extracts of rats at both day 3 and 8 following exposure to the persistent 
TCDD, although cytochrome P4501A1 levels and activity were markedly induced 
(Chapter 6). In addition no unequivocal decrease in T4-TTR binding in plasma of 
TCDD-exposed rats was observed. However, hepatic thyroid hormone metabolism was 
clearly altered: T4 glucuronidation and brain type-2-deiodinase (ID-2) activity were 
increased and hepatic ID-1 activity was decreased, which may explain the observed 
plasma T4 reductions in the TCDD exposed rats. These changes in thyroid hormone 
homeostasis suggest a hypothyroxinemic state of the TCDD-exposed rats, although no 
decreased plasma T3 levels were found. The decrease in ID-1 activity after TCDD 
exposure was not likely to be caused by hydroxylated metabolites, as was described in 
Chapter 4, but may be caused by direct effects of TCDD on ID-1 activity or by the 
assumed hypothyroid state of the TCDD exposed rats. 
While Aroclor 1254 exposure disturbed T4 plasma transport and increase T4 
glucuronidation (Chapter 5), TCDD exposure only enhanced the hepatic elimination of 
T4 (Chapter 6), leading to decreased plasma T4 levels. Although the in vivo studies 
described in this thesis indicate two different mechanisms for decreases in plasma T4 
levels after PHAH exposure, we can not exclude a third possible mechanism since 
several studies described changes on thyroid gland histology and thyroid hormone 
secretion after exposure to Aroclor 1254, TCDD and related compounds. 
Structural basis for interactions of hydroxy-PCB metabolites with TTR 
The selective retention of a specific hydroxylated PCB metabolite in vivo (Chapter 5), 
inspired us to look into the interactions of hydroxylated PCB metabolites with TTR in 
more detail, and to try to find a structural basis for the structural requirements for TTR 
binding as described in Chapter 2. X-ray crystallographic analysis of a complex of TTR 
with a hydroxylated PCB metabolite, eg. 4,4'-(OH)2-3,3',5,5'-tetraCB, refined to a 2.7 A 
resolution, revealed a hydrogen bond formation between a para-hydroxy group of the 
metabolite with the paired Serine 117 amino acid residues, present in the centre of the 
TTR binding channel (Chapter 7). The location of this hydroxylated PCB metabolite, 
deep in the binding channel, and the hydrogen bond formation could explain the 
stronger TTR binding affinity of this metabolite than the natural ligand T4. The chlorine 
atoms present on the weto-positions of the 4,4'-(OH)2-3,3',5,5'-tetraCB metabolite, fitted 
easily in the T4-iodine binding pockets present in the TTR binding channel. Additional 
computer-assisted graphics modelling studies on the interactions of several hydroxylated 
PCB metabolites with TTR, showed that hydroxy groups present on /weta-positions 
could also form hydrogen bonds with the paired Serine 117 residues in the centre of the 
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binding channel (Chapter 7). Furthermore, the modelling studies showed no significant 
differences between the interactions of hydroxylated PCB metabolites and the structur-
ally related pentachlorophenol (PCP) with TTR, although in vivo studies by others 
indicated the disruption of the complex of retinol binding protein (RBP) and TTR after 
binding of a hydroxylated PCB metabolite but not by PCP in rodents. In conclusion, the 
detailed structural studies described in Chapter 7 confirmed the necessity of para- or 
/weta-hydroxylation and adjacent chlorine substituents as structural elements of hydroxy-
lated metabolites of PCBs and related compounds for interactions with TTR (Chapter 2), 
leading to selective retention of a specific hydroxylated PCB metabolite in plasma of 
rats exposed to a complex PCB mixture in vivo (Chapter 5). 
2,3,3',4,4'-PentaCB 4-OH-2,3,3',4',5-PentaCB 
HOOC — H C -
I 
NH, 
thyroxine 
Figure 1 Formation of the 4-OH-2,3,3',4',5-pentaCB metabolite from one possible parent 
compound, 2,3,3',4,4'-pentaCB, by cytochrome P4501A (P4501A), and its structural 
resemblance to thyroxine. 
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Concluding remarks 
The outcome of the present study clearly reveals the structural requirements that are 
essential for interactions of PHAH metabolites and other related chemicals for interacti-
ons with TTR. Hydroxylated PHAH metabolites can structurally resemble the thyroid 
hormone T4. Overall the structural requirements for TTR interaction were hydroxy-
substitution on the para- or meta positions of one or both of the phenyl rings, with 
adjacent chlorine substitutions, herewith confirming some of the suggestions for TTR 
interactions of related hydroxylated PHAH metabolites by Rickenbacher et al. (1986). 
Especially the observation by X-ray crystallographic structure analysis that a hydrogen 
bond could be formed in the TTR binding channel upon binding of a hydroxylated PCB 
metabolite, provides strong evidence that para- or meta-hydroxylation of the PHAH 
compound forms an essential prerequisite for binding to the T4 binding site of TTR. No 
interactions with TTR were found for the tested parent PHAH compounds, contradictory 
to earlier suggestions of McKinney et al. (1985) which were based mainly on computer 
modelling and few in vitro binding studies (Rickenbacher et al, 1986). It should be 
noted that graphics modelling may show that parent PHAH compounds may fit the TTR 
binding site, but gives little information on binding affinity to TTR. In an affirmative in 
vitro T4-TTR binding assay, several parent PCB congeners (3,3',4,4'-tetraCB, 3,3',4,-
4',5-pentaCB, 3,3',4,4',5,5'-hexaCB, 2,3,3',4,4'-pentaCB, 2,2',5,5'-tetraCB), TCDD and 
Aroclor 1254, a commercial PCB mixture, were tested at high concentrations and 
exhibited no inhibition of T„-TTR binding (unpublished data). 
PHAH metabolites that are predicted to have high binding affinities for TTR are 
indeed detected in plasma of rodents experimentally exposed to PCBs or PCDFs (Morse 
et al., 1995b, Koga et al, 1990, Kuroki et al., 1993). For instance, exposure to a 
complex mixture of PCBs, Aroclor 1254, led to the selective retention in blood of a 
single PCB metabolite, 4-OH-2,3,3',4',5-pentaCB, which met the structural requirements 
for TTR binding (Bergman et al, 1994). 
On the basis of the proposed structural requirements we can give an explanation 
for the interactions of related compounds with TTR as found by others, for instance 
pentachlorophenol (Van den Berg, 1990, Van Raay et al., 1994, Den Besten et al., 
1991), natural compounds like flavones and halogenated aurones (Cody, 1989; Ciszak et 
al., 1992) and certain drugs like milrinone (Wojtczak et al., 1993). Moreover, these 
structural insights make it possible to predict whether other related classes of environ-
mental contaminants can interact with TTR. In addition, due to combined exposure in 
the environment, one may expect additivity of binding to TTR of hydroxylated PHAH 
metabolites with other structurally related environmental or natural compounds. 
An important question is whether these experimental data can be extrapolated to 
other species. Two factors are essential for the TTR mediated selective retention of 
hydroxylated PHAH metabolites namely the presence of TTR in blood and the formati-
on of relevant PHAH metabolites. It is most likely that hydroxylated metabolites can be 
formed in many species other than rodent. Recently hydroxylated PCB metabolites were 
identified in human and seal plasma, which were environmentally exposed to back-
ground PCB levels (Bergman et al, 1994). The major metabolites were again the 4-OH-
2,3,3',4',5-pentaCB metabolite and to a lesser extent 4-OH-2',3,3',4',5-pentaCB in seal 
and human plasma and 4-OH-2,2',3,4',5,5',6-heptaCB in human plasma. Thus the 
hydroxylated PCB metabolites detected in vivo completely matched the structural 
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requirements for TTR binding. The PHAH metabolite patterns in plasma of both 
experimentally and environmentally exposed animals and humans are species specific 
and depend not only on the structural requirements for binding to TTR, but also on the 
exposure situation and the capacity of biotransformation of PHAHs of the species. 
The species-specific metabolism of PHAHs decreases in the order: terrestrial 
mammals > aquatic mammals > birds > fish (Safe, 1989). Several mammalian and avian 
species, like rats, seals, porpoises and eiderducks could form hydroxylated metabolites in 
in vitro microsomal incubations with the model substrate 3,3',4,4'-tetraCB (TCB). 
However fish, like trout and flounder, could not metabolise TCB, although cytochrome 
P4501A-like activity, responsible for biotransformation of planar PHAHs, can be 
induced (Murk et al., 1994, Morse et a!., 1995c, Ishida et al., 1991). 
The selective retention of specific hydroxylated PHAH metabolites in plasma 
through binding to TTR is expected in species that both can metabolise PHAHs and 
posses TTR as a plasma thyroid hormone binding protein. TTR is a evolutionary 
conservative protein present in plasma of not only rodents but also other placental 
mammals, birds and to a lesser extent in reptiles. No TTR was detected in the lower 
species like fish and amphibians. In higher mammals like man, however, not only TTR 
but also thyroxine binding globulin (TBG), is present in blood as a primary thyroid 
hormone transport protein. In conclusion, hydroxylated PHAH metabolites can be 
formed and selectively retained by TTR in blood of a wide variety of species. 
The toxicological consequences of the TTR mediated selective retention of 
hydroxylated PHAH metabolites in plasma are not yet fully understood. The TTR 
protein plays a primary role in the transport of thyroid hormones in the blood of many 
species. Although TTR binds less T4 than TBG in human serum, TTR may be responsi-
ble for much of the immediate delivery of T4 and T3 to cells due to the lower binding T4 
affinity. Furthermore TTR is important for the transport of retinol in blood by forming a 
complex with retinol-binding protein (Robbins, 1991). 
Disturbances in thyroid hormone plasma levels are found in several species 
experimentally or environmentally exposed to PHAHs, like rodents, seal (Brouwer et al., 
1989) and man (Koopman Esseboom et al., 1994), species in which hydroxylated PCB 
metabolites were also present in plasma. Disruption of thyroid hormone homeostasis 
after exposure to PHAHs can however be caused by at least two mechanisms, eg. the 
disturbed plasma T4 transport through competitive binding of hydroxylated PHAH 
metabolites to TTR, but also the Ah-receptor mediated induction of T4 glucuronidation 
by parent compounds. 
The possible disruption of the TTR-RBP complex upon binding of a hydroxy-
lated PHAH metabolite can also markedly decrease plasma retinol levels in rodents 
(Brouwer, 1987). It was suggested that seals exposed to PHAHs in the environment, 
have an impaired function of the immune system (de Swart, 1995), possibly resulting 
from disturbed retinoid levels (Brouwer, 1991, Brouwer et al. 1989). Hydroxylated 
PHAH metabolites may attribute to these effects on thyroid hormone and retinoid 
homeostasis through interactions with TTR in plasma. It is not known whether similar 
effects occur in man. 
TTR is the major thyroid hormone binding protein in cerebro-spinal fluid (CSF), 
suggesting a role in distribution of thyroid hormones in the central nervous system. This 
TTR is produced in the choroid plexus and is present in high concentrations in CSF of 
rats and humans, even at a very early stage in development. Moreover, in all species 
Chapter 8 121 
where TTR is present in blood, TTR has also been detected in brain. Because TTR is an 
important carrier for T4 to target tissues, for instance brain, one may expect that it may 
also act as a facilitated transport system for hydroxylated PHAH metabolites. This is in 
accordance with observations of a strong accumulation of hydroxylated PCB metabolites 
of maternal origin in the plasma and brain of late gestational fetuses from pregnant rats 
or mice exposed to PCBs (Morse et al, 1995b,d, Darnerud et al., 1995). In rat fetuses 
perinatally exposed to Aroclor 1254 the selective accumulation of the 4-OH-2,3,3',4',5-
pentaCB metabolite in maternal plasma and fetal plasma and brain led to decreases in 
brain T4 levels, while brain T3 levels were only lightly changed. In addition plasma and 
hepatic retinoid concentrations were decreased in fetal and neonatal offspring (Morse et 
al., 1995a). The hydroxylated metabolites accumulated to high levels in fetal rat brain 
and may themselves attribute to observed neurochemical changes (Morse, 1995). 
Hydroxylated PHAH metabolites have been shown to possess biological activity 
in vitro (Brouwer, 1994). Hydroxylated PCB metabolites can interfere with mitochondri-
al structure and function in vivo and in vitro (Lans et al., 1990, Narashimhan et al., 
1991). Moreover, they can bind to the Ah-receptor and weakly induce EROD activity. In 
addition, an in vitro marker of tumor promoting potential, the gap-junctional intercellular 
communication, could be weakly inhibited. Hydroxylated PCB metabolites can also exert 
(anti)-estrogenic activities in vivo (Bergeron et al., 1994) and in vitro (Kramer et al., 
1994). No clear structure activity relationships for (anti)-estrogenicity could be found for 
the tested hydroxylated PCB metabolites. However, the hydroxylated PCB metabolites 
selectively retained in fetal plasma and brain (Morse et al., 1995d) do have a weak 
(anti)-estrogenic activity. The intrinsic capacity to disrupt endocrine systems, eg. thyroid 
and estrogen status, and the relatively large accumulating levels of hydroxylated PCB 
metabolites in late gestational rat fetuses, suggests there is a potential risk for adverse 
developmental effects by these hydroxylated PHAHs. This possible hydroxy PCB-
mediated route of developmental toxicity should be investigated in a sound in vivo 
experimental setup. 
Subtle changes in plasma thyroid hormone levels and parameters for neurological 
development were described in children exposed to background levels of PHAHs in 
utero and through lactation (Koopman-Esseboom et al., 1994, Sauer et al., 1994, Pluim 
et al., 1993). Hydroxylated PHAH metabolites did not interact with TBG, the major T4 
binding protein in human plasma (Lans et al., 1994). However, the hydroxylated PCB 
metabolites which are recently detected in human plasma (Bergman et al., 1994) are 
mainly bound to TTR, as was found after selective purification of TTR from human 
plasma (unpublished results). Therefore TTR-mediated accumulation of hydroxylated 
PCB metabolites or related compounds in fetal plasma and brain and subsequent 
decreases in T4 levels, as found in late gestational rat fetuses, may be of concern for 
fetal growth and (brain) development in a wide variety of species, including man. 
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Samenvatting en slotopmerkingen 
Samenvatting 
Polygehalogeneerde aromatische koolwaterstoffen (PHAK's) kunnen verstoringen in de 
reproductie- en schildklierhormoon-systemen veroorzaken waardoor uiteindelijk de 
(hersen)ontwikkeling, reproductie en het gedrag van diverse diersoorten negatief worden 
beinvloed kan worden. In dit proefschrift is voornamelijk aandacht besteed aan de 
effecten van verschillende klassen van PHAK's, nl. de polychloor-bifenylen (PCBs), 
polychloor-dibenzofuranen (PCDFs), polychloor-dibenzo-p-dioxinen (PCDDs) en hun 
gehydroxyleerde metabolieten op het schildklierhormoon-regulerend systeem. De 
veranderingen van schildklierhormoon-concentraties in het bloed na blootstelling aan 
deze stoffen lijken gedeeltelijk te worden veroorzaakt door een toename van de 
glucuronidering van het schildklierhormoon, een Ah-receptor-gemedieerd proces. 
Bovendien kan door aantasting van de schildklier door PHAK's de hormoon-productie 
en secretie beinvloed worden. Gehydroxyleerde metabolieten van PCBs, PCDFs en 
PCDDs zouden daarnaast het schildklierhormoon-transport in het bloed mogelijk kunnen 
verstoren. In eerder onderzoek uitgevoerd door Brouwer (1987) was reeds aangetoond 
dat blootstelling aan 3,3',4,4'-tetrachloor-bifenyl (TCB) het plasma transport van 
thyroxine (T4) en retinol in ratten verstoort. Dit werd veroorzaakt door de specifieke 
competitie van een gehydroxyleerde PCB metaboliet, nl. 4-OH-3,3',4',5-tetraCB met het 
T4 voor de schildklierhormoon bindingsplaats op het transthyretine (TTR), het 
belangrijkste transporteiwit voor schildklierhormonen in knaagdieren. Deze waarneming 
leidde tot de vraag of structureel verwante gehydroxyleerde PHAK metabolieten een 
vergelijkbare interactie zouden kunnen hebben met TTR, als ook met andere 
schildklierhormoon bindende eiwitten, zoals thyroxine bindend globuline (TBG) en type-
1-deiodinase (ID-1). Hierdoor zou het schildklierhormoontransport en metabolisme na 
blootstelling aan PHAK's in vivo, mede door gehydroxyleerde PHAK metabolieten 
verstoord kunnen worden. Speciale aandacht is besteed aan de structuur-activiteitsrelaties 
van gehydroxyleerde PHAK metabolieten voor interacties met TTR door middel van in 
vitro en in vivo studies en Rontgen-diffractie eiwitkristallografie. 
In vitro experimenten: 
Interacties van gehydroxyleerde PHAK metabolieten met 
T4-bindende eiwitten 
In verscheidene in vitro experimenten werden de interacties van gehydroxyleerde PHAK 
metabolieten met 3 verschillende T4 bindende eiwitten: TTR, thyroxine bindend 
globuline (TBG) en type-1-dejodase (ID-1), onderzocht (Hoofdstuk 2, 3 en 4). De 
remming van de binding van T4 aan TTR door gehydroxyleerde PHAK metabolieten 
werd onderzocht in in vitro T4-TTR bindingsstudies. Hieruit bleek dat de structurele 
voorwaarden die nodig waren voor de binding van gehydroxyleerde PHAK metabolieten 
aan TTR, bestonden uit: de para- of meta-hydroxylatie van een of beide fenylringen, 
met aan een of weerszijden chlooratomen (Hoofdstuk 2). De PHAK metabolieten met 
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deze structurele kenmerken vertonen een opmerkelijke overeenkomst met T4, het 
natuurlijke ligand voor TTR, met als gevolg dat deze stoffen het T4 competitief van de 
T4-bindingsplaats op het TTR verdringen. Zowel niet-planaire gehydroxyleerde PCB 
metabolieten met ortfio-chloorsubstituties, als planaire, rigide gehydroxyleerde PCDF of 
PCDD metabolieten kunnen de binding van T4 aan TTR remmen. De ort/zo-gehydroxy-
leerde PHAK metabolieten en de PHAK uitgangsstoffen zoals TCDD, 2,3,3',4,4'-
pentaCB en 3,3',4,4'-tetraCB remmen de T4-TTR binding echter niet in vitro. 
Vervolgens Week uit in vitro bindingsstudies met TBG, het belangrijkste 
schildklierhormoon-transporteiwit bij de mens, dat de geteste gehydroxyleerde PHAK 
metabolieten de T4-TBG binding niet remden (Hoofdstuk 3) Dit wijst erop dat interacties 
van liganden met TTR en TBG duidelijk verschillend zijn. Aanvullende in vitro 
experimenten met iodothyronine derivaten, toonden aan dat triiodofenol en in mindere 
mate di-iodotyrosine de T4-TTR binding maar niet de T4-TBG binding konden remmen. 
Tenslotte kon de enzymatische activiteit van het ID-1 enzym in de lever, dat een 
rol speelt bij de (in)activatie van schildklierhormonen, competitief geremd worden door 
di-para-gehydroxyleerde, meta-gehalogeneerde PHAK metabolieten, terwijl mono-
gehydroxyleerde PHAK metabolieten 10 tot 100 keer minder sterk remden (Hoofdstuk 
4). De verschillen tussen de structurele voorwaarden van gehydroxyleerde PHAH 
metabolieten die nodig zijn voor interacties met TTR, TBG en ID-1, zijn in 
overeenstemming met eerdere studies waarin verwante gehydroxyleerde PHAK 
metabolieten of iodothyronine derivaten zijn gebruikt. Concluderend: specifieke 
gehydroxyleerde PHAK metabolieten kunnen in vitro de T4-TTR binding verstoren en 
ID-1 activiteit remmen, waardoor gehydroxyleerde PHAK metabolieten een additionele 
rol zouden kunnen spelen in de waargenomen veranderingen in de 
schildklierhormoonconcentraties in het bloed na blootstelling aan PHAK's in vivo. 
In vivo experimenten: 
Effecten van Aroclor 1254 en TCDD op schildklierhormoon-transport 
en -metabolisme 
Er zijn twee in vivo experimenten uitgevoerd om de rol te onderzoeken die de 
verstoringen in het plasma T4 transport en het T4 metabolisme in de lever, veroorzaakt 
door gehydroxyleerde PHAK metabolieten, spelen in de waargenomen verlagingen in 
plasma T4 gehaltes na blootstelling aan PHAK's. Ratten werden blootgesteld aan Aroclor 
1254, een commercieel PCB mengsel dat zowel persistente als metaboliseerbare PCB 
congeneren bevat (Hoofdstuk 5), of aan het persistente 2,3,7,8-tetrachloordibenzo-p-
dioxin (TCDD) (Hoofdstuk 6). 
In volwassen Wistar ratten, blootgesteld aan een hoge dosis Aroclor 1254, 
werden verlaagde plasma T4 gehaltes gevonden op dag 3 en dag 8 na de blootstelling 
(Hoofdstuk 5). Tegelijkertijd werden op dag 8 hoge gehaltes van een specifieke 
gehydroxyleerde PCB metaboliet, 4-OH-2,3,3',4',5-pentaCB, aangetoond in het plasma 
van de ratten terwijl op dag 3 lagere hoeveelheden van deze metaboliet aangetroffen 
werden. De T4-bindingscapaciteit in het plasma van de hoog gedoseerde groep ratten 
was echter alleen op dag 8 en niet op dag 3 verlaagd. Dit geeft aan dat er vermoedelijk 
een drempelniveau bestaat voor het verstoren van de T4-TTR binding door 
gehydroxyleerde PCB metabolieten. Zowel op dag 3 als dag 8 waren de cytochroom 
P450 gehaltes en activiteiten in de lever geinduceerd, wat van belang is voor de vorming 
van de gehydroxyleerde metabolieten. De T4 glucuronidering in de lever was echter 
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tegelijkertijd geinduceerd. De verlaagde T4 concentraties in het plasma die in alle 
blootgestelde groepen werd waargenomen, kunnen daarom toegeschreven worden aan 
zowel verstoord plasma T4 transport door gehydroxyleerde PCB metabolieten en/of aan 
verhoogde T4 glucuronidering in de lever. Er werden geen significante verschillen 
gevonden in plasma T3 gehaltes na blootstelling aan Aroclor 1254. De ID-1 activiteit in 
de lever was eveneens niet geremd, wat suggereert dat de in vitro remming van ID-1 
activiteit door gehydroxyleerde PCB metabolieten niet in vivo optreedt. In een eerder 
experiment (Adams et al., 1990) werd de ID-1 activiteit in de lever echter wel in vivo 
geremd door zowel het gemakkelijke metaboliseerbare 3,3',4,4'-tetraCB als het 
persistente TCDD. In de lever van de ratten die blootgesteld waren aan Aroclor 1254 in 
vivo (Hoofdstuk 4) zouden geen of te lage hoeveelheden PCB metabolieten met de 
vereiste structuur-voorwaarden voor ID-1 remming (Hoofdstuk 4), aanwezig kunnen zijn 
geweest. 
Een opmerkelijke bevinding was dat in ratten die blootgesteld zijn aan een 
complex mengsel van PCB congeneren, slechts een enkele specifieke gehydroxyleerde 
PCB metaboliet, nl. 4-OH-2,3,3',4',5-pentaCB, in hoge concentratie in het plasma 
aanwezig was (Fig. 1). Dit was het gevolg van de gecombineerde aanwezigheid in het 
Aroclor 1254 mengsel van PCB congeneren die de cytochroom P450 activiteit sterk 
induceren en PCB congeneren die makkelijk metaboliseerbaar zijn. Daarnaast blijven 
door de selectiviteit van het TTR eiwit alleen gehydroxyleerde metabolieten aanwezig in 
het plasma die voldoen aan de structurele vereisten voor TTR binding zoals beschreven 
in Hoofdstuk 2. Verrassend was dat de 4-OH-2,3,3',4',5-pentaCB metaboliet die werd 
gevormd en selectief in het plasma aanwezig bleef, een hydroxygroep bezat op de 
hoogst gechloreerde ring, terwijl verwacht wordt dat voornamelijk metabolieten met een 
para- of weto-groep op de minst gechloreerde ring zouden worden gevormd. De binding 
van T4 aan TTR werd door de 4-OH-2,3,3\4',5-pentaCB metaboliet (Hoofdstuk 5) en de 
structured verwante 4'-OH-2,3,3',4,5'-pentaCB metaboliet (Hoofdstuk 2) met vrijwel 
gelijke potentie geremd. Er zijn vooralsnog geen duidelijke verklaringen voor de 
selectieve retentie van de 4-OH-2,3,3',4',5-pentaCB metaboliet in het plasma van de rat. 
Mogelijk spelen de farmacokinetiek en de weefselgehaltes van de vermoedelijke 
uitgangsstoffen 2,3,3',4,4'-pentaCB (CB 105) of 2,3',4,4',5-pentaCB (CB 118) hierin 
een rol. 
In ratten, blootgesteld aan TCDD, werden met GC-MS analyse geen 
detecteerbare hoeveelheden gehydroxyleerde TCDD metabolieten aangetoond in plasma 
extracten op dag 5 na blootstelling, hoewel de cytochroom P450 gehaltes en activiteit 
sterk geinduceerd waren (Hoofdstuk 6). Bovendien werd geen eenduidige afname 
gevonden van de T4-TTR binding in het plasma van TCDD blootgestelde ratten. Het 
schildklierhormoon metabolisme was echter wel duidelijk veranderd: zowel de T4 
glucuronidering in de lever als de type-2-deiodinase (ID-2) activiteit in de hersenen 
waren toegenomen, terwijl de ID-1 activiteit in de lever was afgenomen. Deze 
veranderingen zouden de verlaagde plasma T4 gehaltes in de blootgestelde ratten kunnen 
verklaren. De veranderingen in het schildklierhormoon-metabolisme zouden eveneens 
kunnen wijzen op een hypothyroide status van de ratten hoewel geen verlagingen in de 
plasma T3 concentraties zijn aangetoond. De afname in ID-1 activiteit na TCDD 
blootstelling werd mogelijk niet veroorzaakt door gehydroxyleerde TCDD metabolieten 
maar zou veroorzaakt kunnen worden door directe effecten van TCDD op de ID-1 
activiteit of door de mogelijke hypothyroide status van de blootgestelde ratten. 
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Terwijl de verlaagde plasma T4 waarden na blootstelling aan Aroclor 1254 
werden veroorzaakt door zowel het verstoorde plasma T4 transport en de verhoogde T4 
glucuronidering (Hoofdstuk 5), werd na blootstelling aan TCDD alleen verhoogde T4 
glucuronidering als oorzaak voor plasma T4 verlagingen vastgesteld. De in vivo 
experimenten zoals beschreven in dit proefschrift, geven aan dat er 2 verschillende 
mechanismen kunnen zijn voor verlagingen in plasma T4 concentraties na blootstelling 
aan PHAK's. Een derde mechanisme kan echter niet uitgesloten worden omdat in 
verscheidene studies veranderingen in de structuur van de schildklier en secretie van 
schildklierhormonen bescheven worden na blootstelling van ratten aan Aroclor 1254, 
TCDD en verwante stoffen. 
Structured onderbouwing voor de interacties van gehydroxyleerde PCB 
metabolieten met TTR 
De selectieve retentie van een specifieke gehydroxyleerde PCB metaboliet in het plasma 
van ratten in vivo (Hoofdstuk 5), leidde ertoe de interacties van gehydroxyleerde PCB 
metabolieten met TTR in meer detail te onderzoeken en hiermee de structurele 
kenmerken die nodig zijn voor binding aan TTR, zoals die beschreven zijn in Hoofdstuk 
2, te onderbouwen. De drie-dimensionale structuur van een eiwitcomplex van TTR met 
een gehydroxyleerde PCB metaboliet, 4,4'-(OH)2-3,3',5,5'-tetraCB, werd met behulp van 
Rontgen-diffractie kristallografie opgehelderd tot een 2.7 Angstrom resolutie. Hierin 
werd aangetoond dat een waterstofbrug gevormd kon worden tussen de para-hydroxy 
groep van de metaboliet met de gepaarde Serine 117 aminozuur residuen, die aanwezig 
zijn in het centrum van het bindingskanaal van het TTR eiwit (Hoofdstuk 7). De locatie 
van deze PCB metaboliet, diep in de T4 bindingsplaats van TTR, en de waterstofbrug-
vorming verklaarden de sterkere affiniteit voor TTR van deze metaboliet vergeleken met 
het natuurlijke ligand T4. De chloor-atomen die aanwezig zijn op de meto-posities van 
de 4,4'-(OH)2-3,3',5,5'-tetraCB metaboliet, pasten gemakkelijk in de bindingsplaatsen 
voor de jood-atomen van T4 die aanwezig zijn in het bindingskanaal van TTR. 
Aanvullende computer-ondersteunde grafische modellering van de interacties van 
verschillende PCB metabolieten met TTR, toonden aan dat hydroxy-groepen die 
aanwezig zijn op meta-posities eveneens waterstof-bruggen konden vormen met de 
Serine 117 aminozuur residuen (Hoofdstuk 7). Bovendien toonden deze model-studies 
aan dat er geen significante verschillen waren in de binding van gehydroxyleerde PCB 
metabolieten en het structureel verwante pentachloorfenol (PCP) met TTR. Eerdere in 
vivo experimenten met ratten wezen echter op een verstoring van het complex van TTR 
met retinol bindend eiwit (RBP) na binding van een gehydroxyleerde PCB metaboliet, 
maar geen verstoring van dit complex door PCP. Concluderend: de gedetailleerde 
structuuropheldering van het eiwitcomplex van TTR met de PCB metaboliet zoals 
beschreven in Hoofdstuk 7, onderbouwt de structurele voorwaarden voor PCB 
metabolieten om aan TTR te binden (Hoofdstuk 2) welke leiden tot de selectieve retentie 
van een specifieke PCB metaboliet in het plasma van ratten die blootgesteld zijn aan een 
complex PCB mengsel (Hoofdstuk 5). 
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Figuur 1 Vorming van de 4-OH-2,3,3',4',5-pentaCB metaboliet van een van zijn uitgangsstoffen, 
2,3,3',4,4'-pentaCB, door cytochroom P4501A (P4501A), en zijn structurele overeenkomst met 
thyroxine 
Concluderende slotopmerkingen 
In dit proefschrift zijn de structurele kenmerken die nodig zijn voor de interacties van 
PHAK metabolieten en andere verwante stoffen met TTR duidelijk opgehelderd. Globaal 
zijn de structurele voorwaarden die nodig zijn voor binding aan TTR: hydroxylering op 
de metct- of para-positie van een of beide fenylringen, met aan een of weerszijden 
chlooratomen. Gehydroxyleerde PHAK metabolieten met deze structurele kenmerken 
lijken qua structuur sterk op het schildklierhormoon T4. De hier beschreven structurele 
voorwaarden bevestigen de resultaten van een onderzoek naar interacties van verwante 
gehydroxyleerde PCB metabolieten met TTR zoals beschreven door Rickenbacher et al, 
1986. Vooral het aantonen van de waterstofbrugvorming na binding van een 
gehydroxyleerde PCB metaboliet in het TTR bindingskanaal met behulp van Rontgen-
diffractie eiwitkristallografie, versterkt de bevinding dat para- of /weta-hydroxylatie van 
de PHAK een essentiele structurele voorwaarde vormt voor de binding van deze stoffen 
op de T4 bindingsplaats van TTR. 
PHAK metabolieten waarvan voorspeld kan worden dat ze een hoge bindingsaffi-
niteit voor TTR hebben, zijn inderdaad aangetoond in plasma van ratten die blootgesteld 
waren aan PCBs of PCDFs (Morse et al, 1995b,d, Koga et al, 1990, Kuroki et al, 
1993). Na blootstelling van ratten aan het complexe PCB mengsel Aroclor 1254, werd in 
het bloeplasma de PCB metaboliet 4-OH-2,3,3',4',5-pentaCB aangetoond, die voldoet 
aan de structurele kenmerken die nodig zijn voor binidng aan TTR (Bergman et al., 
1994). 
In in vitro studies werden geen interacties van de geteste PHAK uitgangsstoffen 
met TTR gevonden, wat in tegenspraak is met eerdere bevindingen van McKinney et al., 
1985, die voornamelijk gebaseerd waren op computermodelling studies en slechts enkele 
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in vitro bindingsstudies (Rickenbacher et al, 1986). Nadrukkelijk moet worden gesteld 
dat computer ondersteunde grafische modellering kan aantonen dat uitgangsstoffen in de 
bindingsplaats van TTR passen, maar dat deze methode weinig informatie geeft over de 
bindingsaffiniteit van deze stoffen voor TTR. Daarom zijn in een aanvullende in vitro 
T4-TTR bindingsstudie verschillende uitgangsstoffen zoals 3,3',4,4'-tetraCB, 3,3',4,4',5-
pentaCB, 3,3',4,4\5,5'-hexaCB, 2,3,3',4,4'-pentaCB, 2,2',5,5'-tetraCB, TCDD en 
Aroclor 1254 tot in hoge concentraties getest, waarbij wederom geen remming van T4 
binding aan TTR gevonden werd (niet gepubliceerde data). 
Met de voorgestelde structurele voorwaarden voor gehydroxyleerde PHAK 
metabolieten voor interacties met TTR kunnen we eveneens de interacties met TTR 
verklaren van verwante verbindingen zoals pentachloorfenol (PCP) (Van den Berg, 
1990, Van Raay, 1994, Den Besten et al, 1991), natuurlijke stoffen zoals flavonen en 
gehalogeneerde auronen (Cody, 1989; Ciszak et al, 1992) en bepaalde geneesmiddelen 
zoals milrinone (Wojtczak et al, 1993). Bovendien maken deze structurele inzichten het 
mogelijk om te voorspellen of andere klassen van milieuvervuilende stoffen eveneens 
aan TTR zouden kunnen binden. Daarnaast kan men additiviteit voor binding aan TTR 
verwachten van gehydroxyleerde PHAK metabolieten met andere structureel verwante 
milieucontaminanten of natuurlijke stoffen. 
Een ander belangrijk aspect is of de experimentele gegevens, zoals beschreven in 
dit proefschrift, geextrapoleerd kunnen worden naar andere diersoorten. Voor de 
selectieve retentie van gehydroxyleerde PHAK metabolieten door binding aan TTR in 
bloed zijn twee factoren van belang, namelijk de aanwezigheid van TTR in het bloed en 
de mogelijke vorming van gehydroxyleerde metabolieten. Waarschijnlijk kunnen andere 
diersoorten dan knaagdieren eveneens gehydroxyleerde PHAK metabolieten vormen na 
blootstelling aan PHAK's. Recentelijk zijn gehydroxyleerde PCB metabolieten 
aangetoond in het bloed van mensen en zeehonden, die blootgesteld waren aan 
achtergrondniveau's van PCBs (Bergman et al., 1994). De belangrijkste metabolieten 
zijn wederom de 4-OH-2,3,3',4',5-pentaCB metaboliet en in mindere mate de 4-OH-
2',3,3',4',5-pentaCB metaboliet in het plasma van zeehonden en de mens, en de 4-OH-
2,2',3,4',5,5',6-heptaCB metaboliet in menselijk plasma. Dus de gehydroxyleerde PCB 
metabolieten die in vivo aangetoond zijn, zowel na experimentele als achtergrond- of 
milieu-blootstelling, voldoen volledig aan de structurele voorwaarden voor binding aan 
TTR. De karakteristieke patronen van PHAK metabolieten in het plasma van mens en 
dier na experimentele of achtergrond-blootstellling, zijn soort-specifiek en hangen niet 
a/leen af van de structurele vereisten voor binding aan TTR maar eveneens van de 
blootstellingssituatie en de mogelijkheid tot biotransformatie van PHAK's van de 
diersoort. 
Het soort-specifieke metabolisme van PHAK's neemt af in de volgorde: 
landzoogdieren > zeezoogdieren > vogels > vissen (Safe, 1989). Verscheidene zoogdier-
en vogel-soorten, zoals ratten, zeehonden, dolfijnen en eidereenden kunnen 
gehydroxyleerde metabolieten vormen van het modelsubstraat 3,3',4,4'-tetraCB (TCB) in 
in vitro micocomale incubaties. Vissen, zoals de forel en de bot, kunnen TCB echter niet 
metaboliseren, hoewel het cytochroom P4501A isoenzym dat verantwoordelijk is voor 
de biotransformatie van planaire PHAK's, wel geinduceerd kan zijn (Murk et al., 1994, 
Morse et al, 1995a, Ishida et al, 1991). 
De selectieve retentie van specifieke gehydroxyleerde PHAK metabolieten in 
plasma door de binding aan TTR wordt voornamelijk verwacht in soorten die zowel 
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PHAK's kunnen omzetten en in het bezit zijn van TTR als transport-eiwit voor 
schildklierhormonen in plasma. TTR is een, door de evolutie heen, geconserveerd eiwit 
dat aanwezig in het plasma van knaagdieren, maar ook van andere zoogdieren, vogels en 
in mindere mate van reptielen. In de lagere diersoorten zoals vissen en amfibieen werd 
echter geen TTR in plasma aangetroffen. In de hogere diersoorten zoals de mens, is 
naast TTR nog een ander, belangrijker transport eiwit in plasma aanwezig, het thyroxine 
bindend globuline (TBG). Concluderend kunnen de gehydroxyleerde PHAK metabo-
lieten in een groot aantal diersoorten gevormd worden en selectief in plasma aanwezig 
blijven door binding aan TTR. 
De toxicologische gevolgen van de selectieve retentie van gehydroxyleerde 
PHAK metabolieten in plasma door binding aan TTR, zijn nog niet volledig bekend. Het 
TTR eiwit speelt een primaire rol bij het transport van schildklierhormonen in het bloed 
van vele diersoorten. Hoewel TTR minder T4 bindt dan TBG in humaan serum, is TTR, 
door de lagere bindingsaffiniteit, waarschijnlijk verantwoordelijk voor het merendeel van 
de directe levering van T4 en T3 aan cellen. Verder is TTR belangrijk voor het transport 
van retinol in het bloed door het vorming van een complex met het retinol bindend eiwit 
(RBP) (Robbins, 1991). 
In verschillende diersoorten die experimenteel of in het milieu blootgesteld zijn 
aan PHAK's, zoals knaagdieren, zeehonden en de mens, zijn veranderingen in 
schildklierhormoon concentraties in plasma aangetoond, terwijl in deze soorten eveneens 
gehydroxyleerde PHAK metabolieten in het plasma aangetoond zijn. Verstoringen in de 
schildklierhormoon-homeostase door blootstelling aan PHAK's kunnen echter niet alleen 
veroorzaakt worden door het verstoorde plasma T4 transport door competitieve binding 
van gehydroxyleerde PHAK metabolieten aan TTR , maar eveneens door de Ah-receptor 
gemedieerde inductie van T4 glucuronidering door de PHAK uitgangsstoffen. 
De mogelijke verstoring van het TTR-RBP complex na binding van een gehy-
droxyleerde PHAK metaboliet zou eveneens een sterke daling van de retinolgehaltes in 
het plasma van knaagdieren teweeg kunnen brengen (Brouwer, 1987). Er werd gesugge-
reerd dat zeehonden die blootgesteld zijn aan PHAK's in het milieu, een verzwakt 
immuunsysteem bezitten (De Swart, 1995), wat een mogelijk gevolg zou kunnen zijn 
van verstoorde retinoiden gehaltes (Brouwer, 1991, Brouwer et al, 1989). Gehydroxy-
leerde PHAK metabolieten kunnen aan deze effecten van PHAK's op de schildklierhor-
moon- en retinoiden-homeostase bijdragen door interacties aan te gaan met TTR in het 
plasma. Het is onduidelijk of deze effecten voorkomen in de mens. 
TTR is het belangrijkste schildklierhormoon bindende eiwit in de cerebro-spinale 
vloeistof (CSF) zodat gesuggereerd wordt dat TTR een rol speelt in de distributie van 
schildklierhormonen in het centraal zenuwstelsel. Dit TTR wordt in de choroid plexus 
geproduceerd en is, zelfs zeer vroeg in de ontwikkeling, in hoge concentraties aanwezig 
in het CSF van ratten en mensen. Bovendien is in alle diersoorten waar TTR aanwezig 
is in plasma, ook TTR in de hersenen aangetoond. Omdat TTR een belangrijke leveren-
cier is van T4 naar de doelweefsels, zoals de hersenen, kan men verwachten dat TTR 
eveneens als een gefaciliteerd transport systeem voor gehydroxyleerde PHAK metabolie-
ten werkt. Dit is in overeenstemming met de aangetoonde sterke accumulatie van 
gehydroxyleerde PCB metabolieten, afkomstig van de moeder, in het plasma en de 
hersenen van foetussen laat in de gestatie, in zwangere ratten en muizen die blootgesteld 
zijn aan PCBs (Morse et al., 1995b,d, Damerud et al, 1995). In rattefoetussen, 
perinataal blootgesteld aan Aroclor 1254, leidde de ophoping van de 4-OH-2,3,3',4',5-
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pentaCB metaboliet in maternaal plasma en foetaal plasma en hersenen, tot dalingen in 
T4 concentraties in de hersenen, terwijl de T3 concentraties in de hersenen slechts weinig 
veranderde. Bovendien werden verlagingen in de plasma en lever retinolconcentraties 
waargenomen in de foetale en neonatale nakomelingen (Morse et al, 1995a). De 
gehydroxyleerde metabolieten die tot hoge concentraties in foetale rattehersenen 
accumuleerden, zouden kunnen bijdragen aan de neurochemische veranderingen in de 
foetale hersenen die waargenomen werden na blootstelling van zwangere ratten aan 
Aroclor 1254 (Morse, 1995). 
Gehydroxyleerde PHAK metabolieten bezitten in vitro bepaalde biologische 
activiteiten (Brouwer, 1994). Gehydroxyleerde PCB metabolieten kunnen bijvoorbeeld 
de functie van mitochondria verstoren (Lans et al., 1990, Narashimhan et al., 1991). 
Bovendien kunnen ze binden aan de Ah-receptor en in lichte mate de cytochrome P450 
1A1 activiteit induceren. Daarnaast kan een in vitro marker voor tumor promotie 
werking, de gap-junction intercellulaire communicatie, zwak geremd worden door 
gehydroxyleerde PCB metabolieten. Gehydroxyleerde PCB metaboieten vertonen 
eveneens een (anti)-estrogene werking, zowel in vivo (Bergeron et al., 1994) als in vitro 
(Kramer et al., 1994). Er is geen duidelijk structuur activiteitsrelatie gevonden voor de 
(anti-)estrogeniteit van de geteste gehydroxyleerde PCB metabolieten. De 
gehydroxyleerde PCB metaboliet die selectief in het plasma en de hersenen van 
rattefoetussen ophoopt, na blootstelling van zwangere ratten aan Aroclor 1254 (Morse et 
al, 1995d), heeft echter een zwak (anti-)estrogene activiteit. De intrinsieke eigenschap 
om endocriene systemen, zoals schildklierhormonen en estrogenen, te verstoren en de 
relatief grote hoeveelheden gehydroxyleerde PCB metabolieten die accumuleren in de 
foetussen laat in de gestatie, zouden kunnen betekenen dat er een potentieel risico 
bestaat voor verstoringen van de ontwikkeling door gehydroxyleerde PHAK's. Deze 
mogelijke route van ontwikkelingstoxiciteit door gehydroxyleerde PHAK metabolieten 
zou in een degelijk in vivo experiment onderzocht moeten worden. 
Subtiele veranderingen in plasma schildklierhormoon concentraties en parameters 
voor neurologische ontwikkeling werden eveneens in kinderen gevonden die in de 
baarmoeder en via lactatie blootgesteld waren aan achtergrondniveau's van PHAK's 
(Koopman-Esseboom et al., 1994, Sauer et al., 1994, Pluim et al., 1993). Hoewel 
gehydroxyleerde PHAK metabolieten niet binden aan TBG, het belangrijkste T4 
bindende eiwit in humaan plasma (Lans et ah, 1994), zijn de gehydroxyleerde PCB 
metabolieten die recentelijk in humaan plasma aangetoond zijn (Bergman et al., 1994) 
voornamelijk gebonden aan het TTR, zoals werd gevonden na de opzuivering van TTR 
uit humaan serum (ongepubliceerde resutaten). De ophoping van gehydroxyleerde PCB 
metabolieten of verwante stoffen in foetaal plasma en hersenen door binding aan TTR 
en de daaropvolgende verlagingen in plasma T4 concentraties, zoals gevonden is in 
rattefoetussen laat in de gestatie, kunnen daarom zorgwekkend zijn voor de foetale groei 
en (hersen)ontwikkeling van een groot aantal diersoorten, waaronder de mens. 
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List of abbreviations 
3MC 3-methylcholantrene 
Ah-receptor Aryl hydrocarbon receptor 
AHH aryl hydrocarbon hydroxylase 
CSF cerebrospinal fluid 
diOH-TCB 4,4'-(OH)2-3,3 ',5,5 '-tetrachlorobiphenyl 
DIT diiodo-tyrosine 
DRE dioxin-responsive element/enhancer 
DTT dithiotreitol 
EROD ethoxyresorufm-O-deethylase 
ID-I type-1 iodothyronine deiodinase 
ID-II type-2 iodothyronine deiodinase 
ID-III type-3 iodothyronine deiodinase 
IRD inner ring deiodination 
MFO mixed function oxidases 
MIT monoiodo-tyrosine 
OH-PCB hydroxy-PCB metabolite 
ORD outer ring deiodination 
PAGE poly-acrylamide gel electrophoresis 
PB phenobarbital 
PBB polybromo-biphenyl 
PCB polychloro-biphenyl 
PCDD polychloro-dibenzo-p-dioxin 
PCDF polychloro-dibenzofuran 
PCP pentachlorophenol 
PHAH polyhalogenated aromatic hydrocarbon 
RBP retinol-binding protein 
rT3 3,3',5'-triiodo-L-thyronine, reverse T3 
T3 3,3',5-triiodo-L-thyronine, triiodothyronine 
T4 3,3',5,5'-tetraiodo-L-thyronine, thyroxine 
TBG thyroxine binding globulin 
TBPA thyroxine binding prealbumin (=TTR) 
TCB 3,3',4,4'-tetrachlorobiphenyl 
TCDD 2,3,7,8-tetrachlorodibenzo-/)-dioxin 
TEF toxic equivalency factor 
TEQ toxic equivalency 
TIP 2,4,6-triiodophenol 
TR thyroid hormone receptor 
TRE thyroid hormone response element 
TRH thyrotropin releasing hormone 
TSH thyroid stimulating hormone 
TTR transthyretin 
Tyr tyrosine 
UDPGA uridinyl-5'-diphosphoglucuronic acid 
UGT UDP-glucuronyl-transferase 
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